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General introduction 
1. Introduction 
Orthodontic treatments are performed on a large scale In the 
Netherlands, and the demand is thought to increase in the following 
years. A longitudinal study amongst Dutch youngsters between 1987 and 
1999 showed that the percentage that received orthodontic treatment 
increased from 23 to 40%. 1 Also, increasing numbers of adults are 
treated, as they have become more interested in orthodontics and more 
aware of the treatment possibilities.2 Although aesthetics is the major 
reason for treatment, orthodontic therapy may also be required for 
craniofacial defects and malfunction of the orofacial musculature. It can 
be usefully applied in impaired mastication, impaired speech, and 
susceptibility to periodontal problems or dental caries, when plaque 
accumulates due to crowding or unfavourable inclination.3'5 
An overwhelming amount of orthodontic literature has been 
produced over the years. These studies have mainly focused on clinical 
aspects of orthodontics, while the biological aspects have received far 
less attention. However, biological processes are the basis of orthodontic 
tooth movement and orthodontic problems such as relapse and root 
resorption. To reduce these problems and to enhance treatment 
effectiveness and efficiency, more knowledge of the biological 
mechanisms in orthodontics is required. 
In order to move a tooth, the surrounding structures of the root, 
the 'periodontium', have to be remodelled. At the side of the root in the 
direction of the force, bone has to be resorbed, while new bone has to be 
deposited at the opposite side. These sides of the root are therefore 
referred to as 'resorption side' and 'apposition side' respectively. The 
periodontal ligament, which is the fibrous structure that connects the 
teeth to the bone, also undergoes extensive remodelling. A group of 
enzymes, the matrix metalloproteinases (MMPs), and their natural 
inhibitors are thought to play an important role in periodontal remodelling 
during orthodontic tooth movement.6,7 MMPs can degrade extracellular 
matrix (ECM) components, whereas the tissue inhibitors of 
metalloproteinases (TIMPs) inhibit their function.8 Both are in balance in 
the normal maintenance and turnover of the periodontium. During tooth 
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movement, this balance is thought to shift towards the MMPs, resulting in 
an accelerated ECM degradation.6,9 The periodontal tissues are still 
maintained because the synthesis of new ECM is also enhanced.10 
Periodontitis is a complicating factor in orthodontics. This is the 
pathological breakdown of the periodontium due to inflammatory 
processes that are initiated by microorganisms. It will eventually lead to 
progressive destruction of the periodontal ligament and the alveolar 
bone.11 In periodontitis, the balance between MMPs and TIMPs also shifts 
towards the MMPs, but the synthesis of new matrix does not keep up with 
degradation, resulting in a net loss of periodontal structures.1213 
Orthodontic treatment of penodontitis-affected teeth may enhance 
destruction of the alveolar bone.1415 
MMPs and TIMPs have mainly been studied in inflammation-
induced periodontal remodelling in periodontitis. Although the first steps 
have been made to investigate their role in orthodontics, much remains 
unknown in this field. The investigation of MMPs and TIMPs in tooth 
movement may offer possibilities to increase the efficiency of orthodontic 
tooth movement, and to prevent unwanted side effects such as relapse 
and root resorption. Relapse is a major concern in orthodontics, because 
the teeth move back to their original position, which partly reverses the 
treatment effect. A common side-effect in orthodontics is root resorption, 
which can damage the roots. In 5% of adult orthodontic patients, severe 
root resorption of more than 5 mm occurs.16 This will lead to increased 
mobility and a shortened lifespan of the tooth, especially in cases of 
periodontitis. 
The next sections give an overview of the involvement of MMPs 
and TIMPs in periodontal remodelling. In addition, synthetic inhibitors of 
MMP, which are developed to reduce MMP activity in disease, are 
discussed. 
2. Periodontal remodelling 
2.1 The periodontium 
In order to move a tooth, the periodontal tissues have to be remodelled. 
The periodontium refers to the tissues that anchor the teeth to the jaw 
12 
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bone (Fig. 1). I t contains two hard tissues: the root cementum and the 
alveolar bone, and two soft tissues: the periodontal ligament and the 
gingiva.11 
The periodontal ligament (PDL) is essential in orthodontic tooth 
movement. Its high turnover rate enables adaptation to orthodontic 
forces. Anatomically, it is situated between the cementum of the root and 
the alveolar bone, anchoring the tooth to the bone. It functions as a 
shock-absorber and contains mechanosensors that have a regulatory 
function in mastication.17 
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Fig. 1. Schematica! drawing of 
the periodontium. 
Bone, cementum, gingiva, and 
periodontal ligament are 
indicated. 
The PDL plays an important role in initiating biological responses in 
orthodontic tooth movement.1 8 When subjected to mechanical forces, 
cells of the PDL are triggered to increase remodelling of the PDL and the 
surrounding alveolar bone. This results in bone resorption at the side of 
the root in the direction of the force and bone apposition at the opposite 
side. Hardly any data are available on the MMP and TIMP levels within the 
PDL. However, it is known from histological studies in rats and mRNA 
analysis in humans that some MMPs are expressed in the PDL.7,19,20 Also, 
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m several studies MMPs and TIMPs in gingival crevicular fluid have been 
described.2 1"2 4 
The coronal part of the PDL blends into the gingiva and is 
demarcated from it by the collagen fibres that connect the alveolar bone 
crest with the root.2 5 The gingiva is connected to the teeth by an 
epithelial attachment, which prevents infection of the underlying 
periodontal tissues.2 5 The fibroblasts, which are the main cell type of the 
gingiva as well as the PDL, produce the fibres of the connective tissue, 
which mainly consist of collagen. The collagen fibres, especially the 
transseptal fibres that connect two adjacent teeth, have often been 
pointed out as the cause of orthodontic relapse.2 6 , 2 7 However, very little 
experimental evidence is available for this theory. Next to the synthesis 
of ECM proteins, the fibroblasts are also able to degrade the ECM.28 
Several MMPs and TIMPs are present in the gingiva, and are involved in 
normal and pathological turnover of the ECM.1 2 , 2 2 , 2 9 , 3 0 
Next to the soft tissues gingiva and PDL, the periodontium contains 
two hard tissues: the root cementum and the alveolar bone. The 
cementum plays only a minor role in orthodontic tooth movement. It is 
the mineralised tissue that covers and protects the root surface, and 
anchors the collagen fibres that connect to the bone. Cementoblasts are 
located on the surface of the tissue. They become cementocytes when 
they are enclosed in the cementum they have produced. Both cell types 
have been shown to express MMPs and TIMPs during tooth eruption.3 1 A 
common problem during orthodontic tooth movement is root resorption. 
This involves resorption of the cementum and the underlying dentin, and 
can lead to severe shortening of the roots. Both cathepsin Κ and MMPs 
contribute to the resorption of the cementum.3 2 
The other hard tissue of the periodontium is the alveolar bone. This 
is the part of the jaws that holds the teeth. 2 5 In contrast to cementum, 
bone is vascularised, continuously remodelled, and is therefore able to 
adapt to functional demands. The bone cells: osteoblasts, osteocytes, 
and osteoclasts, are responsible for remodelling. At the apposition side of 
an orthodontically moved tooth, osteoblasts deposit new bone. They 
synthesise the organic bone matrix and induce mineralisation. At the 
resorption side, osteoblasts are also involved in bone resorption, but 
14 
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more indirectly. They secrete MMPs to remove the non-mineralised 
organic matrix, thereby paving the way for osteoclasts to resorb the 
bone.33,34 The process of periodontal remodelling during tooth movement 
will be discussed in more detail in the following section. 
2.2 Periodontal remodelling in orthodontic tooth movement 
Mechanical forces applied to a tooth increase remodelling of the 
periodontal tissues. The initial responses take place in the PDL, after 
which bone is resorbed at one side of the tooth, and deposited at the 
other side.18 An intact PDL is a prerequisite for tooth movement. Teeth 
cannot move if the PDL is locally interrupted by ankylosis, which is a 
bony connection of the tooth with the alveolar bone.35 
Tooth movement occurs in four phases.36 In the initial phase, the 
tooth only moves in its socket, stretching the periodontal fibres at one 
side of the tooth and relaxing them at the opposite side. This phase takes 
only hours to days. At the side that will later be referred to as the 
resorption side, blood flow is impaired and local ischemia will follow, 
which results in necrosis of the periodontal ligament. This Is called 
hyalinisation.37 The presence of hyalinised tissue obstructs further tooth 
movement and leads to a temporary arrest. 
Hyalinisation characterises the second phase, or'hyalinisation 
phase'.36 The hyalinised tissue will be removed by neutrophils and 
macrophages. Thereafter, PDL cells will up-regulate the production of 
collagen types I and I I I . 3 8 An increase in production of collagen type I I I 
relative to type I occurs.39 Collagen type I I I is thought to play a role in 
the regulation of ECM assembly. The collagen type I I I fibres are 
eventually replaced by type I fibres.40 The specific MMPs and TIMPs that 
are involved in these remodelling processes will be discussed later. 
During this phase, bone deposition by osteoblasts starts at the apposition 
side.41 The osteocytes, which are located within the bone, are able to 
detect mechanical stimuli, and can communicate with other osteocytes or 
cells at the bone surface through processes that run into narrow 
canaliculi in the bone. Of all bone-related cells, osteocytes are the most 
responsive to mechanical stimuli.42 I t has been proposed that they are 
sensitive to fluid flow in the canaliculi, which is caused by force-induced 
stram m the bone.43 In short, the strain of the PDL fibres is transduced to 
the bone, which causes canalicular fluid flow. This flow activates the 
osteocytes to produce factors that will induce the recruitment of 
osteoblasts and bone deposition at the apposition side.44 At the 
resorption side, the PDL fibres relax, resulting in reduced strain to the 
bone. This underloading results m the recruitment of osteoclasts, which 
resorb the bone.45 At this side, osteoblasts are indirectly involved in bone 
resorption. They express cytokines that stimulate osteoclasts, and 
secrete MMPs, which remove the non-mineralised organic matrix to 
enable osteoclasts to resorb the bone.3334 The tooth can only be moved 
further once the hyahmsed tissue is removed. 
True tooth movement takes place in the next phase. Enhanced 
remodelling continues, and ongoing accelerated tooth movement occurs. 
In this phase local root resorption by odontoclasts may occur. This is an 
unwanted and irreversible side effect of orthodontic treatment.46 Root 
resorption and bone resorption are similar with regard to collagenolytic 
enzyme production,32 and it has been suggested that odontoclasts and 
osteoclasts are the same cells.47 In the last phase, the linear phase, tooth 
movement has reached a constant speed. Osteoclasts continuously 
resorb bone at one side of the tooth, whereas osteoblasts deposit new 
bone at the apposition side for as long as the orthodontic force is 
present 48 
After removal of the force, relapse will generally occur. This 
tendency of teeth to move back to their original position happens in all 
cases, but the degree vanes.49 It is one of the mam problems m 
orthodontics. The same processes are thought to take place as in 
orthodontic tooth movement. However, the exact cause of relapse 
remains largely unknown. Transseptal collagen fibres have long been 
regarded as the mam cause.2627 More recently, it has been suggested 
that an increase of elastic fibres m the PDL and gingiva plays a role.50 
Orthodontic appliances (e.g. night retainer, CC-bar) are required to 
prevent relapse, with the common disadvantages of discomfort and 
plaque retention. It would be preferable to target the underlying 
biological process instead of introducing yet an other mechanical device. 
Up to now, no biological means of intervention have been developed to 
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overcome relapse. The inhibition of MMP activity might serve as a focus 
for such interventions. 
2.3 Periodontal remodelling in periodontitis 
Increased periodontal remodelling also occurs in periodontitis. In contrast 
to the remodelling in orthodontics, which is induced by mechanical forces, 
the remodelling in periodontitis is induced by inflammation. In 
periodontitis, ECM degradation has the upper hand, leading to a loss of 
periodontal structures. An exaggerated host response to periodontal 
bacteria disturbs the delicate balance between degradation and synthesis 
of ECM. Some bacteria are associated with periodontitis more strongly 
than others, and are therefore called 'periodontal pathogens'. For 
example, P. gingivalis, A. actinomycetemcomitans, T. forsythia, and T. 
denticola are strongly associated with periodontitis.51 The major part of 
the tissue destruction is caused by host enzymes, although bacterial 
collagenases also play a role.52,53 
During normal periodontal remodelling, collagen is mainly 
degraded intracellularly, whereas during periodontitis this shifts towards 
extracellular digestion.54 The relative overactivity of MMPs then results in 
the breakdown of periodontal structures.55 I t has been proposed that 
procollagenases are stored in the extracellular matrix, and that they are 
quickly activated during an outburst of periodontitis.54 
Periodontitis-affected teeth should not be subjected to orthodontic 
forces as long as the disease is active, since it might induce enhanced 
destruction of the alveolar bone.15 The levels of active and latent MMPs 
are higher in GCF from deep pockets than in fluid from healthy sulci.21'24 
The amounts of TIMPs were found to be lower in the GCF of periodontitis 
patients than in that of healthy subjects.22,24 This reflects the increased 
breakdown processes that take place during this disease. The first clinical 
results of a chair-side MMP-8 test to distinguish between healthy and 
periodontitis-affected sites are promising.56,57 
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3. Matrix metalloproteinases and their inhibitors 
Several enzymes are involved in the breakdown of the ECM in the 
periodontium, such as cathepsms,22 5Θ 6 1 MMPs,12 2 1 2 A 3 0'3 8 6 2 6 4 
ß-glucuromdase,65 hyaluronidase,66 and neutrophil elastase.67 A 
dismtegrm and metalloprotease with thrombospondm type 1 motif 
(ADAMTS) types 1, 4, and 5 were also detected in the periodontal 
ligament, but only during tooth eruption.66 The focus of this thesis is on 
the MMPs, since they are thought to be the most important group of 
proteases involved m the degradation of periodontal tissues.69,70 
Especially the collagenases and gelatmases, two major groups of MMPs, 
will be highlighted. The characteristics of MMPs as well as their naturally 
occurring inhibitors, the TIMPs, will be discussed m this section. In 
addition, the synthetic MMP inhibitors will be reviewed. 
3.1 Matrix metalloproteinases 
The tissues of the periodontium, except the cementum, undergo 
continuous remodelling during life. In orthodontic tooth movement, 
remodelling is increased to allow displacement of the teeth. The MMPs 
are a family of zinc-dependent endopeptidases that are able to degrade 
ECM components. They play a key role m the remodelling of the 
periodontium.71,72 All MMPs share common characteristics like 
dependence on zinc for activity, dependence on calcium for stability, 
maximal activity at neutral pH, production and secretion as inactive 
proenzymes, and activation m vitro by limited proteolysis or 
organomercunals.73,74 At this moment 23 human MMPs are known.7576 
They more or less share the same molecular structure and have a Mr 
mostly of 50-60 kDa.9 The Mr and substrate preferences of the MMPs are 
shown in table 1. 
MMPs are usually divided into subgroups based on their molecular 
structure and substrate preference: collagenases, gelatmases, 
stromelysms, matnlysms, membrane-type MMPs, and a rest group of 
MMPs.76 The proteins consist of a signal peptide (mtracellularly), 
propeptide, catalytic domain (which contains one or more zinc atoms), 
and a haemopexm domain. The general structure and the variations in 
18 
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the main groups of MMPs are shown In figure 2. First, the function of the 
domains and their variations will be discussed. Next, the structure of the 
domains will be further discussed in detail. 
The signal peptide at the N-terminus directs the MMP to the cell 
membrane, where it is clipped off when the MMP is secreted. The 
prodomain occupies the zinc at the active site, thereby inactivating the 
enzyme. Once the prodomain is removed, the catalytic domain can bind 
to its substrates. Mostly, the activation takes place at a cysteine that is 
coupled to the catalytic zinc. However, some MMPs such as the 
membrane-type (MT)MMPs, have a furin cleavage site, which enables 
intracellular activation.72 The binding to substrates is determined by the 
structure of the substrate binding site, especially by a 'pocket' next to the 
zinc atom. This pocket varies in depth among MMPs, and plays an 
important role in substrate specificity.77 In contrast to the other MMPs, 
the gelatinases contain a fibronectin domain within the catalytic domain, 
which enables binding to gelatin, elastin, and type IV collagen.78,79 The 
haemopexin domain is also important for substrate specificity, especially 
for the binding of collagenases to collagen.80 In the gelatinases it serves 
as a binding site forTIMPs.81 Specifically for pro-MMP-2, the binding of 
TIMP-2 to the haemopexin domain leads to activation, if the TIMP is 
subsequently bound to MT1-MMP. An other MT1-MMP that is not bound 
by TIMP-2 will activate the pro-MMP-2.82 
The matrilysins differ from the other MMPs by the lack of the 
haemopexin domain. The membrane-type MMPs contain a 
transmembrane domain, which anchors the MMP to the cell surface. This 
is thought to be essential to maintain the required orientation of the MMP 
on the cell surface for interaction with substrates or other proteins.83 
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Fig. 2. MMP structure. 
The domains of the main groups of MMPs are depicted. 
A three-dimensional representation of the molecular structure of pro-
MMP-2 is shown in figure 3. It shows, from the N-terminus to the C-
terminus, the prodomain, the catalytic domain, the three fibronectin type 
I I domains, and the haemopexin-like domain. Intracellularly, a signal 
peptide is present at the prodomain of the MMR, which is removed once 
the MMP is secreted. The MMP is still in a non-active state, because of the 
presence of the prodomain. This consists of three α-helices connected by 
2 0 
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loops.84 The loop between the first and second helix is sensitive to 
protease cleavage, which will lead to partial activation. The peptide part 
after the third helix is imbedded in the substrate binding site of the 
catalytic domain.72 This part contains the cysteine switch, the crucial step 
in MMP activation85 that will be discussed further on. The catalytic domain 
consists of a 5-stranded ß-pleated sheet, three α-helices, and connecting 
loops. This domain usually contains two zinc atoms, one of which is 
involved in the catalytic properties of the MMPs, and three calcium 
atoms.7 2 The catalytic domain contains a 'cleft' which binds to its 
substrates.8 6 The catalytic zinc is surrounded by three histidines, and the 
glutamic acid that is connected to the first histidine is essential for 
catalysis. In the case of MMP-2 and MMP-9 three fibronectin domains are 
present in the catalytic domain, between the fifth ß-strand and the 
catalytic site helix.87 The catalytic domain is connected to the 
haemopexin domain by a 'hinge' region, which has a high proline content. 
This plays a crucial role in the collagenolytic activity of MMP-8.88 
Moreover, the hinge region firmly bonds with the catalytic and the 
haemopexin domain, stabilizing the configurations of these domains 
within the molecule, which is required for their action.84 Finally, the 
haemopexin domain has a four-bladed propeller-like shape. This part of 
the MMP determines the substrate specificity to a large extent.89 I t is also 
involved in the activation of MMP-2 by binding to MT1-MMP as described 
earlier. 
21 
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Fn 
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Fig. 3. Three-dimensional 
structure of pro-MMP-2. 
Indicated are, from the N-
terminus (Nt) to the C-
terminus (Ct): the 
prodomain (light-brown), 
the catalytic domain (pink) 
with its structural and 
catalytic zinc (purple 
spheres), and two calcium 
ions (orange spheres), the 
three fibronectin type II 
domains (yellow, dark 
blue, lime), and the four 
blades of the haemopexin-
like domain (light-blue) 
with up to three ions 
(yellow/green spheres) In 
its centre. (With courtesy 
of Dr. Morgunova, who 
developed the model, and 
Prof. W. Bode, who 
adapted it.90 This figure is 
a modification of the latter. 
Reprinted with permission 
from John Wiley & Sons 
Inc.). 
The activation of MMPs is schematically represented in figure 4. 
The activation can be direct or stepwise. Proteolytic activation can 
directly activate the MMP, although in many cases proteolytic activation 
will also follow the stepwise pathway. Stepwise activation results in an 
intermediate active MMP form.72,91 Activation of the pro-enzyme may 
occur by proteolytic enzymes like plasmin,92,93 but also other MMPs, like 
MMP-3,94·95 and MT1-MMP.83 In addition, MMPs can be activated by 
chemical agents, low pH, reactive oxygens, and heat.96,97The pro-enzyme 
is activated through disturbance of the interaction between the zinc and 
the cysteine in the catalytic domain. This is also described as the 
'cysteine switch',85 as shown in figure 4. In stepwise activation, firstly, a 
part of the prodomain is removed, which destabilizes the rest of the 
prodomain. This can then be removed by other MMPs. Although most 
MMPs are only activated extracellularly, MMP-11 can be activated 
intracellularly by furin.98 MT1-MMP is known to be involved in MMP-2 
22 
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activation. This involves the dimerisation of two MTl-MMPs, of which one 
binds to TIMP-2. Pro-MMP-2 binds to TIMP-2 with its haemopexin domain 
and to the other MT-MMP with its prodomain. The MTl-MMP then cleaves 
the prodomain, thereby partially activating MMP-2. 
Fig. 4. Activation of M MPs. 
The activation of MMPs can be direct or stepwise. The thiol group of a cysteine 
(CYS) at the prodomain (red) binds to the catalytic zinc atom (Zn), thereby 
inactivating the catalytic domain (green). Once the prodomain is displaced by 
conformational change or proteolysis, the cysteine-zinc connection is disrupted 
and the thiol group is replaced by water. This is also known as the 'cysteine 
switch'. A conformational change occurs in the stepwise activation, in which a 
part of the prodomain is removed first. This results in an intermediate active 
MMR. The intermediate form can be further activated after removal of the rest of 
the prodomain. 
23 
Table 1 
Matrix metalloproteinases and their substrates 
Name 
Collagenases 
Gelatmases 
Stromelysms 
Matnlysms 
MT-MMP 
Other 
Number 
MMP-1 
MMP-8 
MMP-13 
MMP-2 
MMP-9 
MMP-3 
MMP-10 
MMP-11 
MMP-7 
MMP-26 
MMP-14 
MMP-15 
MMP-16 
MMP-17 
MMP-24 
MMP-25 
MMP-12 
MMP-19 
MMP-20 
MMP-21 
MMP-23 
MMP-27 
MMP-28 
M w ( k D 
Latent 
58/52 
85/75/64 
60 
72(68) 
92 
60/57 
57 
64 /58 /51 
47/45 
30/28 
28 
66/63 
72 
64 
57 
73 
57 
54 
58, 55 
57/54 
58 /51 
58/28 
56 
59 
a) 
Active 
4 4 / 4 1 , 37, 28 
55/58/48/45 
48 
66/62 
82/69 
55/45 
44 
44/28 
21/19 
19 
60 /56 /45 
60/50/45 
52/45 
53 
58 
45 
45/22 
45 /47 , 28 
46/22 
46 
45/19 
45 
45 
Substrate 
Collagen type I, I I , I I I , V I I , V I I I , X, gelatin 
Idem + aggrecan 
Idem + collagen type IV, IX, and XIV 
Gelatin, collagen type I, I I , I I I , IV, V I I , X 
Gelatin, collagen type IV, V 
Collagen type I I , IV, IX, X, XI , gelatin 
Collagen type IV, lammm, fibronectin, elastm 
Idem as MMP-10, + aggrecan, - elastm 
Fibronectin, lammm, collagen type IV, gelatin 
Fibrinogen, f ibronectin, gelatin 
Gelatin, f ibronectin, lammm 
Idem 
Idem 
Idem 
Idem 
Idem 
Elastm, f ibronectin, collagen type IV 
Aggrecan, elastm, f ibri l l in, collagen type IV, 
gelatin 
Aggrecan, enamelm 
Aggrecan 
Gelatin, casein, f ibronectin 
No substrates defined 
No substrates defined 
Substrates and molecular weights of human M MPs. 
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The main function of MMPs is the degradation of ECM components. The 
substrates of the MMPs are displayed in table 1. Overlap exists for many 
MMPs, although they have certain substrate preferences. Moreover, the 
ECM contains numerous biologically active proteins that are released 
during ECM degradation. Thereby, MMPs can indirectly induce a wide 
variety of biological effects, like cell migration, apoptosis, differentiation, 
and so on, through increased availability of growth factors (overview 
in72). 
3.2 Tissue inhibitors of metalloproteinases 
MMP activity is controlled by endogenous inhibitors like a2-macroglobulin, 
reversion inducing cysteine-rich protein with Kazal motifs (RECK), 
thrombospondin-1 and -2, and the tissue inhibitors of MMPs (TIMPs).105 
TIMPs are thought to be the main mechanism of inhibition of MMPs in the 
tissue.106 To date, four TIMPs are known. They form a 1:1 complex with 
MMPs, and can essentially bind to all MMPs.78 The TIMPs consist of two 
domains, each being stabilized by three disulfide bonds.107 These are a 
C-terminal domain of 65 amino acids and an N-terminal domain of about 
125 amino acids (Fig 5). The Mr of TIMPs ranges from 21 to 28 kDa 
(table 2).8 The C-terminal domain is responsible for the formation of non-
inhibitory complexes, whereas the N-terminal domain is responsible for 
the inhibition of MMP-activity.108 A three dimensional picture of the 
secondary structure of TIMP-2 is shown in figure 5. 
Table 2 
Molecular weights of TIMPs 
TIMP-1 
TIMP-2 
TIMP-3 
TIMP-4 
28 kDa 
21 kDa 
27/24 kDa 
23 kDa 
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Fig. 5. Secondary structure of TIMP-2. 
The three-dimensional structure of TIMPs is 
wedge-shaped, which is essential to fit into the 
active centre of an MMP. (From RCSB Protein Data 
Bank, accession no. Ibr9) 
The structural basis of MMP inhibition has thoroughly been studied for 
TIMP-1 and MMP-3. As the other TIMPs, TIMP-1 has a wedge-like shape, 
which inserts into the catalytic site and the substrate binding part of the 
MMP-3 molecule. The TIMP molecule binds to six different parts of MMP-
3. Upon binding, the N-terminal domain of the MMP forms a cap over the 
TIMP.106 
Although all TIMPs bind to all MMPs, their affinity for specific MMPs 
may differ slightly. TIMP-2 and -3 can inhibit MT-MMPs, whereas TIMP-1 
and -4 do not. TIMP-3 is the only TIMP that inhibits TNF-α convertase, 
which is also a metalloproteinase.1 0 9 The TIMPs also differ in the 
formation of non-inhibitory complexes. For instance, TIMP-2 and -4 are 
known to bind to MMP-2, which may lead to its activation. TIMP-1 binds 
to MMP-9, and has also been suggested to activate i t . 8 1 Especially the 
ratio of MT-MMPs to TIMP-2 is important in the activation of MMP-2. If 
more MTl-MMP is present than TIMP-2 activation of MMP-2 will occur. If 
more TIMP-2 is present, inhibition occurs.8 2 Previous studies have shown 
that it is very difficult to extract TIMP-3 from tissues since it strongly 
binds to ECM components through its C-domain.1 1 0 In conclusion, 
although the TIMPs share common characteristics, they have distinctive 
features with regard to MMP inhibition. 
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Next to their effects on MMPs, TIMPs display several other 
biological functions. TIMP-1 can stimulate cell proliferation,111,112 but 
tumour cell growth is inhibited.113 Overexpression of TIMP-3 can even 
result in apoptotis of cancer cells.114 TIMP-2 inhibits endothelial cell 
growth and stimulates the growth of other mesenchymal cells.106 Despite 
the importance of TIMPs in ECM turnover, the role of TIMPs in periodontal 
remodelling, such as during orthodontic tooth movement, has not been 
studied extensively. 
3.3 Synthetic inhibitors 
Next to the naturally occurring inhibitors of MMPs, synthetic MMP 
inhibitors have been developed. They are thought to have therapeutic 
potential in diseases that involve extensive tissue destruction like 
arthritis, Sorby's fundus dystrophy, Alzheimer's disease, liver fibrosis, 
emphysema, metastasis and periodontitis.74 Synthetic inhibitors are 
thought to function as chelating agents that 'block' the active centre of 
the MMP molecule. Several zinc-binding MMP inhibitors have been tested 
including phosphoric acid dérivâtes, hydroxymates, aminocarboxylates 
and tetracycline dérivâtes. Hydroxymates have been studied most 
extensively, although the interest in tetracyclines has also increased 
because of their biocompatibility and easy administration.115 This makes 
them most promising for therapeutic use. About seven of these synthetic 
inhibitors are currently being studied for clinical use and one has already 
been approved for therapeutic use in periodontitis.116117 
Tetracyclines are commonly used as antibiotics, but in the eighties 
it was discovered that they are also able to inhibit MMPs.118 The 
tetracycline molecule typically consists of four hydrocarbon rings. The 
dimethylamino group is required for the antimicrobial activity of 
tetracyclines. By removing this group, the tetracycline molecule loses its 
antibacterial properties, but its 'anti-MMP' property remains.119 These 
modified tetracyclines were called 'Chemically Modified Tetracyclines' 
(CMTs). An example of one of these, chemically modified tetracycline-3, 
is shown in figure 6. 
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Fig. 6. Molecular structure of CMT-3: 4-dedimehtylamino sancycline. 
Molecular formula: C19H17O7N Mw: 371,346 (Figure produced with Wm-PLT 
V7.1). 
CMTs might have an important therapeutic application in 
pathological processes that include increased breakdown of extracellular 
matrix.115 CMTs have been studied for the treatment of 
periodontitis,120121 osteoporosis,122 osteoarthritis,123 and tumour 
metastasis.124 Especially CMT-3, currently named COL-3, has been 
studied for several applications. These studies show that CMT-3 
significantly improves survival and lung injury in acute respiratory 
distress syndrome after sepsis,125 it reduces tumour activity in patients 
with AIDS-related Kaposi's sarcoma,117 reduces tumour incidence and 
metastasis of prostate cancer,124 and inhibits intimai hyperplasia after 
arterial injury.126 
Several researchers have explored the potential therapeutic 
application of synthetic MMP inhibitors in pathological MMP-mediated 
breakdown, as has been extensively reviewed.116127 The test results in 
cancer were with varying success and part of the failure of the MMP 
inhibitors was due to methodological deficiencies. Moreover, at higher 
dosages musculoskeletal side effects have emerged. Many synthetic 
inhibitors have therefore not been developed further for clinical use. 
However, tetracyclines have already been used safely for a long time, in 
higher dosages than required for MMP inhibition (e.g. tetracycline, 
doxycycline, minocycline). Obviously, the newer tetracycline dérivâtes 
(CMTs) have to be studied thoroughly before clinical use. Since 
periodontal ECM degradation occurs due to the activity of MMPs in 
orthodontic relapse, CMTs might help to prevent this problem. Similarly, 
they might be useful to prevent root resorption. Also, CMTs may be 
28 
General introduction 
useful in periodontitis-affected patients that require orthodontics, since 
previous studies have shown that CMTs reduce alveolar bone loss in 
periodontitis.120128 
4. MMPs and TIMPs in periodontal remodeiiing 
4.1 Orthodontic tooth movement 
MMPs and TIMPs are actively involved in periodontal remodelling 
induced by mechanical forces.129 Experimental orthodontic tooth 
movement in animals, mostly rats, shows an increased expression of 
MMP-1, -8, and -13, and TIMP-1 and -3, in the PDL and alveolar 
bone.619,32,38 MMP-1 was also up-regulated in the gingiva during tooth 
movement in dogs.130 MMP-1, -8, and -13, also known as the 
collagenases, are the initial MMPs involved in breakdown of the collagen 
triple helix. MMP-2 and -9, the gelatinases, are required for further 
processing of the cleaved collagen molecules. An immunohistological 
study in rats showed that MMP-2 and -9, and TIMP-1 and -3 were 
transiently increased at both the resorption side and the apposition side 
during orthodontic tooth movement.6 
Studies in orthodontic patients show that MMP-2 and -8, and 
sometimes also MMP-1, are increased in the GCF.7·129·131'132 MMP-1 mRNA 
expression was increased at both the resorption side and the apposition 
side, but TIMP-1 mRNA was increased only at the apposition side.7 An 
other study showed that MMP-1 and MMP-2 protein was specifically 
increased at the resorption side.131 Both at the apposition and the 
resorption side, extensive remodelling takes place. At the resorption side, 
not only the ECM of the PDL has to be degraded, but also the alveolar 
bone. At the apposition side, fibres of the ECM are elongated and 
ruptured, which requires remodelling to adapt to the new situation. The 
up-regulation of MMPs and TIMPs during orthodontic tooth movement 
may occur directly by the mechanical force,132133 or indirectly via the up-
regulation of cytokines that stimulate MMP production. The interleukins 
IL- lß and IL-6, TNF-c, and prostaglandin E are all transiently expressed 
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in the PDL when an orthodontic force is applied.135137 These cytokines are 
known to stimulate the expression of MMPs and TIMPs.138141 
In conclusion, the MMPs and TIMPs involved m orthodontic tooth 
movement have not been studied extensively, and, if so, mainly in animal 
studies. The studies described m this thesis attempt to broaden this 
knowledge. 
4.2 Periodontitis 
As in orthodontic tooth movement, increased periodontal remodelling 
occurs m periodontitis remodelling. In contrast, the balance between 
synthesis and degradation of the extracellular matrix (ECM) is disturbed 
in periodontitis. A relative over activity of MMPs compared to TIMPs 
results in the breakdown of periodontal structures.55 MMPs and TIMPs in 
periodontitis have been studied more extensively than in orthodontics. 
The present knowledge is mainly based on MMPs and TIMPs in gingival 
crevicular fluid and gingival tissue itself. PDL tissue is hardly studied, but 
histological studies in rats showed that MMPs are expressed in the 
PDL.19-20 
In gingival crevicular fluid (GCF) from deep pockets more active 
and latent MMP-1, -3, -8, and -9 were found than m that from healthy 
sulci. The amounts of TIMP-1 and -2 were lower m the GCF of 
periodontitis patients compared to that of healthy subjects.2122 '24 The 
total MMP-2 content was also reported to be higher in GCF from inflamed 
pockets,22 whereas others have found no MMP-2 at all.142 This might be 
due to the use of different analytical methods. Overall, these earlier 
studies indicate a relative overexpression of MMPs compared to TIMPs in 
GCF during periodontitis. 
Controversy exists on the MMP and TIMP content in gingiva. The 
total amounts of MMP-1, -2, -3, and -9 are shown to be higher in 
inflamed gingiva.1222 Others found higher levels of both the latent and 
the active form of MMP-2, and the active form of MMP-9 in inflamed 
gingival.143 However, the total amounts of MMP-2 were similar m healthy 
and diseased gingiva. Smith and co-workers found more pro-MMP-9 m 
diseased gingiva, and equal amounts of latent and active MMP-2, 
although these findings were not quantified.144 MMP mRNA levels were 
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also contradictory In different studies; MMP-1 mRNA was reported to be 
increased in inflamed gingival tissue.29145 An other study shows that the 
levels of MMP-1, -2 , and -14 mRNA in healthy and diseased gingiva are 
similar.30 According to the authors, this might have been due to the large 
individual variation. In summary, MMP levels in diseased gingiva tend to 
be higher than in healthy gingiva, although the data are not consistent. 
Controversial results are also reported for TIMP levels. These have 
been found to be reduced,22 similar,12 or even higher in inflamed 
gingival.143 These differences are probably due to the different methods 
used. So far, the MMP and TIMP levels in gingiva, PDL and GCF of 
periodontitis patients and healthy subjects have not been compared 
directly in one study. This might clarify some of the controversies found 
in the previous studies. 
When periodontitis-affected teeth are subjected to orthodontic 
forces, enhanced destruction of the alveolar bone takes place.15 The 
surplus of MMPs induced by the mechanical factor adds to the 
overexpression of MMPs due to the inflammatory process. Therefore, the 
clinician has to be aware of periodontitis-affected teeth before and during 
orthodontic treatment to prevent periodontal destruction. 
5. Aims of the study 
The specific MMPs and TIMPs involved in periodontal remodelling during 
orthodontic tooth movement are largely unknown. Up to now, most 
studies on MMPs and TIMPs in the periodontium investigate their role in 
periodontitis. Knowledge of the remodelling processes during orthodontic 
tooth movement, and the role of MMPs and TIMPs may contribute to 
increased effectiveness and efficiency of orthodontic treatment. The 
analysis of MMPs and TIMPs may provide the clinician information about 
active remodelling during and after orthodontic tooth movement, and the 
occurrence of active periodontal destruction in patients prone to 
periodontitis. Moreover, synthetic MMP inhibitors might have therapeutic 
potential in orthodontics for the reduction of relapse or root resorption. 
31 
The general aim of this thesis is to gain more knowledge on the 
role of MMPs and TIMPs in periodontal remodelling. The following specific 
subjects are investigated: 
- The effect of CMTs on gelatinase production by PDL cells in a 
two-dimensional culture (chapter 2). 
- The effect of MMP inhibitors on MMP and TIMP production by PDL 
cells in a three-dimensional culture (chapter 3). 
- The MMPs and TIMPs in the healthy and diseased periodontium 
(chapter 4). 
- The effect of CMT-3 on tooth movement in a rat model 
(chapter 5). 
- MMPs and TIMPs in GCF from orthodontic patients (chapter 6). 
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Abstract 
Background and Objective 
The purpose of this study was to investigate the effects of Chemically 
Modified Tetracyclines (CMTs) on the production of gelatmases [matrix 
metalloprotemase (MMP)-2 and -9] by human periodontal ligament (PDL) 
cells, and on the activity of recombinant gelatmases. 
Material and Methods 
Human PDL cells were cultured with CMT-1, -3, -5, -7, or -8 in 
concentrations of 0, 1, 5, 10, 20, 50, 100, 200, and 500 μΜ. Gelatin 
zymography was used to determine MMP-2 and -9 production of the cells. 
The amount of DNA present in the cultures was analyzed using a 
fluorescent assay. The cytotoxicity of the CMTs was also determined. 
Recombinant human MMP-2 and -9 were incubated with the CMTs 
(0-500 μΜ) and their activity was analyzed using an internally quenched 
fluorogemc substrate. 
Results 
MMP-2 production was stimulated up to sevenfold by CMT-1, -3, -7, and 
-8 at low concentrations (10-200 μΜ). No significant amounts of MMP-9 
were produced. In contrast, MMP-2 and -9 activity was reduced by 
~ 10-40-fold at higher concentrations (200-500 μΜ). CMT-5 had no effect 
on the production or on the activity of MMP-2 and -9. Only CMT-3 and -8 
had cytotoxic effects on the PDL cells at the highest concentrations. 
Conclusion 
Surprisingly, CMTs are able to stimulate MMP-2 production at relatively 
low concentrations. However, at higher concentrations they exert a much 
stronger inhibitory effect on gelatmase activity. A possible stimulatory 
effect of CMTs on MMP production should be considered in their clinical 
use. 
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Introduction 
The primary function of the periodontal l igament (PDL) is to attach 
the teeth to the alveolar bone. In addit ion, the PDL provides 
resistance against tensional and compressive forces, and it regulates 
mastication through mechanoreceptors.1 The PDL is a highly cellular 
tissue that contains several cell types, such as fibroblasts, 
cementoblasts, osteoblasts, osteoclasts, epithelial cells, and 
progenitor cells.2 The fibroblasts are the predominant cell type and 
they are responsible for the synthesis and degradation of the 
extracellular matrix molecules. The PDL has a relatively high turnover 
rate compared with other connective tissues.3 I t can therefore adapt 
quickly to mechanical forces, such as during orthodontic tooth 
movement.4 ,5 
Matrix metalloproteinases (MMPs) play an important role in 
the degradation of the extracellular matrix of the PDL during 
remodeling.6,7 At present, 23 human MMPs are known.7"9 Besides 
their role in physiological remodeling of the periodontium and its 
adaptation to orthodontic tooth movement,10 they also play a role in 
pathological tissue degradation, such as in periodontit is.11 Several 
MMPs have been detected in crevicular f luid, and MMP-2, -3 , -8 , -13, 
and -14 were found to be elevated in fluid samples from teeth that 
were affected by periodontitis.11"13 Elevated MMP levels have also 
been detected in the crevicular fluid of orthodontic patients.14 
Proteolytic enzymes, such as urokinase- and tissue-type plasminogen 
activators, can activate MMPs.15,16 Furthermore, MMP-14, a 
membrane-bound MMP, can activate MMP-2.17 At the transcriptional 
level, MMPs are regulated by factors, such as cytokines and 
fibronectin.18 
During the late 1980s, it was discovered that tetracyclines have 
an inhibitory effect on MMP activity.19 This led to the development of 
chemically modified tetracyclines (CMTs), which have lost their 
antimicrobial activity but retain their anti-MMP activity.20 The 
mechanism of action of CMTs is still not completely clear. Several 
mechanisms for the inhibition of activity of MMPs have been 
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postulated. CMTs may down-regulate MMP expression, inhibit pro-
MMP activation, or directly inhibit active MMPs, by binding to the 
active Zn2 + site and the Zn2 + at a secondary site of the MMP 
molecule.21 Moreover, it has become clear that CMTs, by inhibiting 
MMPs, also disturb the balance between MMPs and their naturally 
occurring inhibitors, the tissue inhibitors of matrix metalloprotemases 
(TIMPs).22 Several authors have investigated the effects of CMTs on 
MMP activity m vitro."'26 CMT-3 and -8 appear to be the most potent 
inhibitors of MMP activity. CMT-1 also affects MMP activity, but it is 
less powerful. CMT-5 has no inhibitory effects on MMP activity and is 
therefore often used as a control CMT. Only a few studies have 
focused on the effects of CMTs on the production of MMPs m vitro. A 
marked decrease of MMP-2 mRNA levels is found m keratmocytes by 
doxycyclme, CMT-1, and CMT-8.27 Others have shown that CMT-3 is 
able to inhibit the production of MMP-2 by human colon carcinoma 
cells.28 
PDL cells play an important role in both the periodontal tissue 
breakdown during periodontitis and the remodeling of the 
periodontium during orthodontic tooth movement. Therefore, PDL 
cells were used m this study. Despite their therapeutic potential m 
dentistry, little is known about the effect of CMTs on MMP production 
by human PDL cells. Therefore, the aim of this study was to 
investigate the effect of CMT-1, -3 , -5 , -7 , and -8 on the gelatmases 
(MMP-2 and -9) produced by human PDL cells. 
Material and methods 
Chemically modified tetracyclines 
The CMTs 4-dedimethylamino tetracycline (CMT-1), 4-dedimethylamino 
sancyclme (CMT-3), tetracycline pyrazole (CMT-5), 12a-dehydroxy-4-
dedimethylammo tetracycline (CMT-7), and 4-dedimethylamino 
doxycyclme (CMT-8), were kindly provided by CollaGenex 
Pharmaceuticals, Inc. (Newtown, PA, USA). 
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Cell culture 
Human PDL tissue was obtained from an extracted, fully erupted, healthy 
third molar. After extraction, the third molar was washed in saline and 
stored at 40C in phosphate-buffered saline (PBS) (Gibco, Paisley, UK) 
containing 100 U/ml penicillin and 100 pg/ml streptomycin (Gibco). 
Expiants were obtained by cutting the PDL tissue from the lower half of 
the root, until 2 mm from the apex. The expiants were washed 
extensively in fresh culture medium consisting of Dulbecco's modified 
Eagle's medium (DMEM; Gibco), 10% fetal calf serum (PCS; Gibco), and 
100 U/ml penicillin and 100 pg/ml streptomycin. The expiants were 
incubated in one well of a 24-well culture plate at 370C in a humidified 
atmosphere of 5% CO2 in air. The culture medium was changed three 
times per week. After the outgrowth of fibroblasts, the cultures were 
trypsinized with 0.25% trypsin (Gibco) and consecutively passaged to 
culture flasks of 25, 75, and 175 cm 2 (Greiner Bio-One B.V., Alphen a/d 
Rijn, the Netherlands). After a culture period of ^ 3 wk, the cells (passage 
4) were frozen in 7.5% dimethylsulfoxide (DMSO; ICN Biomedicals, Inc., 
Aurora, OH, USA) in culture medium and stored in liquid N2. The cells 
tested positive for alkaline phosphatase activity, indicating that these 
cells were indeed PDL cells and not from gingival origin. 
Incubation with CMTs 
Before the experiments, the cells were rapidly thawed at 370C, diluted in 
culture medium and centrifuged at 400 g for 5 min. The cell pellet was 
resuspended in culture medium and seeded in a 75-cm2 culture flask. At 
8 0 - 9 0 % confluence, the cells were passaged to two, 75-cm2 flasks. At 
8 0 - 9 0 % confluence, they were trypsinized and transferred to 24-well 
culture plates (100,000 cells/well) for the MMP assays and to 96-well 
culture plates (25,000 cells/well) for the cytotoxicity assay. All cells were 
then cultured in medium with DMEM, but without phenol red, for 1 day. 
Then, the cells were washed with DMEM without phenol red. The 
following 24 h, quadruple cultures were incubated with increasing 
concentrations of CMT-1, -3, -5, -7, and -8. Each CMT was dissolved in 
DMSO and diluted to give final concentrations of 0, 1, 5, 10, 20, 50, 100, 
200, and 500 μΜ in DMEM containing 2% DMSO, but without phenol red. 
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DMSO at 2% did not affect cell viability. DMSO concentrations up to 2% 
also do not affect MMP production by cultured cells, as shown 
previously.2 9 
Gelatin zymography 
Gelatinases m the culture media were analyzed by gelatin 
zymography. Zymograms of samples of recombinant MMPs incubated 
with CMTs ( 0 - 5 0 0 μΜ) showed no inhibitory activity of CMTs during 
zymography. The Polyacrylamide gel (7.5%) contained 3.5 mM 
sodium dodecyl sulphate (SDS) and 1 mg/ml gelatin, as described 
previously.3 0 All samples from the quadruple cultures of each CMT 
were loaded onto four gels and each gel contained the full series of all 
concentrations of that CMT. A mixture of 10 μΙ of culture medium and 
10 μΙ of sample buffer was electrophoresed. A broad-range marker 
(Bio-Rad, Hercules, CA, USA), ranging from 6.4 to 203 kDa, was 
included to determine the molecular weight of the MMPs. 
Recombinant human pro-MMP-9 (Oncogene; CN Biosciences, San 
Diego, CA, USA) was used as a reference sample. After 
electrophoresis, the gels were washed in 2.5% Triton X-100 (Sigma-
Aldrich, St Louis, MO, USA) to remove all SDS. They were then 
incubated m 50 mM Tris-HCI (pH 7.8), containing 5 mM CaCh and 
0 . 1 % Triton X-100, at 37 0 C for 18 h. The gels were stained with 2.5 
g/l Coomassie Blue and destained with 10% acetic acid and 4 0 % 
methanol in water. The MMPs appear as bright bands within the 
stained gel. Thereafter, the gels were scanned with an HP ScanJet 
4C/T (Hewlett-Packard Company, Palo Alto, CA, USA) and the bands 
were analyzed using Quantity One software (Bio-Rad). The amount of 
gelatinolytic activity of each band was calculated as average density χ 
mm 2 /ng of DNA. The pro-MMP-9 served as a reference sample, 
enabling comparison of the four gels of each CMT. The amount of 
gelatinolytic activity of the pro-MMP-9 reference sample was 
arbitrari ly set to 100% in each gel. All experimental samples were 
expressed relative to this reference. Then, the incubations with CMTs 
were expressed relative to the control (0 μΜ) and the results of the 
quadruple gels were averaged. 
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Western blotting 
The identity of the bands in the gelatin zymograms was confirmed by 
western blotting. Concentrated samples of conditioned medium were 
processed for western blotting according to standard procedures.3 1 In 
short, a 10-μΙ sample was dissolved in 10 μΙ of sample buffer and 
electrophoresed through a 7.5% Polyacrylamide gel until the 
bromophenol blue front reached the bottom of the gel. Then, the proteins 
were blotted onto a nitrocellulose membrane (Bio-Rad) and the 
membrane was incubated with blockbuffer, which consisted of 3% bovine 
serum albumin (BSA; Sigma-Aldrich) and 0 . 1 % Tween 20 (Sigma) in 
PBS. Thereafter, the blots were incubated with the first antibodies 
(dilution 1 : 200) at 40C for 18 h. A monoclonal antibody recognizing the 
latent and active forms of MMP-2, and a monoclonal antibody recognizing 
the latent, intermediate and active forms of MMP-9 (both Oncogene) 
were used. After washing with PBS containing 0 . 1 % Tween 20, the blots 
were incubated, for 1 h, with a peroxidase-conjungated goat anti-mouse 
immunoglobulin G (IgG) (GAMPO; BD Biosciences, San Jose, CA, USA), 
diluted 1 : 4000 in PBS containing 1 % BSA and 0 . 1 % Tween. After 
washing, the membrane was incubated with ECL Plus reagent 
(Amersham, Chicago, IL, USA) for 4 min for detection by chemi-
luminescence. Excess ECL reagent was removed and the membrane was 
exposed to a Kodak Biomax film (Eastman Kodak Company, Rochester, 
NY, USA) for 1 h and developed thereafter. 
MMP-actlvlty assay 
The MMP-activity assay was performed to analyze the effect of CMTs on 
the activity of recombinant gelatinases. CMT-1, -3, -5, -7, and -8 were 
dissolved in DMSO and diluted in DMEM without phenol red to give final 
concentrations of 0, 1, 10, 100, and 500 μΜ in 2% DMSO. A standard 
amount of 1 nM of recombinant MMP-2 and -9 were incubated with these 
CMTs at 370C for 1 h. The MMP-activity assay was performed according 
to the method of Beekman et a/.32 In short, the fluorogenic substrate, 
TN0211-F (TNO, Leiden, the Netherlands) was used to determine the 
activity of recombinant MMP-2 and -9 (Oncogene) in the presence and 
absence of CMTs. TN0211-F consists of a fluorophore and a light-
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absorbing group (quencher) attached to an ammo acid sequence that 
serves as a substrate for MMPs. Through enzymatic cleavage by the 
MMPs, the quencher is eliminated and the fluorescence can be measured. 
The fluorescent signal was measured in a Cytofluor I I fluonmeter 
(PerSeptive Biosystems, Frammgham, MA, USA) at emission 485 nm and 
excitation 530 nm, and expressed as relative fluorescence units (RFU) 
per second. 
DNA assay 
The PicoGreen®dsDNA Quantitation reagent (Molecular Probes, Inc., 
Eugene, OR, USA) was used to determine the amount of DNA in the 24-
well plates. PicoGreen is a fluorescent nucleic acid stain for double-
stranded DNA. The assay was performed according to the protocol of the 
manufacturer The fluorescent signal was measured in an FL600 
Microplate Fluorescence Reader (Bio-Tek Instruments Inc., Wmooski, VT, 
USA) at excitation 485 nm, emission 520 nm. Standards ranging from 0 
to 1000 ng/ml of bacteriophage lambda DNA were used. The total 
amount of DNA in each well was calculated. 
Cytotoxicity assay 
To determine the cytotoxicity of the CMTs, the Live/Dead®Viability/Cyto-
toxicity assay (Molecular Probes) was used on the cells in the 96-well 
plates. In this assay, calcein acetoxymethyl and ethidium homodimer-1 
are simultaneously used to determine the percentages of viable and dead 
cells. The assay was performed according to the protocol of the 
manufacturer. The fluorescence was measured m a FL600 Microplate 
Fluorescence Reader (Bio-Tek Instruments Inc.) at excitation 485 nm and 
emission 530 nm for calcein and excitation 530 nm and emission 645 nm 
for ethidium homodimer-1. The data were expressed as the percentage 
of live and dead cells. 
Statistical analysis 
Data are presented as mean ± standard deviation (SD). The effect of 
CMTs on the production of MMP-2 was evaluated by a Kruskall-Wallis 
one-way analysis variance (ANOVA) followed by Dunnett's post hoc test. 
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The effect of CMTs on gelatinase activity was evaluated by a one-way 
ANOVA, followed by the Bonferroni test. The effect of DMSO was tested 
with the Student's i-test. Differences were considered statistically 
significant at ρ <0.05. 
Results 
Gelatinase production 
The gelatin zymograms show that PDL cells mainly produce gelatinase 
activity in bands at 69 and 62 kDa (Fig. 1A). Bands at ~92 kDa were 
rarely seen and, if so, were faint. Sometimes, minor amounts of MMP 
complexes were found at >120 kDa. A pro-MMP-9 reference, used to 
compare the zymograms, shows the latent form (92 kDa), the 
intermediate form (85 kDa, faint) and the active form (68 kDa, fa int) . 
Western blotting with an antibody against MMP-2 shows that the 69-
and 62-kDa bands are the latent and the active forms of MMP-2, 
respectively (Fig. I B ) . MMP-9 was not detected in the medium (Fig. 
I B ) . 
anti-MMP-2 anti-MMP-9 
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Ffg. 1. Representative zymogram and western blots. (A) Gelatin zymography. 
Human periodontal fibroblasts were incubated with chemically modified 
tetracycline-3 (CMT-3) at concentrations ranging from 0 to 500 μΜ. Gelatin 
zymography of the conditioned medium shows bands at 62 and 69 kDa. The last 
lane of the zymogram represents a control with recombinant pro-matrix 
metalloproteinase-9 (pro-MMP-9). (B) Western blotting on concentrated culture 
media, using an antibody against human MMP-2, confirmed the bands at 62 and 
69 kDa to be the active and latent forms of MMP-2. The band of »138 kDa in the 
sample with recombinant pro-MMP-2 probably represents a dimer of pro-MMP-2. 
The antibody against MMP-9 detected the MMP-9 standard, but MMP-9 was not 
found in the conditioned media. 
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Fig. 2. Quantitation of ΜΜΡ-2 
production in the culture media. 
MMP-2 production was analyzed 
with gelatin zymography and 
expressed as mean density χ m m 2 
per ng DNA relative to the MMP-9 
reference sample. The MMP-2 
production in the control was 
arbitrari ly set to 1. The other 
experimental samples were 
expressed relative to the 
control. * Significant difference 
compared with the control. D 
represents the control without 
DMSO. a.u., arbitrary units; CMT, 
chemically modified tetracycline. 
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Fig. 3. The effect ofCMTs on 
gelatinase activity. Recombinant 
MMP-2 and -9 were incubated 
with CMTs and the degradation 
of a fluorescent substrate was 
expressed as relative fluorescence 
units (RFU)/s. A control without 
DMSO (D) showed that DMSO 
alone did not have a significant 
effect on MMP-2 activity. 
* Significant difference compared 
with the control, a.u., arbitrary 
units. 
D 0 5 10 50 100 200 500 
μΜΟΜΤ 
Fig. 4. Cytotoxicity of 
CMTs. The viabil ity of cells 
was analyzed with a 
cytotoxicity assay and 
expressed as percentage 
viable cells. * Significant 
difference compared to the 
control. D, control without 
DMSO. 
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The quantified data of the experimental samples are shown in 
Fig. 2. CMT-1 induced a significant Increase, of 222 ± 6 4 % , in the 
amount of active MMP-2 at 200 μΜ compared with the control. CMT-3 
increased the amount of latent MMP-2 at 50 and 100 μΜ with 383 ± 
1 7 1 % and 722 ± 4 2 2 % , respectively. No significant effect on the 
amount of active MMP-2 was found, although the trend was similar to 
its latent form. CMT-5 had no significant effect on the amount of both 
forms of MMP-2, although there seemed to be a small Increase at 5 0 -
100 μΜ. The amount of active MMP-2 was Increased to 151 ± 1 0 % by 
CMT-7 at 50 μΜ and its latent form was increased at 10, 50, and 100 
μΜ to 294 ± 56, 275 ± 24, and 210 ± 6 0 % , respectively. The amount 
of active MMP-2 was Increased at 200 μΜ, by CMT-8, to 174 ± 1 3 % , 
and the latent form was Increased at 5 and 200 μΜ to 140 ± 2 3 % and 
141 ± 15%, respectively. No significant overall effect of DMSO on 
gelatlnase production was found (p < 0.05). 
Gelatinase activity 
CMT-1, -3, -5, -7, and -8 were tested for their ability to inhibit 
recombinant human MMP-2 and MMP-9. A control without DMSO was 
used to evaluate the effect of DMSO on MMP-2 activity. MMP-2 
activity was not significantly Influenced by DMSO (Fig. 3). MMP-2 
activity was significantly reduced to 42 ± 1 1 % and 5.5 ± 2.0%, at 
200 and 500 μΜ CMT-1, respectively, compared to the control without 
CMT. MMP-9 activity was reduced to 13 ± 2.9% at 500 μΜ CMT-1. 
CMT-3 induced a reduction of MMP-2 activity to 67 ± 6 . 1 , 36 ± 3.6 
and 1.7 ± 0.7% at 100, 200, and 500 μΜ, respectively. This CMT 
showed the strongest inhibitory effect of all CMTs tested. MMP-9 
activity was found to be reduced to 40 ± 21 and 2.9 ± 0.6% at 200 
and 500 μΜ CMT-3, respectively. CMT-5 had no effect on MMP-2 or 
MMP-9 activity. CMT-7 showed an inhibitory effect on both 
gelatlnases; MMP-2 activity was reduced to 37 ± 4.0% at 200 μΜ and 
to 2.1 ± 0.2% at 500 μΜ, and MMP-9 activity was reduced to 49 ± 
1 1 % at 200 μΜ and to 8.2 ± 5.8% at 500 μΜ. With CMT-8, the 
activity of both gelatinases was significantly reduced only at 500 μΜ. 
MMP-2 activity was reduced to 9.9 ± 8.8%, and MMP-9 activity to 21 
± 2 0 % . 
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Cytotoxicity 
Cytotoxic effects of the CMTs were assessed using a cytotoxicity 
assay (Fig. 4) . CMT-1, -5, and -7 showed no significant cytotoxic 
effects on the PDL cells, although CMT-5 showed a decreasing trend 
in the percentage of viable cells. CMT-7 showed a peak in the 
percentage of viable cells at 500 μΜ, but this was caused by the 
yellow color of the CMT itself. CMT-3 and -8, however, showed a 
significant reduction of viable cells at the highest concentrations. 
Discussion 
In this study, the effects of CMTs on PDL gelatinases were 
investigated. Gelatin zymography of the culture media showed bands 
at 62 and 69 kDa that were shown, by western blott ing, to be the 
active and latent forms of MMP-2. MMP-9 was not detected in the 
media. The gelatin zymograms also showed minor amounts of MMP 
complexes at higher molecular weights. An earlier study also showed 
only the latent and active forms of MMP-2, and no MMP-9 in cultures 
of PDL cells.3 3 However, Wu et a/.34 found gelatinase activity at 92, 
70, 68, 57, and 52 kDa in cultured PDL cells from primary and 
permanent teeth, using gelatin zymography. The band at 92 kDa was 
probably the latent form of MMP-9. I t is known that the active forms 
of MMPs occur mainly in situations with high tissue turnover, such as 
in inflammatory processes or as a response to mechanical f o r c e s . 1 4 1 8 
The active form of MMP-2 was found mainly in gingival fibroblasts 
from patients with periodontit is. 3 5 In our study, the latent form of 
MMP-2 was most abundant, indicating that the periodontium of the 
molar used for this study was healthy. 
In this study, all CMTs, except CMT-5, had a strong inhibitory 
effect on the activity of MMP-2 and -9. This is consistent with the 
results of others, although the extent of inhibition was found to 
vary. 2 3 , 2 5 , 3 6 " 3 8 CMT-3 was the most potent inhibitor of gelatinase 
activity m our study, which was also shown in these earlier studies. 
Surprisingly, CMT-7 was the second best inhibitor of MMP activity in 
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our study. Not much is known about the effects of CMT-7 in vitro, but 
when tested in a rat model for periodontit is, CMT-? was the least 
effective of six CMTs.3 9 In vitro, CMTs act directly on cells, whereas in 
1//V0 systemic properties, like the uptake of the agent from the 
digestive tract, also play an important role. 
In our study, all CMTs, except CMT-5, had a st imulatory effect 
on gelatlnase production of up to sevenfold at lower concentrations. 
Their effect on gelatinase activity, however, was much larger. MMP-2 
activity was reduced maximally to 1.7% and MMP-9 activity to 2.9%, 
depending on the CMT tested. MMP-2 production was stimulated only 
about two- to threefold. A significant reduction of gelatinase activity 
only occurred at concentrations of 200 and 500 μΜ, except for CMT-3, 
which already showed a reduction at 100 μΜ. Significant effects on 
MMP production, on the other hand, were found at concentrations of 
< 200 μΜ. Therefore, the net result of CMTs in our experiments was 
an inhibitory effect on gelatinase activity at higher concentrations, 
whereas at lower concentrations the stimulation of gelatinase 
production was more prominent. 
To date, no data are available about the clinical concentrations 
of CMTs in the periodontium during treatment. However, doxycycline, 
a synthetic tetracycline closely related to CMTs, was found at 
concentrations of up to 10 μg/ml in crevicular fluid at therapeutic oral 
doses.4 0 During periodontal pocket irr igation, tetracycline 
concentrations in crevicular fluid ranged from ~1500 μg/ml after 2 h 
to χ20 μg/ml 2 wk later. 4 1 The concentrations of CMTs used in our 
experiments were ~ 2 - 2 0 0 pg/ml, which is within the expected clinical 
range. As low concentrations may stimulate MMP production, topical 
application of CMTs are expected to be more suitable. To date, very 
little data have been reported on the effects of CMTs on MMP 
production. Mäkelä eta/.26 also reported a stimulation of MMP-9 
protein expression by cultured human gingival keratinocytes with 
CMT-3 at lower concentrations. An earlier study,27 on the other hand, 
described an inhibitory effect on MMP-2 and -9 protein expression by 
porcine PDL epithelial cells at similar concentrations. Moreover, other 
synthetic MMP inhibitors have been shown to increase MMP-2 mRNA 
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and protein expression at low concentrations in rabbit periosteal cell 
cultures. 4 2 The increase in MMP-2 expression by PDL cells, as shown 
in our study, has not been previously reported. The mechanism by 
which CMTs might stimulate MMP production is not known. The cells 
might sense a decrease of extracellular MMP activity and in response 
increase their MMP production. However, CMT-5 also showed a trend 
towards stimulation of production of MMP-2 at the intermediate 
concentrations, whereas it did not show any significant effect on 
gelatinase activity, as also shown earl ier. 4 3 This suggests that an 
MMP-independent mechanism could be responsible for the observed 
increase in MMP production. 
This study further shows that CMT-3 and -8 have cytotoxic 
effects on PDL cells at - 5 0 0 μΜ. In contrast, CMT-1, -5, and -7 did 
not have any significant cytotoxic effect in our experiments. Others 
also found CMT-1 not to be toxic at similar concentrations when 
added to PDL epithelial cells. 2 7 Bettany et a/.44 found that CMT-3 had 
cytotoxic effects on monocytes already at lower concentrations, 
whereas CMT-2, -5, and doxycychne had not. 
In conclusion, our study shows that CMTs up-regulate gelatinase 
production of PDL cells at lower concentrations, but strongly reduce 
gelatinase activity at higher concentrations. The clinical application of 
CMTs aims to inhibit MMP-mediated tissue degradation, as occurs 
during periodontit is. They also have a potential therapeutic role in the 
prevention of relapse after orthodontic tooth movement. However, 
the st imulatory effect of CMTs on the production of certain MMPs 
might have unexpected consequences in the clinical situation. 
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Abstract 
Background and Objective 
Orthodontic tooth movement requires remodeling of the periodontal 
tissues. The matrix metalloproteinases (MMPs) degrade the extracellular 
matrix components of the PDL, while the tissue inhibitors of 
metalloproteinases (TIMPs) control their activity. Synthetic MMP inhibitors 
have been developed to inhibit MMP activity. In this study, PDL cells in 
contracting collagen gels serve as a model for enhanced periodontal 
remodeling. The effect of MMP inhibitors (MMPIs) on gel contraction, and 
MMP and TIMP expression is analyzed. 
Material and Methods 
Human PDL cells were cultured in 3-D collagen gels and incubated with 
the MMP inhibitors BB94, CMT-3, doxycyclme, and Ilomastat. Contraction 
was determined with consecutive photographs. The relative amounts of 
MMPs and TIMPs were analyzed with substrate zymography, and mRNA 
expression with quantitative PCR. 
Results 
All MMP inhibitors reduced MMP activity to about 2 0 % of the control. 
They all reduced contraction but CMT-3 and doxycyclme had the 
strongest effect. These inhibitors also reduced MMP-2, MMP-3 and 
α-smooth muscle actm (ASMA) mRNA expression. MMP-1 mRNA seemed 
to be increased by CMT-3. No effects were found on the amounts of MMPs 
and TIMPs. 
Conclusion 
Synthetic MMP inhibitors strongly reduced gel contraction by PDL cells. 
This was primarily due to an inhibitory effect on MMP-activity, which 
reduces matrix remodeling. In addition, ASMA expression was reduced by 
CMT-3 and doxycyclme, which limits the contractile activity of the 
fibroblasts. 
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Introduction 
The periodontal ligament is the connective tissue that attaches the tooth 
to the alveolar bone. It plays a crucial role in the adaptation of the teeth 
to physiological as well as orthodontic forces.1 Its ability to remodel 
rapidly allows the periodontal ligament to quickly adapt to these forces.2 
The mechanical strength of the periodontal ligament is mainly derived 
from collagen type I, which is one of the major proteins in the 
extracellular matrix.3 
Fibroblasts are the main cells in the periodontal ligament, and they 
are responsible for the production and degradation of most extracellular 
matrix components. They produce matrix metalloproteinases (MMPs), 
which represent a major family of enzymes that are able to degrade the 
extracellular matrix.4 The naturally occurring tissue inhibitors of 
metalloproteinases (TIMPs), which are also produced by the periodontal 
ligament fibroblasts, counteract the activity of MMPs.56 A balance 
between MMP activity and the synthesis of new extracellular matrix 
components is thought to be essential for maintaining the periodontal 
structures during physiological turnover and orthodontic tooth 
movement. 
Next to the naturally occurring TIMPs, synthetic MMP inhibitors 
have been developed. They are thought to have therapeutic applications 
in diseases that involve extensive matrix degradation such as 
periodontitis.7 About seven synthetic inhibitors are currently under study 
for clinical use, and one has already been approved for therapeutic use in 
periodontitis.7,8 Matrix metalloproteinase inhibitors have been shown to 
inhibit orthodontic tooth movement in rats,910 and might be used to 
prevent relapse after orthodontic treatment. The production of MMPs and 
TIMPs by human fibroblasts has mainly been studied in two-dimensional 
culture systems.11"13 These studies showed that fibroblasts produce MMP-
1, -2 , -3, -9, -13, and -14, and TIMP-1 and -2. Periodontal ligament cells 
were shown to produce similar MMPs and TIMPs in two-dimensional 
cultures.14"16 Synthetic inhibitors have been reported to decrease MMP-2 
and -9 production by porcine periodontal ligament cells.17 However, other 
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studies have shown a stimulation of expression of MMP-2 by human 
periodontal ligament cells18 and of MMP-9 by keratmocytes.19 
The morphology, proliferation, and cytoskeletal organization of fibroblasts 
in three-dimensional matrices is more physiological than m a two-
dimensional culture.20 23 The production of MMP-1, -2 , -3, and -9 is up-
regulated when (myo)fibroblasts are cultured m a three-dimensional 
collagen matrix compared to a two-dimensional matrix.2425 Periodontal 
ligament cells cultured in a collagen gel express MMP-1, -2 , and -9, and 
TIMP-1 and -2 . 2 6 2 7 
Generally, fibroblasts cultured in a collagen gel remodel and 
contract this artificial tissue.28 Previous studies showed that o-smooth 
muscle actm and MMP-1, -2 , and -3 are required for contraction.29 31 
By contrast, TIMP-1 seems to reduce gel contraction.32 
The periodontal ligament also undergoes extensive remodeling 
during orthodontic tooth movement. We used contracting collagen gels 
with periodontal ligament cells as a model for increased periodontal 
ligament remodeling. The specific aim was to analyze the effects of MMP 
inhibitors on gel contraction and on MMPs and TIMPs. To study this, we 
used the tetracyclme-based MMP-mhibitors CMT-3 and doxycyclme, and 
the hydroxymate-based MMP-mhibitors Batimastat (BB94) and Ilomastat 
(GM6001). 
Materials and Methods 
MMP inhibitors 
The following MMP inhibitors were used: BB94 (Batimastat, British 
Biotech, Inc., Oxford, UK), 4-dedimethylamino sancyclme (CMT-3, 
CollaGenex Pharmaceuticals, Inc., Newtown, USA), GM6001 (Ilomastat, 
Chemicon International, Inc., Billenca, USA), and doxycyclme (Sigma-
Aldnch Chemie, GmbH, Stemheim, Germany). All inhibitors were 
dissolved in dimethylsulfoxide (ICN Biomedicals, Inc., Aurora, Ohio, 
USA). 
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Cell culture 
Human periodontal ligament tissue was obtained from fully erupted 
healthy molars, that were extracted from three subjects as part of an 
overall dental treatment plan. All subjects gave their consent according to 
the guidelines of the local ethical committee. After extraction, the molars 
were washed in saline and stored at 40C in phosphate buffered saline 
(PBS, Gibco) containing 100 U/mL penicillin and 100 pg/mL streptomycin 
(Gibco, Paisly, UK). Expiants were obtained by cutting the periodontal 
ligament tissue from the lower half of the root, until 2 mm from the apex. 
The expiants were washed extensively in fresh culture medium consisting 
of Dulbecco's Modified Eagle Medium (Gibco), 10% fetal calf serum 
(Gibco), and 100 U/mL penicillin and 100 pg/mL streptomycin. The 
expiants were incubated in one well of a 24-wells culture plate at 370C in 
a humidified atmosphere of 5% CO2 in air. The culture medium was 
changed three times per week. After the outgrowth of fibroblasts, the 
cultures were trypsinized with 0.25% trypsin (Gibco) and consecutively 
passaged to culture flasks of 25 and 75 cm 2 . After a culture period of 
about 3 wk, the cells (passage 4) were frozen in 7.5% dimethylsulfoxide 
(ICN Biomedicals, Inc.) in culture medium and stored in liquid N2. The 
cells were considered as PDL cells based on the specific location of 
harvesting and their alkaline phosphatase activity. The alkaline 
phosphatase activity of the PDL cells was determined with p-nitrophenyl 
phosphate as a substrate (Sigma-Aldrich), and was found to be 
consistently higher than that of control oral fibroblasts. Prior to the 
experiments, the cells were rapidly thawed at 370C, diluted in culture 
medium and centrifuged at 400 g for 5 min. The cell pellet was 
resuspended in culture medium and seeded in a 75-cm2 culture flask. At 
80-90% confluence, the cells were passaged to two 175-cm2 flasks. At 
80-90% confluence they were trypsinized and thus ready for use in the 
experiments. 
Experimental design 
Based on the results of a pilot experiment, 5 μΜ BB94, 25 μΜ CMT-3, 25 
μΜ Ilomastat, and 50 μΜ doxycycline were used for the final 
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experiments. For these experiments 4 χ IO5 cells were incorporated in 
gels prepared from 3 mL collagen solution, and incubated with the 
inhibitors. The controls did not contain MMP inhibitors. All gels were used 
to determine the gel contraction. Four gels from each inhibitor group 
were used to determine the DNA content, and the conditioned media of 
these gels were used for zymography. To obtain enough mRNA for 
quantitative polymerase chain reaction (PCR), eight gels were pooled for 
each inhibitor. 
Collagen gels 
The culture plates were pre-coated with 1 % bovine serum albumin in 
phosphate-buffered saline to obtain free-floating gels. The mixture for 
the collagen gels was prepared on ice, and contained 1.2 mg/mL collagen 
type I from rat tail (Serva Electrophoresis, Heidelberg, Germany), 10% 
(v/v) Minimal Essential Medium ( lOx; Gibco), 0.1 M 4-(2-hydroxyethyl)-
l-piperazmeethanesulfonic acid (HEPES; Gibco), 30 mM NaHCCh (Gibco), 
and 2 mM NaOH. A cell suspension was added to the total mixture to 
obtain 1.33 χ IO5 cells/mL. In each well, 3 mL of gel solution (4 χ IO5 
cells) was carefully dispensed The gels were placed m an incubator at 
370C in a humidified atmosphere of 5% CO2 in air to gelate for 1.5 h. 
Thereafter, 2 mL of culture medium with or without MMP inhibitors was 
added to give final concentrations of 25 μΜ CMT-3, 25 μΜ Ilomastat, 5 
μΜ BB94, and 50 μΜ doxycycline. The final concentrations of the 
additives in the cultures were 1 % FCS (Gibco), 100 U/mL penicillin, and 
100 pg/mL streptomycin. The gels were incubated at 370C for 24h. 
Samples of the culture medium were taken at 24 h for zymography. 
Separate gels were used for RNA extraction and to determine the total 
DNA content. 
Measurement of gel contraction 
The surface area of the gels was measured at 0, 1, 2, 4, 6, 12, and 24h. 
Standardized pictures were taken using the digital camera of a Gel Doc 
2000 system (Bio-Rad, Hercules, CA, USA). The gel surface areas were 
subsequently measured using Quantity One software (Bio-Rad). The gel 
66 
MMP inhibitors reduce collagen gel contraction and ASMA expression 
surface area at each time-point was expressed as the percentage of the 
gel surface at ί = 0, and plotted against t ime. 
Quantitative PCR 
RNA isolation and quantitative reverse transcription (RT)-PCR was 
performed to measure the mRNA level of different MMPs, TIMPs, and 
α-smooth muscle actin. First, the periodontal ligament cells were lysed 
by adding RLT buffer (Qiagen, Hilden, Germany) and 10 pL/mL of 
ß-mercaptoethanol (ICN Biomedicals, Inc.) to the gels. The gels were 
then homogenized through a 21 gauge needle, and stored in -80oC until 
use. RNA was extracted using the RNeasy Kit (Qiagen), according to the 
guidelines of the manufacturer, and this included a DNAse I digestion 
step (Qiagen) to degrade genomic DNA. Total RNA was quantified by 
measuring the absorption at 260 and 280 nm. For the RT reaction, about 
1.5 pg of RNA was used. One microlitre of deoxyhbonucleotide 
triphosphates (dNTPs) containing 10 mM of each deoxyribonucleotide 
(dATP, dCTP, dGTP, and dTTP) and 1 pL of 0.5 pg/pL of random primers 
(Promega, Madison, WI, USA) were added, and incubated at 65°C for 5 
min. Then, the samples were put on ice and 4 pL SuperScript™ I I 
Reverse Transcriptase buffer [SuperScript™ I I RT, 5x first-strand buffer 
(250 mM Tris-HCI, ph 8.3, 375 mM KCl, 15mM MgCb)], and 2 pi 0.1 M 
dithiothreitol (Gibco) were added. The samples were heated for 2 min at 
250C, 200 U SuperScript™ I I RT was added and the samples were 
incubated for a further 10 min at 250C. The RT reaction was performed at 
420C for 50 min and was stopped by heating to 70oC for 15 min. 
Thereafter the samples were stored at -200C. 
The PCR reaction was performed in a final volume of 25 pL containing 
12.5 pL SYBR®Green Supermix (Bio-Rad), about 5 pg cDNA, 4.5 pL 
RNAse-free water, 1.5 pL 2.5 M forward primer, and 1.5 pL 2.5 M reverse 
primer. The primers for MMP-2, TIMP-1, and TIMP-2 were obtained from 
TNO (Leiden, The Netherlands). The primer sequences are shown in Table 
1. In order to quantify the gene-expression levels, the cDNA content of 
the samples was normalized, and the linear range of amplification was 
determined for each primer set. Glyceraldehyde-3-phosphate 
dehydrogenase was used as a reference gene. The amount of mRNA was 
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expressed as AQ ( = Q, gene of interest - Q, glyceraldehyde-3-phosphate 
dehydrogenase), where Q is the threshold cycle. All cycles up to 40 were 
included in the calculations, although cycles between 35 and 40 were 
interpreted with caution. Cycles of 40 and more were not included. The 
fold change in gene expression by the MMP inhibitors was expressed, 
relative to the control, as 2 Δ α . The gene expression in the control was 
set to 100%. 
Table 1 
Forward and reverse primers for the matrix metalloprotemases (MMPs), tissue 
inhibitors of metalloprotemases (TIMPs), and α-smooth muscle actm (ASMA) 
Gene 
MMP-1 
MMP-3 
MMP-8 
MMP-9 
TIMP-3 
ASMA 
GAPDH 
Forward primer 
GGGAGATCATCGGGACAACTC 
TGGCATTCAGTCCCTCTATGG 
CCAAÜ1ÜÜÜAACÜCAC1AAC1 1ÜA 
TGGGGGGCAACTCGGC 
CCAÜÜACÜCC MCI ÜCAAC 
GCTCACGGAGGCACCCCTGAA 
TGCACCACCAACTGCTTAGC 
Reverse primer 
GGGCCTGGTTGAAAAGCAT 
AGGACAAAGCAGGATCACAGTT 
TGGAGAATTGTCACCGTGATCTCTT 
GGAATGATCTAAGCCCAG 
L U C C I 1 IACCAGCI ICI 1 CCC 
TCCAGAGTCCAGCAGATG 
GGCATGGACTGTGGTCATGAG 
DNA assay 
The amount of DNA per gel was determined with the PicoGreen®dsDNA 
Quantitation kit (Molecular Probes, Inc., Eugene, OR, USA). PicoGreen is 
a fluorescent stain for double-stranded DNA. The fluorescent signal was 
measured in an FL600 Microplate Fluorescence Reader (Bio-Tek 
Instruments, Inc., Winooski, VT, USA) at excitation 485 nm and emission 
520 nm. Bacteriophage lambda DNA was used as a standard, ranging 
from 0 to 1000 ng/mL. The total amount of DNA in each gel was 
calculated. 
Gelatin zymography 
Gelatmases (MMP-2 and -9) in the conditioned media were analyzed by 
gelatin zymography. All samples were analyzed in quadruplicate. The 
Polyacrylamide gel (7.5%) contained 3.5 mM sodium dodecyl sulphate 
and 1 mg/mL gelatin, as described by others.33 A (1:1) mixture of sample 
and sample buffer was then electrophoresed for 1.5 h at 80 mA. A Broad 
Range Marker (Bio-Rad, Hercules, USA) ranging from 6.4 to 203 kDa was 
included to determine the molecular weight of the MMPs. Recombinant 
human pro-MMP-2 (Oncogene, CN Biosciences, San Diego, CA, USA) was 
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used as a reference sample. After electrophoresis, the gels were washed 
in 2.5% Triton X-100 (Sigma-Aldrich) to remove the sodium dodecyl 
sulphate, and the marker bands were indicated. The gels were then 
incubated in activation buffer, containing 50 mM Tris-HCL (pH 7.8), 5 mM 
CaCb, and 0 . 1 % Triton X-100, at 370C for 18 h. They were stained for 45 
min with 2.5 g/L Coomassie Brilliant Blue R250 (Imperial Chemical 
Industries PLC, London, UK), 10% acetic acid, and 4 0 % methanol in 
water, and thereafter destained with 10% acetic acid and 4 0 % methanol 
in water. The MMPs appear as bright bands within the stained gel. The 
gels were scanned using a HP ScanJet 4C/T, and the bands were 
analyzed with QUANTITY ONE software (Bio-Rad). The amount of enzyme 
in the bands was calculated as average density χ m m 2 per ng of DNA. 
The pro-MMP-2 reference sample enabled comparison of the 
corresponding bands on different gels. First, within each gel, the amount 
of enzyme in the reference sample was arbitrarily set to 1, and all other 
bands were calculated relative to it. Then, the corresponding bands on 
the different gels were averaged and standard deviations were calculated 
to obtain the relative amount of MMPs. 
Reverse zymography 
TIMPs in the conditioned media were analyzed using reverse 
zymography. This technique is similar to gelatin zymography, except that 
conditioned medium from baby hamster kidney cells (BHK-21, ATCC, 
Rockville, MD, USA) was included in the gels. This medium mainly 
contains MMP-2. The MMP-2 degrades all gelatin in the gel, except where 
TIMPs are present. The Polyacrylamide gel (15%) contained 3.5 mM 
sodium dodecyl sulphate, 1 mg/mL gelatin, and 10% conditioned medium 
from BHK-21 cells. A 1:1 mixture of sample and sample buffer was then 
electrophoresed for 3h at 80 mA. A Broad Range Marker (Bio-Rad) was 
included to determine the molecular weight of the TIMPs. Recombinant 
human TIMP-1 and -2 (Oncogene) were used as references. After 
electrophoresis the gels were washed in 2.5% Triton X-100 (Sigma-
Aldrich) to remove the sodium dodecyl sulphate. The gels were then 
incubated in 50 mM Tris-HCL (pH 7.5), 5 mM CaCI2, 0 . 1 % Triton X-100, 
and 0.2 M NaCI at 370C for 18 h. They were stained and destained. 
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following the same method as described for gelatin zymography. The 
TIMPs appear as dark blue bands within the destamed gel. Thereafter, 
the gels were scanned and analyzed as described for gelatin zymography. 
MMP activity assay 
MMP activity in the conditioned media was analyzed in quadruplicate by 
an MMP assay. In short, the degradation of the fluorogenic MMP substrate 
TN0211-F (TNO) was measured using a fluonmeter.3 6 TN0211-F consists 
of a fluorophore and a light-absorbing group (quencher) attached to an 
ammo acid sequence that serves as a substrate for MMPs. Through 
enzymatic cleavage by MMPs, the quencher is eliminated and 
fluorescence can be measured. It is mainly cleaved by MMP-1, -2, -3, -8, 
-9, and -13. The fluorescent signal was measured m a Cytofluor I I 
fluonmeter (PerSeptive Biosystems, Frammgham, MA, USA), and 
expressed as relative fluorescence units per second. The MMP activity m 
the samples was represented as relative fluorescence umts/s per ng of 
DNA. 
Statistical analyses 
For the pilot experiment, repeated-measures analysis of variance was 
used to compare gel contraction m the experimental groups. One-way 
analysis of variance was used to compare the gel surface areas and the 
percentages of live cells m the cytotoxicity test. For the final experiment, 
differences m gel contraction were analyzed with a repeated-measures 
analysis of variance. One way analysis of variance was used to analyze 
gel contraction at the 12-h t ime, the amounts of MMPs or TIMPs in the 
conditioned media, and the amounts of α-smooth muscle actin, MMP, and 
TIMP mRNA. Dunnett's test was used as a post hoctest. Differences were 
considered to be significant at a p-value of < 0.05. 
Results 
Gel contraction 
A pilot experiment showed that optimal inhibitor concentrations were 
were 5 μΜ for BB94, 25 μΜ for CMT-3 and Ilomastat, and 50 μΜ for 
doxycyclme (data not shown). As the pilot experiment showed no further 
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contraction of the collagen gels after 24 h, this was chosen as the end 
point for the final experiment. Figure 1 shows the results of the final gel 
contraction experiments. The gel surface area was measured at f = 1, 2, 
4, 6, 12, and 24 h. The graphs show that contraction of the gels started 
mostly after a lag phase of 1 h. All MMP inhibitors reduced contraction up 
to f =12 {ρ = 0.027, 0.001, < 0.001, and 0.005 for BB94, CMT-3, 
Ilomastat, and doxycycline respectively). At t= 24, the reduction was 
still significant for CMT-3 and doxycycline {p = 0.006 and < 0.001 
respectively). The right panel of Fig. 1 shows the effect of all inhibitors on 
gel surface area at f = 12 h. 
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Fig. 1. Collagen gel contraction. 
The gel surface areas were measured at f = 1, 2, 
4, 6, 12, and 24 h. Data are expressed as means 
(± standard deviation). From i = 0 to 12, all 
matrix metalloproteinase (MMP) inhibitors showed 
a significant reduction of gel contraction 
compared with the control. At f = 24, the 
reduction was still significant for CMT-3 and 
doxycycline. The right panel shows the gel 
surface area at f = 12. The surface areas are 
expressed as a percentage of the gel surface 
areas at f = 0 (means ± standard deviation). 
Asterisks indicate a significant difference 
compared with the control (p < 0.05). Doxy, 
doxycycline; Iloma, Ilomastat. 
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mRNA expression 
The results of the quantitative RT-PCR are shown in Fig. 2. Most data 
were obtained from threshold cycles between 15 and 25, but for MMP-9 
mRNA this was mostly between 35 and 40. Therefore, these results have 
to be interpreted with caution. CMT-3 significantly reduced MMP-2, a-
smooth muscle actin, and TIMP-2 mRNA expression (p = 0.025, 0.010, 
and 0.021 respectively). MMP-3 mRNA expression was reduced by 
doxycyclme (p = 0.027), which also tended to inhibit α-smooth muscle 
actin mRNA expression. There was a trend of increased MMP-1 mRNA 
expression by CMT-3 and doxycycline. 
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Fig. 2. Effect of matrix metalloproteinase (MMP) inhibitors on mRNA expression 
of MMPs, α-smooth muscle actin, and tissue inhibitors of metalloprotemases 
(TIMPs). The panels show the effect of BB94, CMT-3, Ilomastat, and doxycyclme 
on the mRNA expression of MMP-1, -2, -3, α-smooth muscle actm (ASMA), and 
TIMP-2. The fold change in gene expression induced by the MMP inhibitors was 
expressed as 2"Δ α relative to the control, which was set to 100%. Doxy, 
doxycyclme; Iloma, Ilomastat. 
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Relative amounts of MMPs and TIMPs 
Representative zymograms are shown in Fig. 3. The gelatin zymograms 
show that the periodontal ligament cells produced gelatinase activity in 
bands at 92, 82, 74, 69, and 62 kDa. Also, minor amounts of MMP 
complexes were found around 130 kDa. A pro-MMP-2 reference, used to 
compare the zymograms, also showed the complexed form at 130 kDa, 
the latent form at 69 kDa and the active form at 62 kDa. The bands at 92 
and 82 kDa were most likely the latent and active form of MMP-9. These 
forms have been described previously.34 The nature of the 74-kDa band 
remained unknown and was not further analyzed. The reverse 
zymograms show that the periodontal ligament cells produced mainly 
TIMP-1. The bands at 21 kDa, representative forTIMP-2, were mostly 
faint. None of the MMP-inhibitors had a significant effect on the relative 
amounts of MMPs or TIMPs. 
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Fig. 3. Effect of matrix 
metalloproteinases (MMP) 
inhibitors on amounts of 
MMP and tissue inhibitors 
of metailoproteinase 
(TIMP). 
Representative 
zymograms. The 
molecular weights of the 
markers are indicated by 
the arrows. The upper 
panel represents a gelatin 
zymogram, showing 
proteolytic activity of 
complexed MMP-2, 
pro-MMP-9, active MMP-9, 
a 74 kDa gelatinase, pro-
MMP-2, and active MMP-2. 
The lower panel 
represents a reverse 
zymogram, showing 
bands of TIMP-1 and -2. 
Doxy, doxycycline; 
ILoma, Ilomastat. 
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MMP activity 
General MMP activity in the conditioned medium was analyzed using an 
MMP activity assay. As expected, all four MMP inhibitors significantly 
reduced MMP-activity (Fig. 4). BB94 reduced the MMP-activity to 23 ± 
3.8% (p = 0.021), CMT-3 reduced the MMP-activity to 24 ± 2.8% {p = 
0.023), doxycycline reduced the MMP-activity to 18 ± 5.5% {p = 0.014) 
and Ilomastat reduced the MMP-activity to 25 ± 4.6 % {p = 0.025). 
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Fig. 4. The effect of BB94, CMT3, Ilomastat and doxycyciine on general matrix 
metalloproteinase (MMP) activity in the conditioned media. The degradation of a 
fluorescent substrate was expressed as relative fluorescence units (RFU)/s/ng of 
DNA. The asterisks indicate a significant difference compared with the control 
(p < 0.05). Doxy, doxycycline; lloma, Ilomastat. 
Discussion 
In this study, free-floating three-dimensional collagen gels with 
periodontal ligament cells were used as a model for increased PDL 
remodeling. MMP inhibitors might be used to reduce matrix degradation. 
All MMP inhibitors used in this study were able to inhibit gel contraction 
by periodontal ligament cells, as also shown for other cell types.3 0 '3 5 '3 6 
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expression, but no effect on the amounts of protein. This might be due to 
the difference between the two-dimensional and the three-dimensional 
culture systems. In our study, we found that periodontal ligament cells 
cultured in collagen gels produced latent and active MMP-2 as well as a 
complexed form of MMP-2. Also, TIMP-1 protein was present, and in 
some samples small amounts of TIMP-2 were found. Remarkably, the 
periodontal ligament cells produce MMP-9 and a 74-kDa related 
proteinase, whereas in a two-dimensional culture they do not.18 The 74-
kDa proteinase has not previously been described in periodontal ligament 
cells, but it was identified as an activated form of MMP-9 in fibrosarcoma 
cells50 and in mast cells.51 Although it is not known whether the 74-kDa 
proteinase also occurs in vivo, it might play a role m periodontal ligament 
remodeling. 
Periodontal ligament cells produce MMP-2, but no significant 
amounts of MMP-9, in a two-dimensional culture. 16'1B Others showed that 
MMP-9 production increased when fibroblasts or trophoblasts were 
transferred from a two-dimensional to a three-dimensional 
environment.52,53 This might be a result of the interaction of the cells with 
the collagen matrix through integrins.38 I t is known that this interaction 
triggers signal transduction, which leads to metabolic changes in the 
cell.54 MMP-9 is probably required for the migration of cells in a three-
dimensional matrix.55 
In summary, periodontal ligament cells seem to produce other 
MMPs in three-dimensional cultures than in two-dimensional cultures. 
This is probably caused by the interaction with collagen. Periodontal 
ligament cells also responded differently to incubation with MMP 
inhibitors. As a three-dimensional culture system seems to mimic the in 
vivo situation much better, it is more suitable to study periodontal 
ligament remodeling. The activity of MMPs produced by periodontal 
ligament cells in a three-dimensional culture can be greatly reduced by 
synthetic MMP inhibitors, thereby inhibiting collagen gel contraction. This 
might be enhanced by the specific inhibition of MMP-3 expression, which 
reduces transforming growth factor-ß-mediated α-smooth muscle actin 
expression. All inhibitors reduced MMP-activity to an equal extent, but 
CMT-3 and doxycycline showed the largest effect on gel contraction. 
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integrins, and collagen degradation by MMPs. The major integrins are 
a l ß l and a2ß l , of which binding of the latter stimulates MMP-1 
expression.37,38 In addition, MMP-3 and -13 seem to be involved.39,40 
Contraction itself may result from the repeated formation of cellular 
lamellipodia, and cytoskeletal re-arrangement by α-smooth muscle actin 
and myosin I I-B. 4 1 , 4 2 
Messenger RNA analyses revealed that periodontal ligament cells 
express a wide variety of MMPs (MMP-1, -2, -3, -8, and -9), TIMPs (TIMP-
1, -2, and -3) and α-smooth muscle actin. Only few significant effects of 
the MMP-inhlbitors on mRNA expression were found. Doxycycline reduced 
MMP-3 mRNA expression to about 50% of that of the control, and the 
same trend was found for CMT-3. Earlier studies have shown that MMP-3 
production is decreased in mechanically stimulated gels.4 3 , 4 4 In vitro, 
specifically MMP-3 has been shown to release transforming growth 
factor-ß from the extracellular matrix by proteolytic cleavage of the 
latent transforming growth factor-ß binding protein.45 This might be more 
relevant for oral fibroblasts than for skin fibroblasts as they produce 
much more MMP-3.39 Transforming growth factor-ß subsequently 
stimulates α-smooth muscle actin expression, which enhances gel 
contraction and cell migration. 3 9 , 4 6 In our study, α-smooth muscle actin 
mRNA was decreased by CMT-3, and the same trend was found for 
doxycycline. The down-regulation of MMP-3 may have contributed to the 
inhibition of gel contraction via the reduction of transforming growth 
factor-ß-induced α-smooth muscle actin expression. Also, MMP-3 has 
been described as a strong activator of latent MMPs.47,48 Its down-
regulation may therefore reduce contraction through multiple 
mechanisms. 
By contrast, both CMT-3 and doxycycline seem to up-regulate 
MMP-1 mRNA expression. In a previous study, we found an up-regulation 
of MMP-2 protein expression by several CMTs, including CMT-3, in two-
dimensional cultures.1 8 An up-regulation of MMP-2 was also shown for 
periosteal cells incubated with other synthetic inhibitors.4 9 These data 
indicate that MMP inhibitors might have unexpected stimulatory effects 
on MMP production via positive feedback mechanisms. In the present 
experiments, CMT-3 showed a reduction of MMP-2 and TIMP-2 mRNA 
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Abstract 
Background 
Periodontal tissues remodel rapidly, which enables quick adaptation 
to mechanical changes. Matrix metalloproteinases (MMPs) are 
involved in these remodeling processes under control of tissue 
inhibitors of metalloproteinases (TIMPs). In periodontitis, overactivity 
of MMPs results in pathological tissue degradation, which can be 
aggravated by orthodontic forces. The aim of this study was to 
analyze MMPs and TIMPs in healthy and diseased gingiva, periodontal 
l igament (PDL) and crevicular fluid (GCF). 
Methods 
Samples of gingiva, PDL and GCF were obtained from healthy controls 
(gingiva: n = 16, PDL: n=15, GCF: n=8) and subjects with periodontitis 
(gingiva: n = l l , PDL: n=18, GCF: n = 12). MMPs and TIMPs were analyzed 
by gelatin-, collagen-, and reverse zymography and by Western blotting. 
Total MMP activity was analyzed using a fluorogenic substrate. 
Results 
TIMP-1 and -2, active and pro-MMP-2 and -9, and active MMP-1 and -8 
were present in all samples. Large amounts of active MMP-2 complexes 
and collagenolytic fragments were found. Their amounts were higher in 
PDL and GCF from periodontitis patients. In general, TIMP levels were 
lower in diseased periodontal tissues. Especially diseased GCF contained 
more MMPs. Surprisingly, some MMPs were more abundant in healthy 
gingiva and PDL than in diseased tissue. 
Conclusions 
Unexpected variations in MMP and TIMP levels in gingiva, PDL, and GCF 
may result from differences in subject characteristics and disease 
activity. The levels of active MMP-2 complexes and collagenolytic 
fragments are higher in the periodontium of subjects with periodontitis 
and might contribute significantly to periodontal destruction. 
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Introduction 
Periodontal tissues remodel rapidly compared to other connective tissues, 
which allows adaptation of the teeth during function.1 The matrix 
metalloproteinases (MMPs) are believed to be crucial in these remodeling 
processes are the matrix metalloproteinases (MMPs). Twenty-three 
human MMPs are known.2,3 Their activity is controlled by the tissue 
inhibitor of metalloproteinases (TIMPs).4,5 MMPs and TIMPs are important 
in the physiological remodeling of the periodontium6 and its adaptation to 
mechanical forces, as in orthodontics.7 In periodontitis, a relative 
overactivity of MMPs results in the breakdown of periodontal structures.8,9 
This can be enhanced by orthodontic forces.10,11 
The total amounts of MMP-1, -2 , -3, and -9 seem to be increased 
in inflamed gingiva.12,13 Ejeil eta/.6 found higher levels of the latent and 
active forms of MMP-2 in inflamed gingiva, but the total amount of MMP-2 
was similar to healthy gingiva. Smith eta/}4 found more pro-MMP-9 in 
diseased gingiva and equal amounts of latent and active MMP-2, although 
these findings were not quantified. MMP-1 mRNA was reported to be 
increased in inflamed gingival tissue,15,16 but another study17 showed 
similar levels of MMP-1, -2, and -14 mRNA in healthy and diseased 
gingiva. According to the investigators, this might have been due to the 
large individual variation. TIMP levels in inflamed gingiva have been 
found to be reduced,13 similar,12 or even increased6 compared to healthy 
gingiva. In the first study,13 TIMPs were extracted from gingival tissue, 
whereas in the latter two studies they were analyzed in culture medium. 
Alba et a/.is found that the levels of TIMP-1 mRNA were similar in healthy 
and diseased tissue, but protein levels were not analyzed. In summary, 
there is no consensus on the TIMP levels in healthy and diseased gingiva. 
More active and latent MMP-1, -3, -8, and -9 were found in gingival 
crevicular fluid (GCF) from deep pockets than from healthy sulci.2,13,1819 
The total MMP-2 content was also reported to be higher,13 whereas other 
investigators9 found no MMP-2. This might be due to the use of different 
analytical methods. The levels of TIMP-1 and -2 are reduced in the GCF 
of periodontitis patients,13,19 but periodontal treatment does not seem to 
normalize them.9 
83 
In contrast to gingiva and GCF, little data are available on MMP and 
TIMP levels in healthy and diseased periodontal ligament (PDL). However, 
it is known from histological studies in rats that MMPs are present.20 '21 
To the best of our knowledge, MMP and TIMP levels in gingiva, PDL, and 
GCF of subjects with periodontitis patients and healthy subjects have not 
been compared directly in one study. This might clarify some of the 
controversies found in literature. 
In our study, substrate zymography and Western blotting were 
used to analyze MMPs and TIMPs in gingiva, PDL, and GCF of 
periodontitis patients and healthy controls. The analysis of MMPs and 
TIMPs in the healthy and diseased periodontium might contribute to the 
development of therapies to reduce tissue degradation in periodontitis. 
Materials and Methods 
Gingiva 
Healthy gingiva (score 0 according to the Dutch Periodontal Screening 
Index [DPSI]22) was obtained from gingiva correction after the extraction 
of healthy third molars. This tissue was obtained from 18 patients aged 
17 to 41 years (mean: 23.2 ± 5.8 years; nine males and nine females). 
Inflamed gingiva was obtained from discarded material during 
periodontal flap surgery (DPSI > 3-). The tissue was obtained from 11 
patients aged 25 to 71 years (mean: 51.6 ± 10.4 years), five males and 
six females) who had chronic periodontitis. All patients gave their oral 
consent according to the guidelines of the local ethical committee. All 
samples were collected at the Departments of Periodontology and Oral 
and Maxillofacial Surgery of Radboud University Nijmegen Medical Centre 
from January to October 2005. The samples were washed in saline and 
temporarily stored at -80oC in phosphate buffered saline (PBS; Gibco, 
Paisly, UK) containing 100 U/ml penicillin and 100 pg/ml streptomycin 
(Gibco). 
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PDL 
PDL was obtained from teeth that were extracted during routine dental 
treatment. All patients gave their consent according to the guidelines of 
the local ethical committee. PDL samples from healthy periodontium 
(DPSI 0) were derived from fully erupted third molars of 15 subjects aged 
20 to 41 years (mean: 25.9 ± 6.2 years; four males and 11 females). 
Diseased PDL samples (DPSI > 3-) were obtained from teeth that were 
affected by chronic periodontitis and had to be extracted because of 
severe bone loss (18 patients aged 38 to 69 years [mean: 52.0 ± 14.9 
years; 10 males and eight females]). After extraction, the teeth were 
washed in saline and stored at 40C in PBS (Gibco) containing 100 U/ml 
penicillin and 100 pg/ml streptomycin (Gibco). PDL was cut from the 
lower half of the root, excluding the last 2 mm of the apex, and stored at 
-80oC. 
GCF 
GGF samples were taken from volunteers with a healthy periodontium 
(DPSI 0) and patients with chronic periodontitis (progressive disease, 
DPSI > 3-). All patients gave their consent according to the guidelines of 
the local ethical committee. Only patients not on any medication were 
included. The healthy group consisted of eight volunteers aged 27 to 63 
years (mean 41.4 ± 14.3 years; three males and five females), and the 
periodontitis group consisted of 12 subjects aged 38 to 66 years (mean 
49.0 ± 10.2 years; seven males and five females). The teeth at the 
sampling sites were isolated with cotton rolls and gently dried with air. 
Thereafter, a l-μΙ microsyringe (Hamilton, Reno, Nevada, USA) was 
carefully inserted into the sulci or pockets to collect GCF. The GGF 
samples were immediately placed on ice and stored at -80oC until use. 
For analysis, healthy and diseased GCF samples were pooled separately. 
Tissue extraction 
The tissue extraction method was a modification of the procedure of 
Robinson eta/.23 The individual gingiva or PDL samples were put in 
homogenization solution containing 10 mM CaCb and 0.25% Triton X-100 
(Sigma-Aldrich, St. Louis, MO, USA) on ice. The tissues were 
homogenized with a homogemzer with a 5 mm χ 75-mm generator (Pro 
200; Pro Scientific Inc., Monroe, CT, USA). The homogenates were 
centnfuged for 45 minutes at 13,000 χ g and 40C. The supernatants were 
removed, pooled, and stored at -80°C. This procedure was repeated. The 
pellet was homogenized again in extraction buffer containing 50 mM Tns-
HCI pH 7.5, 150 mM NaCb, and 100 mM CaCb. Heat extraction was 
performed at 60oC for 5 minutes while shaking firmly, and the samples 
were placed on ice. The samples were centnfuged for 45 minutes at 
13,000 χ g and 40C, and the supernatant was stored at -80oC. The 
supernatants from the first and third extraction step were pooled, 
because these contained the highest concentrations of MMPs. This yielded 
four pooled samples for healthy and diseased gingiva and PDL tissue. 
As a control for differences in extraction efficiency between healthy 
and diseased tissues, we determined the extraction efficiency of MMP-2 in 
the first and third supernatant compared to the total m all three fractions. 
The extraction efficiency of total extractable MMP-2 was 77 ± 5% for 
healthy gingiva and 83 ± 6% for diseased gingiva, which was not 
significantly different. The extraction efficiency of total protein was 
determined as the percentage of protein present in the extract compared 
to the total protein in the tissue (extracts and pellet), using the 
bicmchonmic acid (BCA) protein assay (Pierce Biotechnology, Rockford, 
IL, USA). This differed significantly for diseased PDL (92 ± 2 %) and 
healthy PDL (48 ± 6 % ) , but not for diseased gingiva (69 ± 9%) and 
healthy gingiva (71 ± 10 % ) . Because the results were expressed per 
nanogram of protein, the data were corrected for the differences in 
protein-extraction efficiency. 
Gelatin zymography 
Gelatmases (MMP-2 and -9) m the pooled samples were analyzed in 
quadruple by gelatin zymography. The Polyacrylamide gel (7.5%) 
contained 3.5 mM sodium dodecyl sulphate (SDS) and 1 mg/ml gelatin.2 4 
A (1:1) mixture of sample and sample buffer was electrophoresed for 1.5 
hours at 80 mA. A Broad Range Marker (Bio-Rad, Hercules, CA, USA) was 
included to determine the molecular weight of the MMPs. Recombinant 
human pro-MMP-2 (Oncogene, CN Biosciences, San Diego, CA, USA) was 
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used as a reference sample. After electrophoresis, the gels were washed 
in 2.5% Triton X-100 (Sigma-Aldrich). The gels were incubated at 370C 
for 18 hours in activation buffer containing 50 mM Tris-HCL (pH 7.8), 5 
mM CaClz and 0 . 1 % Triton X-100; stained for 45 minutes in 2.5 g/l 
Coomassie Brilliant blue R-250 (Imperial Chemical Industries PLC, 
London, UK), 10% acetic acid, and 4 0 % methanol in water; and 
destained. The MMPs appear as bright bands within the stained gel. 
The gels were scanned with a HP ScanJet 4C/T (Hewlett-Packard, 
Amstelveen, The Netherlands), and the bands were analyzed with 
Quantity One software (Bio-Rad). The amount of enzyme in the bands 
was represented as average density χ square millimeter per nanogram of 
total tissue protein. The amount of protein was determined in the sample 
by BCA protein assay (Pierce). The amount of enzyme in the GCF was 
represented as average density χ square millimeter per microliter GCF. 
The pro-MMP-2 reference sample enabled comparison of the 
corresponding bands on different gels. First, within each gel, the amount 
of enzyme in the reference sample was arbitrarily set to 1, and all other 
bands were calculated relative to it. The corresponding bands on the 
different gels were averaged, and standard deviations were calculated. 
Collagen zymography 
Collagenases (MMP-1, -8, and -13) in the pooled samples were analyzed 
in quadruple by collagen zymography. The Polyacrylamide gel (10%) 
contained 3.5 mM SDS and 5 mg/ml collagen type I from calfskin 
(Sigma-Aldrich). A (1:1) mixture of sample and sample buffer was 
electrophoresed. A Broad Range Marker (Bio-Rad) was included on the 
gels. Recombinant human pro-MMP-2 was used as a reference. After 
electrophoresis, the gels were washed in 2.5% Triton X-100 (Sigma-
Aldrich). The gels were incubated in activation buffer at 370C for 43 
hours. They were stained and destained as described for the gelatin 
zymography. Thereafter, the gels were scanned and analyzed as 
described for the gelatin zymography. 
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Reverse zymography 
TIMPs in the samples were analyzed in quadruple by reverse 
zymography. This technique is similar to gelatin zymography, except that 
conditioned medium from baby hamster kidney cells (BHK-21, American 
Type Culture Collection, Manassas, VA, USA) was included in the gels. 
This contains mainly MMP-2. The MMP-2 degrades all gelatin in the gel, 
except where TIMPs are present. The Polyacrylamide gel (15%) 
contained 3.5 mM SDS, 1 mg/ml gelatin and 10% conditioned medium. A 
(1:1) mixture of sample and sample buffer was electrophoresed for 
3hours at 80 mA. A Broad Range Marker (Bio-Rad) was included. 
Recombinant human TIMP-1 and -2 (Oncogene) were used as standards . 
After electrophoresis the gels were washed in 2.5% Triton X-100 (Sigma-
Aldrich). The gels were incubated in 50 mM Tris-HCL (pH 7.5), 5 mM 
CaCI2, 0 . 1 % Triton X-100, and 0.2 M NaCI at 370C for 18 hours. They 
were stained and destained, following the same method as described for 
gelatin zymography. TIMPs appear as dark blue bands within the 
destained gel. Thereafter, the gels were scanned and analyzed as 
described for gelatin zymography, except that TIMP-2 was used as a 
reference to enable comparison of the corresponding bands on different 
gels. 
MMP activity assay 
MMP activity in the samples was analyzed in quadruple by an MMP 
activity assay.25 In short, the experimental fluorogenic substrate 
(TN0211-F; TNO Prevention & Health, Leiden, The Netherlands) was used 
to determine the total activity of the MMPs present in the gingiva, PDL 
and GCF samples. The substrate consists of a fluorophore and a light-
absorbing group (quencher) attached to an amino acid sequence that 
serves as a substrate for MMPs. Through enzymatic cleavage by MMPs, 
the quencher is eliminated, and fluorescence can be measured. It is 
mainly cleaved by MMP-1, -2 , -3, -8, -9, and -13. The fluorescent signal 
was measured in a fluorimeter (Cytofluor I I ; PerSeptive Biosystems, 
Framingham, MA, USA) and expressed as relative fluorescence units 
(RFU) per second. The MMP activity in the gingiva and PDL samples was 
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represented as RFUs/second per nanogram of total tissue protein. The 
amount of protein was determined in the sample by the BCA protein 
assay. The MMP activity In the GCF was represented as RFUs/second per 
microliter of GCF. 
Western blotting 
Pooled GCF and concentrated tissue extracts were analyzed by Western 
blotting according to standard procedures.2 6 In short, 10 μΙ sample was 
dissolved in 10 μΙ sample buffer and electrophoresed on a 7.5% 
Polyacrylamide gel (room temperature, 80 mA). The proteins were 
blotted onto a nitrocellulose membrane (pore size 0.45pm, Bio-Rad) at 
400 mA and 40C for 1 hour. The membrane was incubated In block buffer 
( 5 % milk powder [Elk, Camplna, the Netherlands] and 0 . 1 % Tween 20 
[Sigma] In PBS). Thereafter, the blots were incubated with monoclonal 
antibodies against MMP-1, -2, -8, -9, or -13 and TIMP-1 or -2 
(Oncogene), dilution 1:200 at 40C for 18 hours. After washing with 0 . 1 % 
Tween 20 In PBS, the blots were incubated with a peroxidase-
conjungated goat anti-mouse immunoglobulin G (BD Biosciences, San 
Jose, CA, USA), diluted 1:4,000 in 1 % bovine serum albumin, 0 . 1 % 
Tween in PBS for 1 hour. After washing, the membranes were incubated 
with reagent (ECL Plus; Amersham, Chicago, IL, USA) for 
chemllumlnesence detection. Excess ECL reagent was removed, and the 
membrane was exposed to film (Eastman Kodak Company, Rochester, 
NY, USA) for 1 hour and developed. 
Statistical analysis 
The difference in amounts of MMPs and TIMPs and MMP activity between 
the healthy and diseased tissues were evaluated with the Student f test. 
The Mann Whitney U test was used in case of a non-normal distribution 
or a considerable amount of difference In variances. This was necessary 
for the data for MMP-1 and the collagenolytic fragments in the PDL. For 
clarity, all results are displayed as mean ± SD. Differences were 
considered significant If P< 0.05. When multiple Mests were performed, 
the Bonferronl correction was applied to adjust the l v a l u e . 
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Results 
Zymography 
The gelatin zymograms show that the periodontium contained 
gelatinolytic activity in bands around 130, 92, 69, and 62 kDa (Fig. 1A). 
Also, a faint band around 85 kDa was found in all samples, except the 
inflamed gingiva. The bands at 69 kDa and 62 kDa, were the latent and 
active form of MMP-2 as confirmed by Western blotting. The band at 130 
kDa probably represented the complexed form of MMP-2, because it was 
also found in the MMP-2 reference sample (Fig. 1A, lane 7). However, 
this could not be clearly confirmed by Western blotting (Fig. 1A, Western 
Blotting lane 1). The bands at 92 kDa and 85 kDa represent the latent 
and active form of MMP-9. The latent form was also shown by Western 
blotting (Fig. 1A, Western blotting lane 3). The active form of MMP-9 was 
lacking in diseased gingiva. This active form has also been described as 
the 'intermediate' form, since MMP-9 has an other active form of 67 
kDa.27 We refer to the 85 kDa form as the active form because we did not 
find the 67 kDa form. 
The collagen zymograms showed bands around 55 and 43 kDa and wider 
bands at 30-35 kDa (Fig. IB) . The 55-kDa band was identified as MMP-8 
by Western blotting only in gingiva. The bands at 30 to 35 kDa were 
probably fragments of MMP-8, as shown by Western blotting for gingiva, 
and other fragments. This band was only faintly present in healthy PDL 
and GCF. The band at 43 kDa could not be identified by Western blotting, 
but it most likely was MMP-1 based on its molecular weight. No bands 
were found at the molecular weights of latent MMP-1 (58 kDa) and -8 (64 
kDa) or latent and active MMP-13 (60 and 48 kDa, respectively) by 
zymography or Western blotting. The reverse zymograms showed bands 
around 28 and 21 kDa, representing TIMP-1 and -2 which is indicated by 
the reference samples (Fig. 1C, lanes 7 and 8). The band of TIMP-1 in 
GCF seemed to be divided into two fractions. 
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Fig. 1. Representative zymograms and Western blots are shown for healthy (H) 
and diseased (D) periodontal tissues. The molecular weights of the markers are 
indicated by arrowheads. A) Representative gelatin zymograms of samples of 
healthy gingiva (lane 1), diseased gingiva (lane 2), healthy PDL (lane 3), diseased 
PDL (lane 4), healthy GCF (lane 5), diseased GCF (lane 6), and a reference sample 
of Pro-MMP-2 (lane 7). Western blots for MMP-2 are shown for diseased GCF (lane 
1), and the reference pro-MMP-2 (lane 2). Western blots with anti-MMP-9 are also 
shown for diseased GCF (lane 3) and a standard pro-MMP-9 (lane 4). 
B) Representative collagen zymograms are shown for the same samples as in A. 
Western blots for MMP-8 are shown for diseased GCF (lane 1) and diseased 
gingiva (lane 2). C) Representative reverse zymograms for the same samples as 
in A, but lane 7 contained TIMP-1 as a reference sample and lane 8 contained a 
standard TIMP-2 sample. Correction for total protein content was done afterwards. 
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Quantitative analysis of MMPs and Ή Μ Ρ Β 
The quantified data of all experimental samples are shown in Figure 2. 
Significantly more pro- and complexed MMP-2 were present m the 
healthy gingiva compared to diseased gingiva (P =0.045 and P < 0 . 0 0 1 , 
respectively). In healthy PDL more active- and pro-MMP-2 was present 
than in diseased PDL (P<0.003 and Ρ =0.001, respectively). In contrast, 
the amount of complexed MMP-2 was higher m diseased PDL (P =0.036). 
The amounts of all forms of MMP-2 were higher m diseased GCF than in 
healthy GCF ( P < 0 . 0 0 0 1 , / ' < 0 . 0 0 0 1 , and Ρ =0.042, respectively). 
Significantly more active and pro-MMP-9 was present in the healthy 
gingiva compared to diseased gingiva ( P < 0 . 0 0 1 and Ρ =0.004, 
respectively). In diseased PDL, more active and pro-MMP-9 was present 
than in the healthy tissue (P =0.032 and Ρ =0.001, respectively). The 
amount of active MMP-9 was also higher in diseased GCF (P <0.0001). 
Diseased gingiva contained more MMP-1 than healthy tissue (P =0.011). 
There was no significant difference in the amount of MMP-8 or 
collagenolytic fragments. The fragments might be partly derived from 
MMP-8 as shown for gingiva in Figure I B . More active MMP-1 and -8 were 
present in healthy PDL than m diseased tissue (P =0.029 and P < 0 . 0 0 1 , 
respectively). However, the amount of collagenolytic fragments was 
higher in the diseased tissue (P =0.029). In diseased GCF, more active 
MMP-8 and collagenolytic fragments were present than in healthy GCF 
(P<0.001 and Ρ =0.04, respectively). There was no significant difference 
in MMP-1. 
Healthy gingiva contained significantly more TIMP-1 than diseased 
gingiva (P =0.011). The same trend was observed forTIMP-2. Higher 
amounts of both TIMP-1 and -2 were found in healthy PDL compared to 
diseased PDL (P =0.004 and Ρ =0.015, respectively). Healthy GCF 
contained more TIMP-1 than diseased GCF (P =0.029), but there was no 
significant difference in the amount of TIMP-2. 
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Gingiva PDL GCF 
Healthy Diseased Healthy Diseased Healthy Diseased 
Fig. 2. Quantitation of MMPs and TIMPs in the periodontium. The amounts of 
MMPs and TIMPs in the gingiva and PDL were analyzed by zymography and 
expressed as mean density χ square millimeter per nanogram protein relative to 
the reference sample (pro-MMP-2 or TIMP-2). The amounts of MMPs and TIMPs 
in the GCF were also analyzed by zymography and expressed as mean density χ 
square millimeter per microliter GCF relative to the reference sample concerned. 
*Significant difference (differences were considered significant if P<0.05, except 
for MMP-2 and -9 and the collagenolytic fragments to which the Bonferroni 
correction was applied: P<0.0017 for MMP-2, ^<0.025 for MMP-9, and the 
collagenolytic fragments), au = arbitrary units. 
MMP activity 
The results of the MMP activity assay are shown in Figure 3. MMP activity 
was three times higher in healthy gingiva than in diseased gingiva {P < 
0.0001). Also, the MMP activity of healthy PDL was higher than diseased 
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PDL (Ρ =0.029), although this difference was small (1.2-fold increase). In 
contrast, there was a large difference between healthy and diseased GCF 
(P =0.029). MMP activity was increased 250-fold in diseased GCF 
compared to healthy GCF. 
0 06 
0 04 
3 
11. 
LX 
0,02 
0 00 
Gingiva PDL GCF 
Fig, 3. General MMP-activity in the periodontal tissues. Samples of gingiva, PDL 
and GCF were analyzed in quadruple with an MMP activity assay. The 
degradation of a fluorescent substrate was expressed as RFUs per second per 
nanogram protein for gingiva and PDL, and per microliter for GCF. *Significant 
difference {P<0.0S). 
Discussion 
In this study, MMPs and TIMPs in healthy and diseased gingiva, PDL, and 
GCF were analyzed to investigate tissue degradation in periodontitis. 
MMPs and TIMPs in gingiva and PDL were analyzed after extraction of 
tissue samples, and those in GCF were studied directly. We found a 
difference in extraction efficiency of total protein between healthy and 
diseased PDL. More protein was extracted from diseased PDL than from 
healthy PDL (92% versus 48%). Surprisingly, the extraction efficiencies 
of healthy and diseased gingiva were similar ( 7 1 % versus 59%). This 
might be due to a difference in the course of the inflammatory process or 
the different composition and architecture of PDL and gingiva. Because 
the MMP content was expressed per nanogram total protein, we corrected 
for this difference. 
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MMPs and TIMPs were analyzed by zymography, which allows the 
detection of latent and active MMPs.3 We found latent and active forms of 
MMP-2 and -9, active MMP-1 and -8, and TIMP-1 and 2 in gingiva, PDL, 
and GCF. These MMPs and TIMPs have also been found in earlier 
studies12 '14,1819 on gingiva and GCF. Moreover, we found considerable 
amounts of MMP-2 complexes in all samples. These have been described 
as MMP-2 dinners28'29 but were never quantified. The MMP-2 complexes 
were also found in GCF samples, which indicates that they are also 
present /n vivo, although this was not clearly confirmed by Western 
blotting. The collagen zymograms showed collagenolytic activity around 
30 kDa in gingiva and PDL but relatively few in GCF. Some of these were 
identified as MMP-8 fragments in gingiva. These fragments were 
described previously30 and so were fragments of MMP-13 31 and MMP-1.32 
The MMP-8 fragments in GCF described by other investigators33 seemed 
to disappear after treatment. The fragments may originate from 
autolysis,34 or the activity of other MMPs.35 The binding of TIMPs to these 
fragments seems to be reduced, so they may be active in the presence of 
TIMPs.32 Because the collagenolytic fragments and MMP-2 complexes 
clearly showed proteolytic activity, they might also play a role in the 
tissue degradation in periodontitis. 
The zymographical analyses of GCF shows that diseased GCF 
contained greater amounts of MMP-2, active MMP-9 and-8, and 
collagenolytic fragments than the healthy fluid; this was also reported 
previously.131819 A chairside test for MMP-8 was developed to support the 
diagnosis of periodontitis and to monitor treatment outcome.36,37 The 
total MMP activity in diseased GCF was ~250 times greater than in 
healthy fluid. This seemed to be mainly caused by MMP-2 because it had 
greater activity toward the fluorescent substrate in this activity assay 
than other MMPs.25 Others studies2'9 also found a higher level of total 
MMP activity in the GCF of periodontitis-affected teeth. In addition, the 
authors and other investigators9 found decreased TIMP-1 content in 
diseased GCF. 
To our knowledge, this is the first report to describe MMPs and TIMPs 
extracted from human PDL tissue. In diseased PDL, more MMP-2 
complexes, MMP-9, and collagenolytic fragments were found than in 
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healthy tissue. The amount of collagenolytic fragments was six times 
higher m diseased PDL than in healthy tissue. In addition, TIMPs were 
reduced by approximately half in PDL. Unexpectedly, we found higher 
levels of active and pro-MMP-2 and active MMP-1 and -8 in healthy PDL. 
The total MMP-activity was also slightly higher in the healthy tissue. 
In our study, some profound differences existed between the 
healthy and diseased subjects. The subjects with periodontitis were about 
twice as old as the healthy group (mean age: 52.0 versus 25.9 years). 
This is a common problem in periodontitis studies, because the disease 
usually occurs at a later age. General age-related differences have been 
described for the PDL. These include differences in composition, 
architecture, and width of the PDL, and impaired regeneration.38,39 To the 
best of our knowledge, this is the first report of age-related changes m 
MMP levels m PDL. Studies40,41 on other tissues, like cartilage and 
myocardial tissue, showed a decrease m MMPs with aging. In contrast, 
other investigators42 showed an increase in MMPs in aortic tissue. The 
healthy group consisted mainly of women, whereas the diseased group 
consisted of equal numbers of men and women. Although not much is 
known about sex differences and MMP levels m humans, rat studies43,44 
showed that estradiol promotes MMP-expression. 
In gingiva, 36% more MMP-1 was found in the diseased tissue than 
m healthy tissue. The presence of MMP-1 in gingival epithelium was 
shown previously by in situ hybridization.45 In addition to MMP-8, MMP-1 
was recently associated with periodontal inflammation.46 Higher TIMP-1 
levels were present in healthy gingiva. Unexpectedly, pro- and complexed 
MMP-2, and both forms of MMP-9 were also higher in the healthy gingiva, 
as was total MMP activity. Diseased gingiva was derived from patients 
that displayed ongoing attachment loss, despite good oral hygiene. It is 
conceivable that the gingiva no longer showed profound signs of clinical 
inflammation, whereas the inflammatory process in the depth of the 
pockets persisted. In these cases there may be a subclinical inflammation 
which maintains periodontal breakdown.47 In addition, there was a 
considerable age difference between the healthy (mean age: 23.2 years) 
and the diseased subjects (mean age: 51.6 years). 
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Conclusions 
MMPs and TIMPs in the healthy and diseased periodontium have been the 
focus of many studies. In this study, in addition to other MMPs and 
TIMPs, collagenolytic fragments and MMP-2 complexes have been 
quantified in the gingiva, PDL, and GCF. Their function in vivo is not 
clear, but they exert profound proteolytic activity and might also 
contribute to tissue destruction in periodontitis. In addition, this study 
showed that patient characteristics, such as age, sex, and degree of 
inflammation might explain the apparent controversial results found in 
this and earlier studies. 
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Abstract 
Objective 
Orthodontic tooth movement requires extensive remodeling of the 
periodontal l igament (PDL) and the alveolar bone. Osteoclasts resorb 
bone, allowing teeth to migrate in the direction of the force. Matrix 
metalloproteinases (MMPs) are able to degrade the extracellular 
matrix of the periodontal tissues. Chemically modified tetracyclines 
(CMTs) can inhibit MMPs, but lack antimicrobial activity. We 
hypothesize that CMT-3 will decrease the rate of orthodontic tooth 
movement in the rat. 
Design 
Eighteen Wistar rats received a standardized orthodontic appliance at 
one side of the maxil la. During 14 days, three groups of six rats 
received a daily dose of 0, 6 or 30 mg/kg CMT-3, and tooth 
displacement was measured. Thereafter, osteoclasts were counted on 
histological sections using an ED-1 staining. Mult i- and mononuclear 
ED-1-positive cells in the PDL were also counted. In addit ion, sections 
were stained for MMP-9. 
Results 
CMT-3 significantly inhibited tooth movement (p = 0.03) and also 
decreased the number of osteoclasts at the compression sides in the 
30 mg/kg group (p < 0.05). Significantly more mono- than 
multmuclear ED-1-positive cells were present in the PDL, but no 
significant differences were found between the dosage groups. 
Osteoclasts in the 30 mg/kg group seemed to contain less MMP-9 
than in the control. 
Conclusions 
CMT-3 inhibits tooth movement m the rat, probably by reducing the 
number of osteoclasts at the compression side. This might be due to 
induction of apoptosis in activated osteoclasts or reduced osteoclast 
migration. Reduced MMP activity by CMT-3 might also directly inhibit 
degradation of the organic bone matrix. 
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Introduction 
The periodontal ligament (PDL) has a relatively high turnover rate1 
and can therefore quickly adapt to mechanical forces, as for example 
during orthodontic tooth movement.2 ,3 The PDL is the first tissue to 
react to force application and without remodeling of the PDL, 
orthodontic tooth movement is not possible.4,5 Mechanical loading of 
the PDL induces the recruitment of osteoclasts.5 These cells are 
responsible for bone resorption during tooth movement, allowing the 
tooth to migrate in the direction of the applied force. Matrix 
metalloproteinases (MMPs) are essential for the degradation of the 
extracellular matrix of the periodontal tissues during remodeling.6 
Elevated MMP levels have also been detected in crevicular fluid of 
orthodontic patients.7 MMPs produced by osteoclasts are able to 
solubilize the bone matrix.8 In addition to their role in physiological 
remodeling and tooth movement, MMPs also play a role in 
pathological tissue degradation as in periodontit is.9 
In the 1980s it was found that tetracyclines inhibit MMP activity 
and by that could be useful in the treatment of periodontitis.10 This 
led to the development of chemically modified tetracyclines (CMTs), 
which lacked antimicrobial activity but retained anti-MMP activity.11 
Up to now eight different CMTs have been described.12 Their 
mechanism of action is still not completely clear, but they are 
probably able to down-regulate MMP expression, inhibit pro-MMP 
activation or directly inhibit active MMPs.13 Several authors have 
investigated the inhibitory effects of CMTs on MMP activity in vitro 
and describe CMT-3 as one of the most potent CMTs.14"16 Specifically 
MMP-9 has been shown to be important for the migration of 
osteoclasts.17 I t is conceivable that inhibition of this MMP by CMT-3 
leads to an impaired osteoclast migration. CMTs may also directly 
inhibit the development of the ruffled border and thereby inhibit the 
resorbing activity of osteoclasts.18 Also, osteoclast formation from 
precursor cells might be impaired by CMT-3.19 In a periodontitis 
model in rats, bone loss was prevented by CMTs.20,21 
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We hypothesize that CMT-3 will reduce orthodontic tooth 
movement m our rat model by the inhibition of MMPs and a direct or 
indirect inhibitory effect on osteoclasts. 
Material and methods 
Animals 
Eighteen young adult male Wistar rats (body weight 290-330 g) were 
used. The animals were acclimatized in the animal laboratory for 1 
week before the start of experiment. Housing was under normal 
laboratory conditions and the animals received powdered laboratory 
rat chow (Sniff, Soest, The Netherlands) and water ad libitum. A 
standard 12-h light: 12-h dark cycle was maintained. The experiment 
was approved by the Board for Animal Experiments of the Radboud 
University Nijmegen, The Netherlands. 
Appliance 
All 18 rats received an orthodontic appliance that delivered a mesially 
directed constant force of 10 cN to the three molars together at the 
right side of the maxilla, according to the split-mouth rat model 
described by Ren et al.22 The appliance was placed under general 
anesthesia. 
Administration of CMTs 
The rats were divided into three groups of six rats. The first group 
received a daily dose of ImL of vehicle only, by oral gavage, during 14 
days. The vehicle consisted of 2% carboxymethylcellulose in physiological 
saline. Groups 2 and 3 were given a daily dose of 1 mL vehicle with 6 and 
30 mg CMT-3/kg bodyweight, respectively. CMT-3 was a gift of 
CollaGenex Pharmaceuticals, Inc. (Newtown, Pennsylvania, USA). The 
increase in body weight was similar in all three groups. 
Measurement of orthodontic tooth displacement 
Orthodontic tooth displacement was measured with a digital caliper 
(Mitutoyo CO., Kawasaki, Japan) under general inhalation anesthesia 
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(isofluorane and N2O, Abbott B.V., Hoofddorp, The Netherlands) at days 
0, 3, 7, 10, and 14. The distance between the most mesial point of the 
maxillary molar unit and the enamel-cementum border of the ipsilateral 
maxillary incisor at the gingival level was measured at the experimental 
and the control side. This split-mouth design was used to avoid 
confounding as a result of physiological distal drift of the rat molars, 
growth of the snout and the concomitant forward movement of the 
incisors, and the possible bilateral distal tipping of the incisors that are 
used as anchorage. Calculation of the differences between the incisor-
molar distances at the experimental and the control sides compensated 
for these effects. The net amount of orthodontic tooth displacement was 
considered to be the change in these differences.22 
Histology 
On day 14, the rats were anaesthetized with inhalation gas and were 
perfused through the left heart ventricle with 4 % freshly made 
paraformaldehyde solution in 0.1 M phosphate-buffered saline (PBS). 
After perfusion, the right and left parts of the maxillae were dissected 
and fixated in 4 % paraformaldehyde for an additional 24 h at 4 0C. 
After decalcification in 10% EDTA in water (pH 7.4) and paraffin 
embedding, parasagittal 7 pm sections were cut. Sections were 
mounted on SuperFrost/Plus slides (Menzel-Gläser, Braunschweig, 
Germany) and stained with haematoxylin-eosin for a general tissue 
survey. 
For immunohistochemistry, selected paraffin sections were 
deparaffinated and rehydrated. Osteoclasts were identified by the ED-
1 mouse-ant i - rat monoclonal antibody (Instruchemie, Delfzijl, The 
Netherlands). This antibody recognizes a single-chain glycoprotein of 
90-110 kDa that is expressed predominantly on the lysosomal 
membrane of myeloid cells.23 Next to macrophages and monocytes, it 
binds to osteoclasts and their precursors.24"26 Prior to the ED-1 
staining, the sections were pre-incubated with 0 . 1 % trypsin in 
Tris/HCI buffer and treated with 3% H2O2 in PBS to inactivate 
endogenous peroxidase. The sections were blocked with 5% BSA in 
PBS (Sigma-Aldrich, St. Louis, MO, USA) and incubated with the ED-1 
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antibody 1:200 in 2% normal donkey serum (NDS, Biomeda, Foster 
City, CA, USA) in PBS at 40C overnight. After washing, the sections 
were incubated with a biotinylated donkey antimouse IgG antibody 
(Jackson ImmunoResearch, Westgrove, PA, USA). The sections were 
then incubated with ABC-peroxidase (Vector Laboratories, 
Burlmgham, CA, USA), which was visualized by Sigma Fast™ (Sigma). 
The staining was enhanced with 0.5% CuSCU in 0.9% NaCI. 
For the detection of MMP-9, the immunohistochemical procedure was 
similar to that of ED-1. The sections were washed, heated in 10 mM 
citrate buffer to 70oC m a microwave oven for 10 min, and incubated 
with 0.075% trypsin at 370C for 5 min. The sections were then rinsed in 
0.075% glycine in PBS (PBSG) and pre-incubated in 10% NDS (Biomeda) 
in PBSG for 15 mm. After removal of the pre-incubation medium, the 
monoclonal antibody against MMP-9 (Oncogene) was applied 1:20 m 2% 
NDS in PBS for 1 h. The sections were rinsed in PBSG again three times 
for 5 min and a biotin-conjungated donkey anti-mouse second antibody 
(DaMBiO) 1:500 in 2% NDS in PBS (Biomeda) was applied. The 
immunolocalization was the same as for ED-1 staining. Sections without 
the primary antibodies were used as a negative control and were always 
blank. 
Cell counting 
Three sections with an interval of 20-25 sections were chosen for both 
the experimental and control teeth of each rat. Sections showing the pulp 
of at least one root were selected for each study side. The mesial root of 
the first molar was excluded because it does not run perpendicular to the 
direction of tooth movement. In each section osteoclasts were counted at 
the mesial and distal side of the selected roots. Cells were considered to 
be osteoclasts if they were multinucleated, ED-1-positive, and located on 
or close to the bone surface.25,27 Osteoclasts within bone marrow spaces 
were not included. The counts from the three sections of each side 
(mesial or distal) were averaged to obtain the mean number of 
osteoclasts per side for each study root. 
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The same procedure was followed to count mono- and 
multinuclear ED-1-posltive cells in the PDL. They were counted on the 
same sections of both the experimental and the control teeth of each 
rat. The countings in the PDL were performed next to the same roots 
that were used for the osteoclast countings. Only ED-1-positive cells 
that were not in contact with the bone or the root surface were 
counted. All countings were performed by the same investigator. 
Statistics 
The inhibiting effect of CMT-3 on the amount of tooth movement in 
the three experimental groups was evaluated with a regression 
analysis. Paired f-tests were performed to analyze differences in the 
number of osteoclasts between the mesial and distal sides of the 
roots. The same was done for the ED-1-positive cells in the PDL. The 
osteoclast numbers of the experimental and control roots in each 
group were compared with a Wilcoxon signed rank test because of a 
difference in variance. The differences in osteoclast numbers at either 
side of the roots between the three groups were compared with a 
Kruskall-Wallis one-way analysis of variance. The same was done for 
the countings of the ED-1-positive cells in the PDL. The Student 
Newman Keuls test was used as a post hoc test. 
Differences were considered significant at ρ < 0.05. 
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Results 
Amount of orthodontic tooth displacement 
Figure 1 shows tooth displacement in t ime. After 14 days, the molars 
of the animals in the 0, 6 and 30 mg/kg group had moved over 1.72 
± 0.53, 1.45 ± 0.18 and 1.13 ± 0.13 m m , respectively. The slopes of 
the regression lines through the data points of each rat represent the 
rate of orthodontic tooth movement. A regression analysis showed a 
significant dose-dependent inhibition of tooth movement by CMT-3 ( p 
= 0.03). 
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Fig. 1. The effect of CMT-3 on tooth movement. Orthodontic tooth movement 
was significantly inhibited by CMT-3 in a dose-dependent way (p = 0.03). The 
data are shown as means ± S.D. 
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Histology 
Figure 2A shows an overview of an orthodontically moved second molar. 
ED-1-positive cells are visible as dark spots and are almost exclusively 
located at the mesial bone surfaces and in the marrow spaces. Cells were 
regarded as osteoclasts according to the criteria as described in the 
paragraph on cell counting in Section 2. In panel 2B similar areas as 
indicated by the square in Figure 2A are represented. Figure 2B1 shows a 
control root of a rat that received no CMT-3. Distally from the root 
osteoclasts are present on the alveolar bone. Hardly any positive cells are 
present at the mesial side. Figure 2B2 shows a control root of a rat from 
the 30 mg/kg group. The distribution of ED-1-positive cells is similar. At 
the mesial side of a representative experimental root of the Omg/kg 
group, many osteoclasts are lining the alveolar bone, while at the distal 
side only few are present (Fig. 2B3). However, at an experimental root of 
the 30 mg/kg group (Fig. 2B4), less osteoclasts are present at the mesial 
side compared to the 0 mg/kg group. Figure 2C shows a larger 
magnification of an osteoclast stained with ED-1. The cell is close to the 
bone and has multiple nuclei. 
Representative stainings for MMP-9 are shown in Figure 3. The 
figure shows the mesial side of the experimental roots. Osteoclasts 
are visible as brown cells lining the alveolar bone surface. The 
osteoclasts in the 30 mg/kg group (Fig. 3B) seemed to stain less for 
MMP-9 compared to the 0 mg/kg group (Fig. 3A). 
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(B) 
0 mg CMT-3 
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(C) 25μπη 
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Fig. 2. Histological sections of rat molars stained 
with haematoxylin-eosin and ED-1. (A) Overview of 
an experimental molar. Dentin (D), pulp (P), 
alveolar bone (B), and the periodontal ligament (L) 
are indicated. ED-1-positive cells are stained brown. 
The frame indicates a field of interest, viewed in 
more detail in (B). (B) Control (1 and 2) and 
experimental (3 and 4) roots of rats that received 0 
mg/kg (1 and 3) or 30 mg/kg (2 and 4) CMT-3. The 
small arrows indicate osteoclasts, the large arrows 
indicate the direction of force in the experimentally 
moved teeth. (C) Detailed picture of an ED-1-
stained osteoclast. 
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Fig. 3. Immunohistochemical staining for MMP-9. Both pictures show the mesial 
side of the bone of experimental roots in the Omg/kg group (A) and the 30 
mg/kg group (B). The large arrows indicate the direction of force. The small 
arrows indicate osteoclasts. 
Osteoclast number 
Osteoclasts were counted at the mesial and distal sides of the roots 
(Fig. 4). At the mesial sides of the control teeth, 0.5 ± 0.5, 0.3 ± 0.2 
and 0.3 ± 0.3 osteoclasts were found for the 0, 6 and 30 mg/kg CMT-
3 groups, respectively (Fig. 4A). These differences were not 
significant. At the distal sides of the control teeth 14.3 ± 2.8, 13.6 ± 
5.7 and 14.0 ± 3 . 1 osteoclasts were present, respectively. The 
number of osteoclasts at the distal sides of the control roots did not 
differ significantly between the three CMT groups. Significantly more 
osteoclasts were present at the distal sides than at the mesial sides 
{p < 0.05). 
At the mesial sides of the experimental teeth, 12.0 ± 4.7, 14.8 
± 4.1 and 6.9 ± 3.1 osteoclasts were present in the 0, 6 and 30 
mg/kg group, respectively (Fig. 4B). The number of osteoclasts in the 
30 mg/kg group was significantly lower than in the 0 and 6 mg/kg 
groups {p < 0.05). At the distal sides, 0.9 ± 0.7, 0.9 ± 0.5 and 1.9 ± 
1.4 osteoclasts were present in the 0, 6 and 30 kg/mg group, 
respectively. This was not significantly different. In all three groups 
the number of osteoclasts at the distal side was significantly lower 
than at the mesial side {p < 0.05). 
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F/g. 4. Osteoclast numbers in the experimental and control roots. Osteoclasts 
were counted at the mesial and distal sides of the roots. (A) At the distal sides of 
the control teeth far more osteoclasts were present than at the mesial sides (*p 
< 0.05). (B) The number of osteoclasts was significantly lower at the mesial side 
of the experimental teeth in the 30 mg/kg group, than in the 0 and 6mg/kg 
group {#p = 0.037). In all three groups the number of osteoclasts at the distal 
sides was significantly lower than at the mesial sides {*p < 0.05). 
ED-1-posit ive cells in the PDL 
Mono- and multlnuclear ED-1-positive cells were counted separately 
to discriminate between osteoclasts and precursor cells. Figure 5 
shows that both mono- and multlnuclear cells are present in the PDL 
in all groups. Figure 6 shows the quantified results of these 
observations. 
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Distal Mesial 
30 mg ι 
Fig. 5. Details of histological sections of rat molar roots stained with 
haematoxylln-eosln and ED-1. The pictures show experimentally moved roots of 
rats that received 0 mg/kg (A) or 30 mg/kg CMT-3 (B). The small arrows 
indicate mononuclear ED-1-positive cells in the PDL and the large arrows 
multinuclear ED-1-positive cells. 
| I 
E 
c 
40 -, 
30 -
20 -
10 
1 
• H Multinuclear 
ι ι Mononuclear 
i 1 i 
M D M D M D 
0 6 30 
CMT-3 (mg/kg) 
Fig. 6, Numbers of ED-1-posltlve cells in the PDL at the experimental roots. 
Mononuclear as well as multinuclear cells were counted at the mesial (M) and 
distal (D) sides of the roots. At all sides, significantly more mononuclear cells 
were present compared to multinuclear cells (*p = 0.001). No significant 
differences were found between the numbers of mono- or multinuclear cells in 
the different dosage groups. 
"3 
For the 0, 6 and 30 mg/kg group the numbers of mononuclear 
cells were 32.4 ± 7.0, 26.6 ± 8.1 and 21.7 ± 6.4 at the mesial sides 
and 26.3 ± 7.9, 20.8 ± 8.0 and 21.7 ± 6.4 at the distal sides, 
respectively. In all groups the numbers of mononuclear cells were 
significantly higher than the numbers of multinuclear cells; 7.2 ± 1.7, 
8.8 ± 4.3 and 8.9 ± 3.6 at the mesial sides and 4.7 ± 1.6, 2.9 ± 2.0 
and 5.7 ± 2.5 at the distal sides for the 0, 6 and 30 mg/kg group, 
respectively (p = 0.001). Between the different CMT dosage groups, 
no significant differences were found in the number of mononuclear 
cells or in the number of multinuclear cells. Although there seemed to 
be more mono- and multinuclear ED-1-positive cells at the mesial 
side compared to the distal side within the same dosage groups, this 
difference was not significant. 
Discussion 
The effects of CMT-3 on the rate of tooth movement and the number 
of osteoclasts on the alveolar bone surface were studied in the rat 
model as developed by Ren eta/.22 CMT-3 significantly reduced the 
rate of tooth movement in a dose-dependent way. This is in 
agreement with a previous study using an other synthetic MMP 
inhibitor.28 The present study further showed that a larger number of 
osteoclasts was present at the distal than at the mesial sides of the 
control roots. This corresponds with the earlier findings of Ren et al.27 
The presence of osteoclasts at the distal sides is probably related to 
the physiological distal drift.29 In our 2-week experiment, the amount 
of distal drif t was too small to measure a significant displacement 
and, therefore, the effect of CMTs on this process could not be 
determined. An effect of CMT-3 on distal drift is, nevertheless, not 
likely since the number of osteoclasts at the distal sides of the control 
roots was similar for all CMT-3 concentrations. 
As expected, the mesially directed orthodontic force induced a 
strong increase m the number of osteoclasts at the mesial side of the 
roots and a reduction at the distal side. The reduction at the distal 
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side was independent of CMT-3 administration. However, the increase 
at the mesial side was strongly inhibited by CMT-3. 
Several inhibitory effects of CMTs on osteoclasts have been 
proposed by others. Some in vivo ana in ^/fro studies suggest that 
CMTs inhibit the differentiation of osteoclasts from their precursors or 
stimulate osteoclast apoptosis.18,19,30 Since CMT-3 had no effect on 
the number of osteoclasts at the control roots in our study, an 
inhibitory effect on differentiation is more likely than a stimulation of 
osteoclast apoptosis. However, the number of ED-1-positive cells in 
the PDL was not affected by CMT-3. This suggests that CMT-3 has 
only an inhibitory effect on active osteoclasts, and not on osteoclast 
recruitment. I t might only stimulate apoptosis in activated 
osteoclasts, which explains their lower number. An alternative 
explanation is that the number of ED-1-positive multinuclear cells in 
the PDL is in fact decreased, but it is compensated by osteoclasts 
detached from the bone. Other investigators have shown that 
tetracyclines reduce the number of podosomes in osteoclasts, which 
suggests that the adhesion of osteoclasts to the bone is impaired.31 
Next to an inhibition of their differentiation, the migration of 
osteoclasts might have been impaired by CMT-3. MMP-9 produced by 
osteoclasts is crucial for their migration through the collagen 
matrix.32 An inhibition of MMP-9 activity might therefore lead to 
impaired osteoclast migration and hence to an impaired recruitment 
to the compression side. Our histological sections indeed seem to 
show less MMP-9 expression in the osteoclasts of the 30 mg/kg 
group, although this was not quantif ied. The activity of MMP-9 might 
also have been inhibited by CMT-3, but this cannot be detected by 
immunohistochemistry. 
Since MMPs produced by osteoclasts are involved in bone matrix 
breakdown,8 CMTs may also directly inhibit tooth movement. 
Alternatively, CMTs mayhave an indirect effect on bone resorption by 
inhibiting MMPs produced by osteoblasts. Osteoblast collagenases are 
thought to remove the unmineralized osteoid, allowing osteoclasts to 
adhere to the mineralized bone and start bone resorption.33 
Moreover, inhibition of collagenases may also inhibit osteoclast 
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activation, since collagen degradation fragments are known to 
stimulate their activity.34 Lastly, an other tetracycline derivative, 
minocycline, was shown to increase cytosolic calcium in osteoclasts in 
vitro and thereby inhibit bone resorption.35 This might also occur with 
CMT-3. 
In conclusion, the hypothesis that CMT-3 reduces orthodontic 
tooth movement was confirmed by our study. This effect is most 
likely due to a direct inhibition of MMP activity as well as a decrease 
of the number of osteoclasts. CMT-3 might cause apoptosis m 
activated osteoclasts, their detachment from the bone, or an impaired 
differentiation from mononuclear into multmuclear precursor cells. 
More research has to be done to further elucidate the exact 
mechanisms of CMT action. Orthodontic tooth movement is often 
followed by relapse, which is the tendency of teeth to move back to 
their pre-treatment position. In relapse the same remodeling 
processes are thought to occur as m orthodontic tooth movement. 
Since CMTs are able to reduce the rate of orthodontic tooth 
movement, they might be useful in the prevention of relapse. 
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Summary 
Orthodontic tooth movement requires extensive remodelling of the 
periodontium. Matrix metalloprotemases (MMPs) degrade the 
extracellular matrix during remodelling, while their activity is regulated 
by the tissue inhibitors of metalloprotemases (TIMPs). The aim of this 
study was to investigate differences in MMP and TIMP levels in the 
gingival crevicular fluid (GCF) at the resorption and apposition sides of 
orthodontically moved teeth and to compare these with control teeth. 
GCF samples were collected from eight orthodontic patients wearing fixed 
appliances with superelastic mckel-titamum coilsprmgs. The samples 
were analyzed by gelatin zymography, which allows the detection of both 
active and latent MMPs, and by reverse zymography for analysis of 
TIMPs. Western blotting was performed to confirm the identity of MMPs. 
The data were analyzed using either one-way ANOVA or the Kruskal-
Walhs test. 
In general, higher levels of MMPs and TIMPs were found both at the 
resorption and apposition sides compared with the control teeth. 
Remarkably, partially active MMP-1 was found in GCF from both the 
resorption and the apposition side but was barely present at the control 
teeth. TIMP-1 was strongly increased at the apposition side. Gelatmases 
were mainly present at the resorption side, while gelatinolytic fragments 
were exclusively detected at the apposition side. MMP-9, which is known 
to be involved in bone degradation, and a 48 kDa gelatmase were 
increased at the resorption side. The small increase in TIMP-1 at the 
resorption side might stimulate bone resorption, whereas the large 
increase at the apposition side reduces bone resorption. The analysis of 
MMPs and TIMPs may contribute to the improvement of orthodontic 
treatment regimens. 
122 
MMPs and TIMPs in crevicularfluid during orthodontic tooth movement 
Introduction 
Orthodontic tooth movement requires extensive remodelling of the 
periodontium. Remodelling Is thought to be Initiated In the periodontal 
ligament (PDL).1 A family of proteases that play a key role in the 
remodelling of the extracellular matrix (ECM) are the matrix 
metalloprotelnases (MMPs). To the present, 23 human MMPs have been 
described.2 Based on their molecular structure and substrate preference, 
the MMPs can be divided Into several groups: collagenases (MMP-1, -8, 
and -13), gelatlnases (MMP-2, and -9), stromelysins (MMP-3, -10, and 
-11), membrane-type MMPs (MMP-14, -15, -16, and -17), and a group of 
miscellaneous MMPs.2 MMPs are secreted as Inactive pro-enzymes, which 
can be activated by proteolytic processing In the ECM.2 The activity of 
MMPs Is controlled by the tissue Inhibitors of metalloprotelnases (TIMPs).3 
MMPs and TIMPs play an Important role in the physiological remodelling 
of the periodontium,4 as well as in the response to mechanical forces 
during orthodontics.5 The inhibition of MMPs by synthetic MMP-inhlbitors 
has been shown to reduce orthodontic tooth movement.6,7 
Experimental orthodontic tooth movement In animals, mostly rats, 
shows an Increased expression of MMP-1, -2, -8, -9, and -13, and TIMP-1 
and -3 In the PDL and alveolar bone.8'11 MMP-1 was also Increased In the 
gingiva during tooth movement In dogs.12 In the gingival crevlcular fluid 
(GCF) of orthodontic patients, MMP-2 and -8 are Increased, and 
sometimes also MMP-1.5 '13 '14 In the PDL of orthodontic patients, MMP-1 
messenger RNA (mRNA) expression Is upregulated at both the resorption 
and apposition side, whereas TIMP-1 mRNA Is Increased only at the 
apposition side.15 None of the methods used differentiates between the 
active and latent forms of the MMPs. Previous studies point towards an 
increase In MMPs, specifically collagenases, and TIMPs In orthodontic 
tooth movement at the apposition as well as the resorption side. At both 
sides extensive remodelling takes place to allow orthodontic tooth 
movement. 
The aim of this study was to investigate differences In latent and 
active MMPs, and TIMPs in the GCF at the resorption and apposition side 
of orthodontlcally moved teeth, and to compare these with control teeth. 
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The samples were analyzed by zymography, which allows the detection of 
both active and latent MMPs. 
Subjects and Method 
Collection of gingival crevicular fluid 
GCF samples were collected from eight orthodontic patients [two males, 
six females, aged 10-18 yrs (mean 13.6 ± 2.6)]. All patients were 
treated at an academic orthodontic clinic. They all had fixed appliances 
with superelastic NiTi coilspnngs (GAC international inc., Bohemia, New 
York, USA) that gave light continuous forces of approximately 150 cN. 
The following inclusion criteria were applied: no use of medication, good 
periodontal health (score 0 according to the Dutch Periodontal Screening 
Index, DPSI)16, and the presence of one or more teeth that were not 
orthodontically moved. The study was approved by the local medical 
ethics committee (CMO, Amhem-Nijmegen, the Netherlands). All patients 
gave their written consent to participate in the study. GCF was collected 
at the apposition and resorption sides of teeth that were orthodontically 
moved, and around control teeth. The type and number of teeth differed 
between the patients depending on the treatment plan. In most cases 
both upper first premolars were distahzed. Sampling was performed just 
before a control visit with all orthodontic appliances left in situ. All 
experimental teeth had been moved for about 4 weeks before sampling. 
The teeth at the sampling sites were isolated with cotton rolls and gently 
dried with air. Thereafter, a 1 μΙ microsynnge (Hamilton, Reno, Nevada, 
USA) was carefully inserted into the sulci to collect GCF. This was done 
three times per sampling site with an interval of 2 minutes. The GCF 
samples were immediately placed on ice and stored at -80oC until use. 
The GCF samples were pooled to obtain a pool from the resorption sides, 
a pool from the apposition sides, and a control pool. These were run in 
triplicate (gelatin and reverse zymography) or duplicate (collagen 
zymography). 
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Gelatin zymography 
Gelatinases (MMP-2 and -9) in the samples were analyzed in triplicate by 
gelatin zymography. The Polyacrylamide gel (7.5 per cent) contained 3.5 
mM sodium dodecyl sulphate (SDS) and 1 mg/ml gelatin, as described by 
Waas eta/.17 A (1:1) mixture of sample and sample buffer was then 
electrophoresed for 1.5 h at 80 mA. A Broad Range Marker (Bio-Rad, 
Hercules, California, USA) ranging from 6.4 to 203 kDa was included to 
determine the molecular weight of the MMPs. Recombinant human 
proMMP-2 (Oncogene, CN Biosciences, San Diego, California, USA) was 
used as a reference sample. After electrophoresis, the gels were washed 
in 2.5 per cent Triton X-100 (Sigma-Aldrich, Missouri, USA) to remove 
the SDS, and the marker bands were indicated. The gels were then 
incubated in activation buffer, containing 50 mM Tris-HCL (pH 7.8), 5 mM 
CaCb and 0.1 per cent Triton X-100, at 370C for 18 hours. They were 
stained for 45 minutes with 2.5 g/l Coomassie Brilliant blue R250 
(Imperial Chemical Industries Pic, London, UK), 10 per cent acetic acid 
and 40 per cent methanol in water, and thereafter destained with 10 per 
cent acetic acid and 40 per cent methanol in water. The MMPs appear as 
bright bands within the stained gel. The gels were scanned with a Hewlett 
Packard ScanJet 4C/T, and the bands were analyzed with Quantity One 
software (Bio-Rad). The amount of enzyme in the bands was represented 
as average density χ mm2/Ml GCF. The proMMP-2 reference sample 
enabled comparison of the corresponding bands on different gels. First, 
within each gel, the amount of enzyme in the reference sample was 
arbitrarily set to 1, and all other bands were calculated relative to it. 
Then, the corresponding bands on the different gels were averaged and 
standard deviations were calculated. The amount of pro-MMP-9 in the 
samples was too high for a reliable analysis. Therefore, it was repeated 
after dilution of the samples. 
Collagen zymography 
Collagenases in the samples were analyzed in duplicate by collagen 
zymography. The Polyacrylamide gel (10 per cent) contained 3.5 mM 
SDS and 5 mg/ml collagen type I from calfskin (Sigma-Aldrich). A (1:1) 
mixture of sample and sample buffer was then electrophoresed. A Broad 
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Range Marker (Bio-Rad) ranging from 6.4 to 203 kDa was included to 
determine the molecular weight of the MMPs. Recombinant human pro-
MMP-1, and -8 (Oncogene) were used as a standards. After 
electrophoresis, the gels were washed in 2.5 per cent Triton X-100 
(Sigma-Aldrich) to remove the SDS. The gels were then incubated m 
activation buffer at 370C for 43 hours. They were stained and destained 
as described for the gelatin zymography. The MMPs appear as bright 
bands within the stained gel. Thereafter, the gels were scanned and 
analyzed as described for the gelatin zymography. The collagenolytic 
bands at 44 and 41 kDa were identical to those seen in gelatin 
zymography. For quantification, only the results of the gelatin 
zymograms were used. 
Reverse zymography 
TIMPs m the samples were analyzed in triplicate by reverse zymography. 
This technique is similar to gelatin zymography, except that conditioned 
medium from baby hamster kidney cells (BHK-21, ATCC, Rockville, 
Maryland, USA) was included in the gels. This medium mainly contains 
MMP-2. The MMP-2 degrades all gelatin in the gel, except where TIMPs 
are present. The Polyacrylamide gel (15 per cent) contained 3.5 mM SDS, 
1 mg/ml gelatin and 10 per cent conditioned medium from BHK-21 cells. 
A (1:1) mixture of sample and sample buffer was then electrophoresed 
for 3 hours at 80 mA. A Broad Range Marker (Bio-Rad) was included to 
determine the molecular weight of the TIMPs. Recombinant human TIMP-
1 and -2 (Oncogene) were used as standards. After electrophoresis the 
gels were washed in 2.5 per cent Triton X-100 (Sigma-Aldrich) to remove 
the SDS. The gels were then incubated in 50 mM Tns-HCL (pH 7.5), 5 
mM CaClz and 0.1 per cent Triton X-100 and 0.2 M NaCI at 37°C for 18 
hours. They were stained and destained, following the same method as 
described for gelatin zymography. The TIMPs appear as dark blue bands 
within the destained gel. Thereafter, the gels were scanned and analyzed 
as described for gelatin zymography, except that TIMP-2 was used as a 
reference to enable comparison of the corresponding bands on different 
gels. 
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Western blotting 
GCF samples were analyzed by Western blotting according to standard 
procedures.1 8 In short, a 10 μΙ sample was dissolved in 10 μΙ sample 
buffer and electrophoresed on a 7.5 per cent Polyacrylamide gel (room 
temperature, 80 mA). The proteins were blotted onto a nitrocellulose 
membrane (pore size 0.45pm, Bio-Rad) at 400 mA and 40C for 1 hour. 
Then, the membrane was incubated in block buffer [ 5 % milk powder 
(Elk, Campina, the Netherlands) and 0.1 per cent Tween 20 (Sigma) in 
phosphate-buffered saline (PBS)]. Thereafter, the blots were incubated 
with monoclonal antibodies against MMP-1, -2, -8, -9, or -13 (all 
Oncogene), dilution 1:200, (except for MMP-2; dilution 1:500) at 40C for 
18 hours. After washing with 0.1 per cent Tween 20 in PBS, the blots 
were incubated with a peroxidase-conjungated goat anti-mouse IgG (BD 
Biosciences, San Jose, California, USA), diluted 1:5000 in 1 per cent 
bovine serum albumin, 0.1 per cent Tween in PBS, for 1 hour. After 
washing, the membranes were incubated with ECL Plus™ reagent (GE-
Healthcare, Chicago, Illinois, USA) for chemiluminesence detection. 
Excess ECL reagent was removed, and the membrane was exposed to a 
Kodak Biomax film (Eastman Kodak Company, Rochester, New York, 
USA) for 1 hour and developed. 
Statistical analysis 
The difference in levels of MMPs and TIMPs between the resorption, 
apposition, and control samples was evaluated by one-way analysis of 
variance (ANOVA). The Tukey's HSD test was used as a post-hoctest. 
The Kruskal-Wallis test was used in case of a non-normal distribution or if 
there was a considerable amount of difference in variance. This was the 
case in the data for pro-MMP-2, MMP-2 complex, pro-MMP-9, and the 48 
kDa gelatinase. For clarity, all results are displayed as the mean and SD. 
The Mann-Whitney U test was used after the Kruskal-Wallis test. When 
multiple ANOVAs were performed, the Bonferroni correction was applied. 
Differences were considered significant at P<0.05. 
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Results 
Gelatin zymography 
The gelatin zymograms showed that GCF contains gelatinolytic activity in 
bands around 132, 92, 82, 68, 62, 44, and 41 kDa (Figure 1A). In the 
apposition and resorption samples, a band at 48 kDa was also detected. 
Only the apposition sample showed bands at 33 and 34 kDa. The 
reference samples indicated that the bands at 132, 68, and 62 kDa were 
complexed MMP-2, pro-MMP-2, and active MMP-2, respectively. The 
bands at 92 and 82 kDa (faint) were most likely pro-MMP-9 and active 
MMP-9 respectively. The band at 92 kDa was identified as active MMP-9 
by Western blotting, but the 82 kDa band was not detected. The band at 
48 kDa was only found on the gelatin zymograms and not on the collagen 
zymograms, suggesting that it is a gelatinase. 
Reverse zymography 
The reverse zymograms (Figure IB) showed two distinct bands around 28 
and 30 kDa, representing two forms of TIMP-1, as described earlier.19 
The standard TIMP-2 showed a band at 21 kDa; however, this band was 
not present in the GCF samples. 
Collagen zymography 
The collagen zymograms showed bands comparable with those in the 
gelatin zymograms at 44 and 41 kDa (Figure 1C). The control lacked a 
distinct band at 44 kDa, but showed a faint wide band of collagenolytic 
activity. The MMP-1 standard indicated that the bands around 44 and 41 
kDa were active forms of MMP-1 as confirmed by Western blotting. These 
are referred to as 'partially active' (44 kDa) and 'fully active' (41 kDa) 
MMP-1 as described by Rao et al.20 The standard MMP-1 showed two 
distinct bands around 37 kDa, whereas in the samples only one faint wide 
band was present. MMP-8 and -13 were not detected by Western 
blotting. 
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A Gelatin zymograms Western blots 
Β Reverse zymograms 
anti- antt-
C Res App Pro-2 Pro-9 MMP2 MMP9 
a^ ^ _ ^ ^ _ ^ ^ ^ ^ ^ ^ C Res App TIMP1 ΤΙΜΡ2 
301(03
 - ** S 
Î C Collagen zymograms Western blots 
anti anti- anti-
C Res App MMP1 MMP8 MMP1 MMP8 MMP13 H mm* Fig. 1. Zymograms. Representative zymograms and Western blots of the resorption and apposition sides of orthodontically moved teeth as well as for control teeth. The molecular weights of the bands are indicated by the arrows. (A) Representative gelatin zymograms of samples from the control teeth (C, lane 1), the resorption side (Res, lane 2), the apposition side (App, lane 3), a pro-MMP-2 reference (lane 4), and a pro-MMP-9 standard (lane 5). Because the 
proteolytic activity of pro-MMP-9 in the samples was too high for a reliable 
analysis, it was repeated after dilution (upper part). Western blots for MMP-2 
(lane 6) and -9 (lane 7) are shown for gingival crevicular fluid (GCF) of 
orthodontically moved teeth. 
(B) Representative reverse zymograms of samples of the control teeth (lane 1), 
the resorption side (lane 2), the apposition side (lane 3), a standard sample of 
tissue inhibitor of metalloproteinase (TIMP)-l (lane 4), and a standard sample of 
TIMP-2 (lane 5). 
(C) Representative collagen zymograms for the same samples as in panel A and 
B. Lane 4 and 5 contained MMP-1 and -8 as standard samples. The Western 
blots show that GCF of orthodontically moved teeth contain MMP-1 (lane 6). 
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active M MP-2 
pro-MMP-2 
complex MMP-2 
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ι active MMP-9 
ι proMMP-9 
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»# 
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^ H active MMP~1 
E^rr3 partially active MMP-1 
D 
T 
• • • TIMP.1 30kDa 
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*# 
Fig. 2. Quantification of matrix 
metaiioproteinases (MMPs) and tissue 
inhibitor of metailoproteinase (TIMP)-l. 
MMPs and TIMP-1 were analyzed by 
zymography, quantified and expressed 
as mean density χ mm2/Ml gingival 
crevicular fluid (GGF) relative to the 
reference sample concerned. 
*Significantly different to the control. 
#Significant different to the resorption 
side (differences were considered 
significant at ^ < 0 . 0 5 ) . 
(A) The different forms of MMP-2. 
(B) The different forms of MMP-9. 
(G) The 48 kDa gelatinase. 
(D) The different forms of MMP-1. 
(E) The different forms of TIMP-1. 
Control Resorption Apposition 
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Quantitative analysis of MMPs and TIMPs 
The quantified data of the gelatin and reverse zymography are shown in 
Figure 2. The collagen zymograms were not quantified because there was 
too little sample for multiple analysis. Significantly more active- and pro-
MMP-2 were present at both experimental sides compared with the 
control teeth (P=0.03 and 0.032, respectively. Figure 2A). Also, more 
active MMP-9 was present at the resorption side compared with the 
control (P =0.003, Figure 2B). More 48 kDa gelatinase was present at 
both sides compared with the control {P<0.0001 and ^ = 0 . 0 0 5 
respectively. Figure 2C). The resorption side contained more than the 
apposition side ( ^ = 0 . 0 2 9 ) . At the apposition and resorption side, more 
partially activated MMP-1 was present (both P<0.Q001 compared with 
the control. Figure 2D). The amount of active MMP-1 was less at the 
resorption side compared with the apposition side {P =0.022, Figure 2D). 
The 28 kDa and 30 kDa forms of TIMP-1 were higher at the apposition 
side compared with the resorption side {P<0.0001 and Ρ = 0 . 1 1 , 
respectively) and the control teeth (P<0.0001 and Ρ = 0 . 0 0 1 , 
respectively. Figure 2E). 
Discussion 
The expression of MMPs and TIMPs was studied at the apposition and 
resorption sides of orthodontically moved teeth in comparison with 
control teeth of the same patients. A common problem in the analysis of 
GCF is the small volume available. In order to have sufficient for the 
analyses, samples from the same site were pooled.2 1 The differences 
between the sites represent true differences in MMP and TIMP content, 
since the volume of GCF does not change during orthodontic tooth 
movement.5 , 2 1 , 2 2 
Only a few studies have reported on MMPs and TIMPs during 
orthodontic tooth movement in humans, and they mainly focused on the 
initial phase.1 3 , 1 4 In the present investigation, MMPs and TIMPs were 
analyzed after long-term tooth movement. In general, an increased 
expression of MMPs and TIMP-1 was found at the resorption side as well 
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as the apposition side. TIMP-2 was not detected. Gariet eia/.1 5 also found 
higher MMP-1 mRNA at the resorption and apposition side compared with 
the control and most TIMP-1 mRNA expression at the tension side. This is 
in correspondence with the present data. In another study in humans, 
MMP-1 levels were elevated at the apposition side, but only temporarily 
elevated at the resorption side, whereas MMP-2 levels remained elevated 
at the resorption side.14 However, that study describes MMP levels during 
the initial phase of orthodontic tooth movement, whereas the GCF in the 
present study was collected during the linear phase. In an immuno-
fluorometic assay, MMP-8 was also detected in the GCF of orthodontic 
patients.5 This MMP was not found in the present study, which might be 
due to differences in analysis methods. In two studies in orthodontic 
tooth movement, no MMP-1 was detected by Western blotting.513 One of 
these only investigated MMPs during initial tooth movement,13 while 
MMP-1 might only be increased during linear tooth movement. 
In contrast to others, the different forms of MMPs were also 
investigated. Partially activated MMP-1 was clearly present at both sides 
of the experimental teeth, but minimally around the control teeth, 
whereas active MMP-1 was present at all sites. The partially activated 
MMP-1 might serve as a reservoir of rapidly available MMP-1 during 
remodelling. In total, more MMP-1 was present at both experimental 
sides than at the control. This indicates that MMP-1 is involved in 
increased remodelling in the PDL and the alveolar bone during 
orthodontic tooth movement. A higher level of active MMP-1 was also 
found at the apposition side compared with the resorption side. At the 
apposition side, the fibres of the PDL are stretched and partly torn. They 
are rapidly remodelled and lengthened, which involves an upregulation of 
collagen types I and I I I . 1 0 The ratio of collagen type I I I to type I is 
increased,23 as in healing PDL.24 Type I I I collagen is thought to play a 
role in the regulation of ECM assembly. Finally, part of these fibres are 
replaced by type I fibres.25 This requires MMPs and TIMPs. MMP-1, -8, 
and -13, and, to a lesser extent, MMP-2 are known to cleave collagen 
types I, I I , and I I I into a quarter and a three-quarter fragment.26,27 The 
denatured collagen, also known as gelatin, is then degraded by MMP-2 
and -9. Remarkably, gelatinolytic fragments of 33 and 34 kDa were 
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exclusively found at the apposition side. Although their exact origin is 
unclear, they may be involved in the remodelling processes in vivo, since 
they clearly demonstrate proteolytic activity. The relatively higher 
expression of MMP-1 at the apposition side might be induced by TIMP-1, 
which was also increased. TIMP-1 is known to stimulate the secretion of 
MMP-1 from skin fibroblasts.28 
At the apposition side, extensive bone deposition takes place. The 
increased strain of the PDL fibres is transferred to the bone. It has been 
proposed that small forces on the bone result in fluid flow through the 
canaliculi in the bone, which is detected by osteocytes.29,30 They release 
nitric oxide, which stimulates bone formation.31 Osteoblasts deposit new 
osteoid, which is subsequently mineralized.32 In the present study, the 
highest TIMP-1 levels were found at the apposition side. Previous studies 
show that TIMP-1 is highly expressed in osteoblasts during bone 
formation.33 I t might protect the newly formed bone from degradation by 
metalloproteinases. 
At the resorption side, the compression of the PDL causes a 
slackening of the fibres in the PDL. The degradation of these fibres is 
highly increased, and they are replaced by thin collagen type I I I fibres. 
Moreover, a change in orientation of the PDL fibres occurs. These non-
functional collagen fibres are disorganized and mainly run parallel to the 
bone surface.35 The remodelling of the PDL requires an upregulation of 
both MMPs and TIMPs.11 Bone resorption by osteoclasts is enhanced at 
this side of the tooth.7,35 This might be induced by the absence of strain 
in the bone, as the PDL fibres are non-functional.29 An increase in MMP-9 
expression at the resorption side was found in the present study. MMP-9 
is known to stimulate osteoclast activity by enhancing their migration.36 
Also, a 48 kDa gelatinase fragment, which might be a proteolytic 
fragment of MMP-2,37 was upregulated at the resorption side. Since it 
displays gelatinolytic activity, it might also play a role in the breakdown 
of gelatin in vivo. In the present study, the level of TIMP-1 was lower at 
the resorption side than at the apposition side, but both were higher than 
at the control teeth. This might be explained by the dual effects of TIMPs 
on bone resorption. At low concentrations they stimulate bone resorption 
by directly stimulating osteoclasts.38,39 At higher concentrations, they 
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reduce bone resorption by inhibiting MMP activity.40 This is consistent 
with the present data. 
Conclusions 
Orthodontic tooth movement induces extensive changes in MMP and TIMP 
levels in GCF. The main difference was an increase in MMP and TIMP 
levels between the experimental teeth and the control teeth. This 
probably reflects the general increase in remodelling activity during tooth 
movement. The differences between the resorption and the apposition 
side are caused by the different nature of remodelling. At the resorption 
side, bone resorption takes place, and extensive remodelling of the PDL. 
MMP-1, -2, and -9, a 48 kDa gelatinase, and TIMP-1 are upregulated. At 
the apposition side, only bone apposition takes place and more limited 
PDL remodelling. MMP-1, -2 , and the 48 kDa gelatinase are upregulated. 
However, pro-MMP-2 and the 48 kDa gelatinase levels are significantly 
lower at the apposition side compared with the resorption side. TIMP-1 
levels on the other hand are higher at the apposition side. TIMP-1 might 
play a dual role by stimulating bone resorption at low concentrations at 
the resorption side, and reducing it at higher concentrations at the 
apposition side. Analysis of MMPs and TIMPs in orthodontics may 
contribute to more predictable treatment regimens in the future. It may 
serve as a diagnostic aid to predict the rate of tooth movement, the 
severity of root resorption, and relapse. Chair-side MMP tests have 
already been developed to monitor periodontitis progression.41 
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Introduction 
Biological processes regulate normal periodontal remodelling as well 
as increased remodelling during orthodontic tooth movement and 
periodontitis. Matrix metalloproteinases (MMPs) degrade the extracellular 
matrix and their activity is regulated by the tissue inhibitors of 
metalloproteinases (TIMPs). Most studies on the role of MMPs and TIMPs 
in periodontal remodelling focus on periodontitis, but the results are 
somewhat controversial.1"4 Their role in orthodontic tooth movement is 
largely unknown, although several types of MMPs are present in 
crevicular fluid from patients.5'7 
The potential therapeutic application of synthetic MMP inhibitors in 
pathological MMP-mediated tissue degradation has been reviewed by 
Peterson8 and Hu et a/.9 These inhibitors have been investigated for 
application in conditions such as cancer, and inflammatory-, 
cardiovascular-, and pulmonary diseases. The results of the cancer- and 
cardiovascular studies are highly variable, which may partly be due to 
methodological deficiencies.1011 Moreover, certain MMPs seem to have a 
protective function in these diseases, which makes broad-spectrum MMP 
inhibition unfavourable. The use of MMP inhibitors might be promising in 
the treatment of asthma and bronchitis.1112 The main applications for 
MMP inhibitors seem to lie in therapies for inflammatory diseases. For 
example, subantimicrobial-dose doxycycline (Periostat®) has already 
been FDA approved for the treatment of periodontitis and is used 
clinically.1314 
Synthetic MMP inhibitors may also have therapeutic value for the 
prevention of side effects of orthodontic treatment such as relapse and 
root resorption. The purpose of our studies was to Investigate the role of 
MMPs and TIMPs in periodontal remodelling with the main focus on 
orthodontics, and to study the effects of synthetic MMP inhibitors on 
MMP-mediated processes. This knowledge can be used for the 
development of therapies to reduce root resorption and relapse, and to 
design MMP-based predictors for the rate of tooth movement. The 
specific aims of the studies presented in this thesis were to analyse the 
types of MMPs and TIMPs produced by PDL cells in 2-D and 3-D culture 
models, and the effects of synthetic MMP inhibitors on MMP-mediated 
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processes. In addition, MMPs and TIMPs in healthy and diseased 
periodontal tissues and in crevicular fluid samples from orthodontic 
patients were characterized. A rat model15 was used to study the effect of 
a synthetic MMP inhibitor on tooth movement. In the next sections these 
studies will be discussed and directions for future research are pointed 
out. 
In vitro studies 
In vitro studies with PDL cells were performed to investigate the MMPs 
produced by these specific cells and the effects of MMP inhibitors. One 
of the specific aims was to study the MMPs produced by PDL cells in a 
two-dimensional monolayer culture, and the effects of CMTs on the cells 
(chapter 2). 
MMPs were analysed by substrate zymography, a semiquantitative 
electrophoretic technique that identifies MMPs based on their molecular 
size and substrate specificity.1617 Advantages of this technique over 
antibody-based methods such as ELISA, are that it can distinguish 
between the active and latent forms, and that it is far more sensitive. 
This is especially relevant when only small amounts of sample are 
available, which is the case for GCF and PDL (chapter 4 and 6), or when 
the MMPs are highly diluted, as in culture medium (chapter 2 and 3). 
However, zymography is only suitable to detect a limited number of 
MMPs.16 Therefore, in chapter 3, we used PCR to detect a wider range of 
MMPs. Surprisingly, m the 2-D cultures, CMTs stimulated MMP-2 
production at relatively low concentrations (chapter 2). This might be 
explained by a direct stimulation of tetracyclines on MMP gene 
expression, or an increased secretion from tertiary granules.1819 
A possible stimulatory effect of CMTs on MMP production should be 
considered in their clinical use. 
In chapter 3, a three-dimensional culture system was used 
because it better resembles the physiological cell environment. In 
contrast to the 2-D cultures, none of the synthetic inhibitors had a 
significant effect on gelatmase production in the 3-D cultures. However, 
the concentration in the 3-D cultures was only half of that in the 2-D 
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cultures. In addition, cells in 3-D cultures may be less sensitive to drugs 
because of the presence of ECM components.20 The unphysiological 
flattened morphology in 2-D cultures,21 may also render the cells more 
sensitive. Remarkably, in the 2-D cultures, the only gelatinase produced 
by PDL cells was MMP-2, whereas in the 3-D cultures, the active and 
latent forms of MMP-9 were also produced. Earlier studies also showed 
that cells up-regulate their MMP-9 expression after transfer from a 2-D 
to a 3-D environment.22,23 This might be related to the morphological 
changes of the cells,21,24'25 or the interaction with collagen through 
integrins.26 The exact mechanisms by which these factors influence MMP 
expression remain to be elucidated. 
Quantitative PCR showed that from the inhibitors tested, only 
CMT-3, and to a lesser extent doxycycline, reduced mRNA expression of 
ASMA, TIMP-2, MMP-2, and MMP-3 in the 3-D cultures (chapter 3). All 
MMP inhibitors inhibited gel contraction, especially CMT-3 and 
doxycycline. This seems to be due to the inhibition of MMP activity, which 
is crucial for the remodelling processes in gel contraction. The inhibition 
of gel contraction might be indirectly enhanced by the inhibition of MMP-3 
expression, which reduces TGF-ß-mediated ASMA production. We 
conclude that for future remodelling studies on PDL cells a 3-D culture 
system is to be preferred. 
A 3-D culture system is also more suitable to study the effects of 
mechanical loading as in orthodontic tooth movement. Earlier, a system 
was developed based on collagen gels that applies uni-axial tensile forces 
to the cells, which might be used as a model for the apposition side of 
the tooth.27 MMP-2 and -9 production was increased and MMP-3 
production was decreased when tensile forces were applied in this model. 
However, the collagen fibres in this model are randomly organized. In 
reality, the collagen fibres form a bridge between the cementum and the 
bone, and are embedded in both mineralized tissues. Others showed that 
the fibres of collagen gels can be attached to alkaline phosphatase-coated 
surfaces of artificial tooth-bone constructs. The 'tooth' can then be loaded 
intermittently.28 
As the ECM composition strongly influences cellular behaviour, 
attempts should be made to construct 3-D culture models that resemble 
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the in vivo ECM as close as possible. For instance, the incorporation of 
collagen types I I I and V (which are present in the PDL) in collagen gels 
increases the contractile properties of the cells.29 For orthodontic 
research, it would also be interesting to study the interaction of PDL cells 
with osteoblasts and osteoclasts under loading and unloading conditions. 
Similar studies have recently been performed m an m vitro model of the 
cruciate tendon-bone interface.30 In conclusion, improved 3-D models of 
the periodontal ligament and the surrounding structures will yield more 
information on periodontal remodelling, and the effects of factors such as 
MMP-mhibitors and mechanical loading. 
To obtain a more comprehensive overview of MMPs and TIMPs m 
vivo, they were analysed m tissue samples from patients. The in vivo 
effects of an MMP inhibitor on tooth movement was studied in a rat 
model. 
In vivo studies 
The aim of the first in vivo study (chapter 4) was to analyse the MMPs 
and TIMPs in the healthy and diseased periodontium of humans. Many 
studies have been performed on gingiva and crevicular fluid (GCF) but 
only very few on PDL tissue. Therefore, we analysed samples from 
human gingiva and GCF, and compared these with PDL tissue. We 
showed that MMP-1, -2, -8, and -9, gelatmolytic complexes, 
collagenolytic fragments, and TIMP-1 and -2 are expressed m PDL. 
Especially the observed reduction of TIMPs in penodontitis-affected PDL 
tissue may induce ECM degradation. In all samples from both healthy 
and diseased subjects active MMP-2 complexes and collagenolytic 
fragments were found. Their amounts were substantially higher in the 
PDL and GCF of periodontitis patients than in that of healthy subjects. 
These proteolytic activities are generally not described in other studies, 
but they might contribute considerably to periodontal destruction. 
Contrary to our expectations, m the healthy gingiva and PDL some 
MMPs were more abundant than in diseased tissue. This may indicate 
that certain MMPs are involved only in normal, healthy ECM remodelling, 
rather than in inflammation-induced degradation. Alternatively, it might 
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be explained by age-, and sex differences between the patients and 
control subjects. A better matching of the participants in both groups 
would overcome this problem in future research. This is a common 
problem in periodontitis research, since the disease usually occurs at a 
later age, but periodontally healthy control subjects of similar age 
without interfering medication are rare. For future studies on 
periodontitis it is recommended to include PDL tissue rather than 
gingiva alone. Ideally, healthy as well as periodontitis-affected teeth 
from the same patient should be used in such studies, for instance from 
cases of full dental clearance. 
GCF samples from orthodontic patients were also analysed for 
MMPs and TIMPs to investigate their involvement in tooth movement 
(chapter 5). Some previous studies already showed the involvement of 
MMPs and TIMPs in orthodontic tooth movement, but no distinction was 
made between latent and active MMPs.5'7,31 Therefore, we used 
zymography to analyse MMPs at the apposition as well as the resorption 
side during tooth movement. In general, a higher expression of MMPs 
and TIMPs was found at both the resorption side and the apposition side 
compared to control teeth. At both sides, periodontal fibres have to be 
remodelled to adapt to the new mechanical situation. In addition, the 
alveolar bone is degraded at the resorption side. Remarkably, a partially 
activated MMP-1 was found in GCF from both the resorption and the 
apposition side, but not in that from control teeth. The latter samples 
contained similar amounts of active MMP-1 but no partially active MMP-1 
at all. This specific form of MMP-1 might serve as a reservoir, which can 
be made available rapidly when increased remodelling is required as in 
tooth movement. Nevertheless, to analyse the exact role of MMPs and 
TIMPs in periodontal remodelling during orthodontic tooth movement 
more /n 1//V0 studies are required. 
Orthodontic tooth movement involves an initial inflammatory 
response to a mechanical force.32 In general, as shown in this study, the 
MMPs and TIMPs in the GCF of orthodontic patients (chapter 5) and 
periodontitis patients (chapter 4) are quite similar. Both in the GCF of 
periodontitis-affected teeth and orthodontically moved teeth an increase 
in MMPs was found compared to the controls. However, TIMP-1 was down 
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regulated in periodontitis samples, whereas it was clearly up-regulated 
during tooth movement, especially at the apposition side. In tooth 
movement, the up-regulation of TIMP-1 at the apposition side might 
prevent the degradation of the newly formed tissues. Noticeably, TIMP-2 
and MMP-8 were only found in the GCF of periodontitis patients and their 
controls, but not in that of orthodontic patients. MMP-8 is strongly 
associated with periodontitis.4 3 3'3 4 A previous study showed that MMP-8 
was also present during orthodontic tooth movement,5 although others 
showed that it was only transiently expressed during the first week of 
tooth movement.3 5 The latter observation fits an initial inflammatory 
response in tooth movement as mentioned above. Since in our 
orthodontic study the GCF was collected after four weeks of tooth 
movement, this initial MMP-8 expression might already have been 
reduced. 
Another difference between the orthodontic and the periodontitis 
patients was that larger amounts of active and pro-MMP-2 were present 
in the orthodontic patients. Mechanical loading is known to up-regulate 
MMP-2 production.3 6 3Θ The involvement of this MMP in periodontitis is 
less c lear. 2 , 3 9 4 1 MMP-2 might be particularly involved in mechanically 
induced periodontal remodelling and to a lesser extent in inflammation. 
Age might also play a role m these differences. The patients from the 
periodontitis study were all adults, and those of the orthodontic study 
were children. The effect of age on periodontal MMP levels is largely 
unknown. However, the levels of MMPs m other tissues decrease with 
age. 4 2 4 3 I t is feasible that normal periodontal remodelling is higher during 
growth, which requires more active MMPs. This is supported by the 
differences between the control groups in our studies. Further studies 
into age-related changes in periodontal MMPs might clarify some of the 
observed discrepancies. 
Since MMPs are thought to be the major enzymes involved in 
periodontal remodelling, we hypothesized that their inhibition would 
reduce orthodontic tooth movement, and this was investigated m a rat 
model (chapter 5). There are of course differences between human and 
rat periodontium with regard to periodontal elastic fibres,4 4 bone 
density,4 5 stiffness of cementum,4 6 tooth drift, and narrowing of the 
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interdental bony septum. ^ However, for orthodontic tooth movement, 
the rat is considered to be a suitable animal model as the cellular 
processes are similar.49 In this study, CMT-3 was used, since it showed 
the strongest inhibitory effect in vitro (chapter 2 and 3). CMT-3 
significantly inhibited tooth movement, which can, apart from direct 
inhibition of MMPs, partly be explained by reduced numbers of osteoclasts 
at the resorption sides. It is therefore conceivable that CMT-3 will also 
inhibit relapse, since the same remodelling processes are thought to be 
involved.50·51 
To prevent relapse after tooth movement in the future, agents 
should preferably be applied topically. However, the MMR inhibitor 
doxycycline (Periostat®) is administered systemically to reduce 
periodontal destruction in periodontitis.52 Low dose doxycycline did not 
show significant adverse effects over a 2-year period.53 To avoid the risks 
of unknown systemic effects of MMP inhibition, local application is 
preferred. Favourable characteristics such as easy application, slow 
release, good acceptance, and minimal side effects are united in 
subgingivally applied varnishes or gels that contain MMP-inhibitors (e.g. 
tetracyclines). The effects of these agents on the progression of 
periodontitis,54,55 the levels of MMPs and TIMPs in periodontal pockets,56 
and root resorption57 have been studied. These studies showed protective 
effects on attachment loss and root resorption. It would be interesting to 
investigate whether MMP-inhibitors are also suitable to prevent relapse 
and root resorption during orthodontic tooth movement. Tetracyclines 
might be suitable since they bind to cementum and dentin and will 
subsequently be slowly released.58 
To conclude 
Increased knowledge of the role of MMPs and TIMPs in orthodontic tooth 
movement might eventually find its way into clinical practice through the 
development of clinical markers for the prediction of the rate of tooth 
movement and hence treatment time. This might enable a more 
individualised approach to orthodontic treatment. Moreover, diagnostic 
tools for pathological remodelling processes as in periodontitis may be 
developed. The first steps towards such a clinical application have already 
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been made in a chair-side MMP-8 test.59 This might also be useful in 
orthodontic patients with a history of periodontitis since the application of 
a mechanical force will increase the risk of periodontal breakdown. Next 
to diagnostic and monitoring purposes, strategies may be developed to 
modulate MMP and TIMP activity in order to control the rate of 
orthodontic tooth movement. As shown in our rat study, the application 
of a synthetic inhibitor can reduce orthodontic tooth movement. This 
might be useful in the prevention of clinical relapse. 
However, more research, basic as well as clinical, is needed before 
the translation into the clinic can be made. More insight is required into 
other proteases that are involved m remodelling (such as cathepsms and 
ADAMs). This is also indicated by the fact that inhibition of MMP activity 
only partly reduces tooth movement (chapter 5). Hardly any data are 
available on the role of these additional enzymes in orthodontic tooth 
movement, although cathepsms seem to be up-regulated in this 
process,6061 and also in PDL cells under mechanical loading.62 Further 
development of in vitro models that incorporate specific aspects of the 
physiological periodontal apparatus are required to better understand the 
biological process of tooth movement. 
For the clinical research, more comprehensive and easy applicable 
chair-side tests should be developed, generating a profile of proteases 
and their inhibitors rather than focusing on only one MMP. When 
synthetic inhibitors are to be used clinically, they should ideally be 
topically administered. Lastly, the awareness of clinicians towards the 
biological mechanisms of tooth movement should be increased. Not only 
for future biological interventions, but also to increase understanding of 
the biological principles of daily practice. 
148 
General discussion 
REFERENCES 
1. Alba Τ, Akeno Ν, Kawane Τ, Okamoto H, Horiuchi N. Matrix metalloproteinase-1 
and -8 and TIMP-1 mRNA levels in normal and diseased human gingivae. Eur J 
Ora/ Sa 1996;104:562-569. 
2. Séguier S, Gogly B, Bodineau A, Godeau G, Brousse N. Is collagen breakdown 
during periodontitis linked to inf lammatory cells and expression of matrix 
metalloproteinases and tissue inhibitors of metalloproteinases in human gingival 
tissue? J Periodonto/2001;72:1398-1406. 
3. Soell M, Elkalm R, Tenenbaum H. Cathepsin C. Matrix metalloproteinases, and 
their tissue inhibitors in gingiva and gingival crevicular fluid f rom periodontit is-
affected patients. J Denf «es 2002;81:174-178. 
4. Pozo P, Valenzuela M, Melej C et a/. Longitudinal analysis of metalloproteinases, 
tissue inhibitors of metalloproteinases and clinical parameters in gingival 
crevicular fluid from periodontitis-affected patients. J Periodontal Res 
2005;40:199-207. 
5. Ingman T, Apajalahti S, Mäntylä Ρ, Savolainen Ρ, Sorsa T. Matrix 
metalloproteinase-1 and -8 in gingival crevicular fluid during orthodontic tooth 
movement: a pilot study during 1 month of follow-up after fixed appliance 
activation. EurJOrthod2005;27: 202-207. 
6. Apajalahti S, Sorsa Τ, Railavo S, Ingman T. The in vivo levels of matrix 
metalloproteinase-1 and -8 in gingival crevicular fluid during initial orthodontic 
tooth movement. J D e n i z e s 2003;82:1018-1022. 
7. Cantarella G, Cantarella R, Caltabiano M, Risuglia N, Bernardini R, Leonardi R. 
Levels of matrix metalloproteinases 1 and 2 in human gingival crevicular fluid 
during initial tooth movement. Am J Orthod Dentofacial Orthop 
2 0 0 6 ; 1 3 0 : 5 6 8 . e l l - 1 6 . 
8. Peterson JT. The importance of estimating the therapeutic index in the 
development of matrix metalloproteinase inhibitors. Card/ovasc Res 2006;69: 
677-687. 
9. Hu J, Van den Steen ΡΕ, Sang QX, Opdenakker G. Matrix metalloproteinase 
inhibitors as therapy for inf lammatory and vascular diseases. Nat Rev Drug Discov 
2007;6:480-498. 
10. Sang QX, Jin Y, Newcomer RG, Monroe SC, Fang X, Hurst DR, Lee S, Cao Q, 
Schwartz MA. Matrix metalloproteinase inhibitors as prospective agents for the 
prevention and treatment or cardiovascular and neoplastic diseases. Curr Top Med 
Chem 2006;6:289-316. 
1 1 . Gueders MM, Foidart JM, Noel A, Cataldo DD. Matrix metalloproteinases (MMPs) 
and tissue inhibitors of MMPs in the respiratory tract: potential implications in 
asthma and other lung diseases. Eur J Pharmacol 2Q06;S33:133-144. 
12. Bruce C, Thomas PS. The effect of marimastat, a metalloprotease inhibitor, on 
allergen-induced asthmatic hyper-reactivity. Toxicol Appi Pharmacol 
2005;205:126-132. 
13. Food and Drug Administrat ion, Department of Health and Human Services (2001). 
Approval package for: approval number 50-783. Center for Drug evaluation and 
research, Rockville MD, USA. http://www.fda.gov/cder/foi/nda/2001/50-
783_Periostat_Approv.pdf. 
14. Ciancio SG. Systemic medications: clinical significance in periodontics. J Clin 
Perlodontol 2002;29 suppl 2 : 1 7 - 2 1 . 
149 
15. Ren Y, Maltha JC, Van't Hof MA, Kuijpers-Jagtman AM. Age effect on orthodontic 
tooth movement in rats. J Dent Res 2003;82:38-42. 
16. Snoek-Van Beurden PA, Von den Hoff JW. Zymographic techniques for the 
analysis of matrix metalloprotemases and their inhibitors. Biotechniques 
2005;38:73-83. 
17. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of 
picogram quantities of gelatmases. Analytical Biochemistry 2004;218:325-329. 
18. Mollmedo F, Nakajima M, Llorens A, Barbosa E, Callejo S, Gajate C, Fabra A. 
Major co-localization of the extracellular-matrix degradative enzymes heparanase 
and gelatmase in tertiary granules of human neutrophils. Biochem J 
1997;327:917-923. 
19. Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from 
IL-8-stimulated human neutrophils. JLeukoc5/0/2005,78:279-288. 
20. Sun T, Jackson S, Haycock JW, MaclMeil S. Culture of skin cells in 3D rather than 
2D improves their ability to survive exposure to cytotoxic agents J Biotechnol 
2006;122:372-381. 
21. Gnnnell F. Fibroblast biology m three-dimensional collagen matrices. Trends Cell 
S/o/2003;13:264-269. 
22. Takahra T, Smart DE, Oakley F, Mann DA. Induction of myofibroblast MMP-9 
transcription m three-dimensional collagen I gel cultures: regulation by NF-KB, 
AP-1 and Spi. Int J Biochem Cell Biol 2004;36:353-363. 
23. LaMarca HL, Ott CM, Honer zu Bentrup Κ et al. Three-dimensional growth of 
extravillous cytotrophoblasts promotes differentiation and invasion. Placenta 
2005;26:709-720. 
24. Nehmarkka LO, Nikkari ST, Ravanti LS, Kahan VM, Jarvelamen HT. Collagenase-1, 
stromelysm-l and 92 kDa gelatmase are associated with tumor necrosis factor-
alpha induced morphological change of human endothelial cells m vitro. Matrix 
5/0/1998,17:293-304. 
25. Kheradmand F, Werner E, Tremble P, Symons M, Werb Z. Role of Racl and 
oxygen radicals m collagenase-1 expression induced by cell shape change. 
Science 1998;280:898-902. 
26. Phillips JA, Bonassar U. Matrix metalloprotemase activity synergizes with a2ßi 
integnns to enhance collagen remodeling. Exp Cell Res 2005;310:79-87. 
27 Prajapati RT, Eastwood M, Brown RA Duration and orientation of mechanical 
loads determine fibroblast cyto-mechamcal activation: monitored by protease 
release. Wound Repair Regen 2000;8:238-246. 
28. Berendsen AD. A tissue engineering approach to the regeneration of periodontal 
tissues. PhD [dissertation]. Amsterdam: Academic Centre for Dentistry 
Amsterdam (ACTA); 2008. 
29. Berendsen AD, Bronckers AL, Smit TH, Walboomers XF, Everts V. Collagen type V 
enhances matrix contraction by human periodontal ligament fibroblasts seeded in 
three-dimensional collagen gels. Matrix Biol2006;25:515-522. 
30. Spalazzi JP, Doty SB, Moffat KL, Levine WN, Lu HH. Development of controlled 
matrix heterogeneity on a triphasic scaffold for orthopedic interface tissue 
engineering. Tissue Eng 2006;12:3497-3508. 
150 
General discussion 
31. Gariet TP, Coelho U, Silva JS, Gariet GP. Cytokine expression pattern in 
compression and tension sides of the periodontal ligament during orthodontic 
tooth movement in humans. f i / r J Oa/Sc/2007;115:355-362. 
32. Krishnan V, Davidovitch Z. Cellular, molecular, and tissue-level reactions to 
orthodontic force. Am J Orthod Dentofac/a/ Ortfiop 2006;129-A69.el-32. 
33. Passoja A, Ylipalosaari M, Tervonen T, Raunio T, Knuuttila M. Matrix 
metalloproteinase-8 in shallow crevices associated with the extent of periodontal 
disease. J C//n Periodonto/2008;35:1027-1031. 
34. Sorsa Τ, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. 
Oa/D/s 2004;10:311-318. 
35. Takahashi I, Nishimura M, Onodera K, Bae JW, Mitani H, Okazaki M, Sasano Y, 
Mitani H. Expression of MMP-8 and MMP-13 genes in the periodontal ligament 
during tooth movement in rats. -7Denizes2003;82:546-651. 
36. Shelton L, Rada JS. Effects of cyclic mechanical stretch on extracellular matrix 
synthesis by human sclera fibroblasts. Exp Eye /tes2007;84:314-322. 
37. Zhou D, Lee HS, Villarreal F, Teng A, Lu E, Reynolds S, Qin C, Smith J, Sung KL. 
Differential MMP-2 activity of ligament cells under mechanical stretch injury: an in 
vitro study on human ACL and MCL fibroblasts. J Orthop /?e5 2005;23:949-957. 
38. He Y, Macarak EJ, Korostoff JM, Howard PS. Compression and tension: differential 
effects on matrix accumulation by periodontal ligament fibroblasts in vitro. 
Connect Tissue Res 2004;45:28-39. 
39. Korostoff JM, Wang JF, Sarment DP, Stewart JC, Feldman RS, Billings PC. Analysis 
of in situ protease activity in chronic adult periodontitis patients: expression of 
activated MMP-2 and a 40 kDa serine protease. J Periodontal 2000;7V.3S3-3&0. 
40. Mäkelä M, Salo Τ, Ditto VJ, Larjava Η. Matrix metalloproteinases (MMP-2 and 
MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. 
J Dent Res 1994;73:1397-1406. 
41. Tervahartiala T, Pirilä E, Ceponis A, Maisi P, Salo Τ, Tuter G, Kallio Ρ, Törnwall J, 
Srinivas R, Konttinen YT, Sorsa T. The in vivo expression of the collagenolytic 
matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in 
adult and juvenile periodontitis. J DenfÄes 2000;79:1969-1977. 
42. Takahashi I, Onodera K, Bae JW, Mitani H, Sasano Y, Mitani H. Age-related 
changes in the expression of gelatinase and tissue inhibitor of metalloproteinase 
genes in mandibular condylar, growth plate, and articular cartilage in rats. J Moi 
W/sfo/2005;36:355-366. 
43. Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, 
Sweterlitsch SE, Spinale FG. Age-dependent changes in myocardial matrix 
metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast 
function. 
44. Sawada T, Sugawara Y, Asai T, Aida IM, Yanagisawa Τ, Ohta Κ, Inoue S. 
Immunohistochemical characterization of elastic system fibers in rat molar 
periodontal ligament. J Histochem Cytochem200Ç>;54:109S-1103. 
45. Reitan Κ, Kvam E. Comparative behaviour of human and animal tissue during 
experimental tooth movement. Angie Orthod 1971;41:1-14. 
46. Ho SP, Yu B, Yun W, Marshall GW, Ryder MI, Marshall SJ. Structure, chemical 
composition and mechanical properties of human and rat cementum and its 
interface with root dentin. Acta Biomater2008;5:707-718. 
151 
47. Hardt AB. Bisphosphonate effects on alveolar bone during rat molar drifting. J 
Dent Res 1988;67:1430-1433. 
48. Yilmaz RS, Darling AI, Levers BG Mesial drift of human teeth assessed from 
ankylosed deciduous molars. Arch Oral Biol 1980;25:127-131. 
49. Ren Y, Maltha JC, Kuijpers-Jagtman AM. The rat as a model for orthodontic tooth 
movement - a critical review and a proposed solution. Eur J Orthod 2004;26:483-
490. 
50. Melrose C, Millett DT. Toward a perspective on orthodontic retention7 Am J Orthod 
Dentofacial Orthop 1998;113:507-514. 
51. Van Leeuwen EJ, Maltha JC, Kuijpers-Jagtman AM, van 't Hof MA. The effect of 
retention on orthodontic relapse after the use of small continuous or 
discontinuous forces. An experimental study in beagle dogs. Eur J Oral So 
2003;111:111-116. 
52. Lee JY, Lee YM, Shin SY, Seol YJ, Ku Y, Rhyu IC, Chung CP, Han SB. Effect of 
subantimicrobial dose doxycyclme as an effective adjunct to scaling and root 
planing. J Penodontol2004;75:1500-1508. 
53. Golub LM, Lee HM, Stoner JA, Sorsa Τ, Reinhardt RA, Wolff MS, Ryan ME, 
Nummikoski PV, Payne JB Subantimicrobial-dose doxycyclme modulates gingival 
crevicular fluid biomarkers of periodontitis m postmenopausal osteopemc women. 
J Penodontol 2008;79:1409-1418. 
54. Yaffe A, Herman A, Bahar H, Bmderman I. Combined local application of 
tetracycline and bisphosphonate reduces alveolar bone resorption in rats. 
J Penodontol 2003;74:1038-1042. 
55. Gupta R, Pandit N, Aggarwal S, Verma A. Comparative evaluation of subgingivally 
delivered 10% doxycyclme hyclate and xanthan-based Chlorhexidine gels in the 
treatment of chronic periodontitis. J Contemp Dent Pract 2008;9:25-32. 
56. Pourtaghi N, Radvar M, Mooney J, Kmane DF The effect of subgingival 
antimicrobial therapy on the levels of stromelysm and tissue inhibitor of 
metalloprotemases m gingival crevicular fluid. J Penodontol 1996;67:866-870 
57 Chen H, Teixeira FB, Ritter AL, Levin L, Trope M. The effect of mtracanal anti­
inflammatory medicaments on external root resorption of replanted dog teeth 
after extended extra-oral dry time. Dent Traumatol2008;24:74-78. 
58. Demirel K, Baer PN, McNamara TF. Topical application of doxycyclme on 
penodontally involved root surfaces in vitro: comparative analysis of 
stubstantivity on cementum and dentin. J Penodontol 1991;62:312-316. 
59. Mantyla P, Stenman M, Kmane DF, Tikanoja S, Luoto H, Salo Τ, Sorsa T. Gingival 
crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of 
periodontitis. J Periodontal Res 2003;38:436-439. 
60. Sugiyama Y, Yamaguchi M, Kanekawa M, Yoshii M, Nozoe T, Nogimura A, Kasai K. 
The level of cathepsm Β m gingival crevicular fluid during human orthodontic 
tooth movement. Eur J Orthod 2003;25:71-76. 
61 Yoshimatsu M, Shibata Y, Kitaura H, Chang X, Mornshi T, Hashimoto F, Yoshida N, 
Yamaguchi A. Experimental model of tooth movement by orthodontic force m 
mice and its application to tumor necrosis factor receptor-deficient mice. J Bone 
Miner Metab 2006;24:20-27. 
62 Yamaguchi M, Ozawa Y, Nogimura A, Aihara N, Kojima T, Hirayama Y, Kasai Κ 
Cathepsms Β and L increased during response of periodontal ligament cells to 
mechanical stress m vitro. Connect Tissue Res 2004;45:181-189. 
152 
Chapters 
Summaries in English and Dutch 

Summary 
Summary 
Orthodontic tooth movement requires extensive remodelling of the 
periodontium, in which MMPs and TIMPs are strongly involved. MMPs 
degrade the extracellular matrix during remodelling, while their activity is 
regulated by TIMPs. They are not only thought to play a role in 
orthodontic tooth movement but also in negative side effects such as 
relapse and root resorption. For clinicians as well as researchers, it is 
important to gain more insight into the role of MMPs and TIMPs in tooth 
movement. This might promote the development of more effective 
orthodontic therapies. Synthetic inhibitors that reduce MMP activity, 
might have therapeutic value in reducing the side effects of treatment. 
The purpose of our research was to investigate the role of MMPs and 
TIMPs in periodontal remodelling, especially in orthodontic tooth 
movement. The effects of synthetic MMP inhibitors were also studied. 
In chapter 1, the background of these studies is discussed. It 
presents an overview of the biological aspects of periodontal remodelling 
with the main focus on orthodontic tooth movement. MMPs and TIMPs are 
introduced, and an overview is given of their role in periodontal 
remodelling. The properties of synthetic MMP inhibitors are also reviewed. 
The effect of CMTs on gelatinase production by PDL cells in two-
dimensional cultures is investigated in chapter 2. Remarkably, some 
CMTs stimulated MMP-2 production at relatively low concentrations. 
A much stronger inhibitory effect on gelatinase activity was found at 
higher concentrations, which confirms earlier findings. At these higher 
concentrations, the direct inhibition of activity compensates the 
increased production, resulting in a net decrease of MMP activity. 
Nevertheless, a possible stimulatory effect of CMTs on MMP production 
should be considered in their clinical use. 
In the study described in chapter 3, a three-dimensional culture 
system for PDL cells was used, which is a better representation of the 
physiological situation. It consists of a collagen gel in which PDL cells are 
seeded. This culture model reflects certain aspects of increased matrix 
remodelling during tooth movement. Alpha smooth muscle actin (ASMA) 
is thought to be involved in the contractile properties of these cells. 
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Therefore, the expression of ASMA was also analysed beside that of 
MMPs. In this 3-D environment, the PDL cells also produced MMP-9 next 
to MMP-2. The synthetic MMP-inhibitors BB94, CMT-3, Ilomastat and 
doxycycline all reduced MMP activity and gel contraction, but CMT-3 and 
doxycycline had the strongest effect. These inhibitors also reduced MMP-
2, -3, and ASMA mRNA expression. The inhibitory effect on gel 
contraction was primarily due to inhibition of MMP activity. In addition, 
ASMA expression was reduced by CMT-3 and doxycycline, which might 
limit the contractile activity of the fibroblasts. 
In chapter 4, MMPs and TIMPs in samples of gingiva, PDL and GGF 
from healthy controls and periodontitis patients were analysed by 
zymography, and total MMP activity was determined. TIMP-1 and -2 , 
active and pro-MMP-2 and -9, and active MMP-1 and -8 were present in 
all samples. In general, TIMP levels were lower in diseased periodontal 
tissues. Especially diseased GGF contained much higher amounts of MMPs 
as reported by others. Surprisingly, in healthy gingiva and PDL some 
MMPs were more abundant than in diseased tissue. These specific MMPs 
might be involved in physiological rather than pathological remodelling 
processes. In all samples active MMP-2 complexes and collagenolytic 
fragments were found, but much more in the PDL and GGF samples from 
periodontitis patients than in those from healthy subjects. These forms 
of MMPs are generally overlooked, but their proteolytic activity might 
contribute considerably to periodontal destruction. 
In chapter 5, a rat model was used to study the effect of CMT-3 on 
orthodontic tooth movement. I t was hypothesized that CMT-3 inhibits 
tooth movement due to its inhibitory effect on MMPs. During 14 days, 
three groups of rats received different dosages of CMT-3, and tooth 
displacement was measured. CMT-3 significantly inhibited tooth 
movement and also decreased the number of osteoclasts at the 
resorption sides. The latter phenomenon might be due to the induction of 
apoptosis in activated osteoclasts or reduced osteoclast migration. CMT-3 
might also directly inhibit MMP-mediated degradation of the organic bone 
matrix. 
In chapter 6, MMPs and TIMPs in GGF from orthodontic patients 
were analyzed by zymography. In general, a larger amount of MMPs and 
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TIMPs was found at both the resorption side and the apposition side 
compared to the control teeth. The general increase in MMPs and TIMPs 
around the experimental teeth probably results from increased 
remodelling induced by tooth movement. Especially MMP-1 seems to be 
involved in this increased remodelling, since partially active MMP-1 was 
found in GCF from both experimental sides, but not in that from control 
teeth. MMP-9, which is known to be involved in bone degradation, and a 
48 kDa gelatinase were higher at the resorption side. The small increase 
in TIMP-1 at the resorption side might stimulate bone resorption, 
whereas the high increase at the resorption side reduces bone resorption. 
The analysis of MMPs and TIMPs may contribute to more predictable 
treatment outcomes in orthodontics. 
In chapter 7, the previous chapters are discussed. Suggestions for 
future research and possible applications are given. 
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Om tanden orthodontisch te kunnen verplaatsen, moet uitgebreide 
remodellering plaatsvinden van de weefsels die de tand omringen, het 
parodontium. Een enzymgroep die een belangrijke rol speelt bij deze 
remodellering, zijn de 'matrix metalloproteinasen' (MMPs). De activiteit 
van MMPs wordt gereguleerd door hun natuurlijke remmers, de 'tissue 
inhibitors of metalloproteinases' (TIMPs). Behalve bij orthodontische 
tandverplaatsing spelen MMPs en TIMPs ook een rol bij 'bijwerkingen' van 
de behandeling, zoals relaps en wortelresorptie. Voor zowel clinici als 
onderzoekers is het van belang de kennis over de rol van MMPs en TIMPs 
bij tandverplaatsing te vergroten, waardoor uiteindelijk de effectiviteit 
van de behandelingen verbeterd kan worden. Synthetische MMP-remmers 
zouden een therapeutische toepassing kunnen hebben in de orthodontie 
bij het voorkomen van relaps en wortelresorptie. Het doel van het 
onderzoek dat in dit proefschrift is beschreven, was het inzicht te 
vergroten omtrent MMPs en TIMPs in parodontale remodellering, met 
name in de orthodontie. Daarnaast is het effect van synthetische MMP-
remmers op parodontale MMPs onderzocht. 
Hoofdstuk 1 is de algemene introductie, waarin de eigenschappen 
van MMPs, TIMPs en synthetische MMP-remmers worden beschreven. 
Voor zover bekend, wordt de rol van MMPs en TIMPs bij parodontale 
remodellering in orthodontische tandverplaatsing en parodontitis 
weergegeven. Uiteindelijk worden de specifieke doelen van de 
uitgevoerde studies toegelicht. 
In hoofdstuk 2 wordt het effect van CMTs op de gelatinase-
productie van PDL cellen in een tweedimensionale kweek beschreven. 
Ook wordt het effect van CMTs op de MMP-activiteit van gezuiverd MMP-2 
en -9 beschreven. Een opmerkelijke bevinding was dat sommige CMTs in 
relatief lage concentraties de MMP-2 productie bleken te stimuleren. 
Echter, bij hogere concentraties trad een veel sterker remmend effect op, 
zoals ook in eerdere studies werd gevonden. Bij deze hogere 
concentraties compenseert de directe remming van de activiteit de 
toegenomen productie, waardoor uiteindelijk het remmende effect 
domineert. Desondanks zal rekening gehouden moeten worden met een 
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eventueel stimulerend effect van CMTs op MMP-productie bij de 
toepassing van deze MMP-Vemmers'. 
In het onderzoek dat in hoofdstuk 3 beschreven wordt, is een 
driedimensionale (3D) kweekmethode gebruikt. Dit weerspiegelt de 
natuurlijke weefselmatrix van PDL cellen beter dan een tweedimensionale 
monolayer kweek. Het 3D kweekmodel bestaat uit collageengelen, waarin 
de PDL cellen worden gezaaid. Het bootst een aantal kenmerken na van 
de verhoogde remodellering bij orthodontische tandverplaatsing. Tijdens 
de kweek wordt de gel gecontraheerd door de PDL cellen. Alpha smooth 
muscle actine (ASMA), dat deel uitmaakt van het cytoskelet, draagt bij 
aan de contractie van de PDL cellen. Daarom werd naast de expressie 
van MMPs en TIMPs ook de expressie van ASMA geanalyseerd. In deze 
3D omgeving bleken PDL cellen naast MMP-2 ook MMP-9 te produceren. 
De cellen werden geïncubeerd met de synthetische MMP-remmers BB94, 
CMT-3, Ilomastat en doxycycline. Allen reduceerden de MMP-activiteit en 
de gelcontractie, waarbij CMT-3 en doxycycline het sterkste effect 
hadden. Deze laatste remmers verminderden bovendien de mRNA 
expressie van MMP-2, -3 en ASMA. Het remmende effect op de 
gelcontractie werd hoogstwaarschijnlijk primair veroorzaakt door de 
remming van MMP-activiteit, wat de matrixremodellering reduceert. 
Daarnaast werd de ASMA-expressie gereduceerd door CMT-3 en 
doxycycline, wat de contractie door de PDL cellen mogelijk verder 
verminderde. 
In hoofdstuk 4 worden de verschillen in MMPs en TIMPs beschreven 
in gingiva, PDL en creviculaire vloeistof (GCF) van pardontaal gezonde 
personen en parodontitispatiënten. De totale MMP-activiteit in de 
monsters werd gemeten met een fluorescent substraat en de soorten 
MMPs en TIMPs werden geanalyseerd met behulp van zymografie. TIMP-1 
en -2, actief en latent MMP-2 en -9, en actief MMP-1 en -8 waren in alle 
monsters aanwezig. Over het algemeen waren de hoeveelheden TIMPs 
lager in de monsters van parodontitispatiënten. Vooral in de creviculaire 
vloeistof van parodontitispatiënten waren grotere hoeveelheden MMPs en 
een hogere MMP-activiteit aanwezig. Opmerkelijk was dat in gezonde 
gingiva en PDL sommige MMPs in grotere hoeveelheden aanwezig waren 
dan in de patiëntenmonsters. Deze specifieke MMPs zijn waarschijnlijk 
159 
vooral bij fysiologische remodellermg betrokken in plaats van 
pathologische remodellering. In alle weefsels werden tevens actieve 
MMP-2 complexen en collagenolytische fragmenten aangetroffen, maar 
veel meer in PDL en GCF van parodontitispatiénten dan in dat van 
gezonde personen. Deze vormen van MMPs blijven in andere 
onderzoeken vaak onderbelicht. Desondanks hebben ze een sterke 
proteolytische activiteit en kunnen daardoor bijdragen aan parodontale 
afbraak bij parodontitis. 
In hoofdstuk 5 werd een rattenmodel gebruikt om het effect van 
CMT-3 op tandverplaatsing te bestuderen. De hypothese was dat CMT-3 
tandverplaatsing zou verminderen door het remmende effect op MMPs. 
Voor dit experiment kregen drie groepen ratten een verschillende dosis 
CMT-3 en werd de tandverplaatsing gemeten. CMT-3 bleek tand-
verplaatsing significant te remmen en tevens het aantal osteoclasten aan 
de resorptiezijde te reduceren. Dit laatste is mogelijk het gevolg van de 
apoptose van geactiveerde osteoclasten of een verminderde migratie van 
deze cellen. De remming van MMP-activiteit door CMT-3 kan bovendien 
direct de afbraak van de organische botmatrix verminderen. 
De analyse van MMPs en TIMPs in GCF van orthodontische 
patiënten is beschreven in hoofdstuk 6. De monsters werden 
geanalyseerd met behulp van zymografie. Over het algemeen werden 
hogere concentraties MMPs én TIMPs gevonden aan zowel de resorptie 
als de appositiezijde van verplaatsende elementen vergeleken met de 
controle elementen. Dit is hoogstwaarschijnlijk het gevolg van de 
toegenomen parodontale remodellering aan beide zijden van het 
element. Met name MMP-1 lijkt bij deze toegenomen remodellering een 
grote rol te spelen, aangezien deels geactiveerd MMP-1 wel bij 
orthodontisch verplaatste elementen werd aangetroffen, maar helemaal 
niet bij controle-elementen. Verhoogde concentraties MMP-9, een MMP 
die een belangrijke rol speelt in botafbraak, en een 48 kDa gelatinase 
waren aanwezig aan de resorptiezijde. De geringe toename van TIMP-1 
aan de resorptiezijde zou botresorptie kunnen stimuleren, terwijl de 
sterkere toename aan de appositiezijde botresorptie juist zou kunnen 
remmen. De analyse van MMPs en TIMPs in de klinische situatie zou 
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kunnen bijdragen aan meer voorspelbare behandelingsduur en 
behandelresultaten. 
Hoofdstuk 7 is de algemene discussie, waarin de resultaten van de 
voorgaande hoofdstukken worden besproken. Suggesties voor toekomstig 
onderzoek en mogelijke toepassingen worden eveneens gegeven. 
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waren Inmiddels zijn sommigen van jullie zelf promovendi geworden 
Uiteraard mogen ook alle overige collega's van de afdeling Orthodontie 6L Orale Biologie met 
onvermeld blijven. Jullie waren altijd geïnteresseerd en waar nodig behulpzaam In het 
bijzonder wil ik daarbij alle dames van het secretariaat vermelden Dank voor jullie 
ondersteuning Jacqueline, dank voor alle hulp tijdens en ook na het project. Dat geldt ook 
voor de ICT-mannen die dankzij hun creatieve oplossingen voor de meest uiteenlopende 
computerproblemen onmisbaar waren tijdens dit project, achtereenvolgens: Servaas Mottet, 
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Bloemen leven licht-zinnig in hun bladen. 
Dieren lopen vanzelfsprekend; ze zwijgen 
van wat ze zouden kunnen zi jn; hun daden 
gebeuren altijd nu; dieren zijn eigen. 
Mensen doen alsof. Bestaan in ijskoude, 
denken, denken, denken dat ze bestaan. 
Geen mens kent een mens. Men wil zich vasthouden. 
Angst laat niet los. Men kijkt zijn spiegel aan. 
En hangt zich op aan winterse systemen 
of takken van geloof. Maar dood is dood. 
Men neemt zich mee en is niet mee te nemen. 
En ik ben eenzelfde. Maar leg mij bloot, 
omdat ik zien wil wie ik toch nog ben. 
Ik moet toch een mens zijn die ik herken. 
H. And re us 
(uit: Sonnetten van de kleine waanzin, 1957) 
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